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Preface
Colorectal cancer and peptic ulcer are two o f  the most commonly encountered diseases in 
present day medical practice. The work which is reported in this thesis links these two 
very different diseases, by investigation o f the effects o f  various forms o f  treatment for 
one, on the the incidence and behaviour o f  the other, both in a deleterious and potentially 
beneficial fashion to the patient.
Many reports have suggested that patients who have previously undergone definitive 
surgery for peptic ulcer are left with the legacy o f an increased propensity for developing 
malignant disease approximately 15 to 20 years later. Gastric cancer has regularly been 
identified as being one such cancer. To a much lesser extent, colorectal cancer has also 
been reported as occurring with undue frequency in a number o f patient series studied. 
With few exceptions, the majority o f patients studied have previously undergone partial 
gastric resection as opposed to vagotomy. The latter procedure, although reducing 
gastric acid output to a similar degree as partial gastrectomy, differs markedly from it by 
virtue o f  the chronic elevation o f circulating gastrin levels, secreted from the non-resected 
stomach, which occurs post-operatively. This may be an important factor in the 
development o f colorectal cancer, as a significant body o f evidence suggests that gastrin is 
trophic for a proportion o f such neoplasms. There may therefore be implications for the 
prolonged use o f  the latest pharmaceutical agents used against acid-peptic disorders, 
namely the proton-pump inhibitors o f  which omeprazole is the original. Similar to 
vagotomy, these drugs induce a chronic elevation o f circulating gastrin, secondary to  the 
reduction in acid output. In view o f this association, one o f the main purposes o f  the 
work which follows was to study the cancer incidence, in particular that o f  colorectal
21
cancer, in a group o f patients who had undergone surgery for peptic ulcer disease, the 
majority o f whom had vagotomy as opposed to antrectomy.
Somewhat conversely, the remainder o f the work in this thesis concentrates on 
investigating a possible inhibitory action o f omeprazole on colorectal tum our growth, 
despite the chronic hypergastrinaemia which it produces. This is in response to two 
recent reports which suggest that the drug may have such an effect on these tumours, 
under experimental conditions.
Hence, it seems appropriate to open this account with a brief overview o f  the diseases 
under scrutiny; namely colorectal cancer and peptic ulcer; and to continue by explaining 
the rationale behind both surgical and medical treatment for the latter. This should give 
the reader a clear understanding o f the pathophysiological changes that occur in response 
to such treatment, and why they may have potentially deleterious effects, or otherwise, 
elsewhere in the gastrointestinal tract. In the latter part o f  the introductory chapter, the 
evidence, both for and against the phenomena under investigation, will be reviewed, and 
this will illustrate the stimulus to the work carried out for this thesis.
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Chanter 1 - Introduction
1. Colorectal Cancer - an overview
Colorectal cancer is the fourth commonest malignancy worldwide with the third highest 
mortality o f  all cancers (1). An estimated 468,000 people died from the disease globally in 
1993 (1). It is more prevalent in countries o f the developed world (United States, 
W estern Europe, Australasia and Scandinavia) (2). In Scotland, in 1993, it was the third 
most frequently diagnosed cancer in both males and females, accounting for 13.4% o f all 
cancer registrations in their respective sex category (Figure 1) (3). Only lung and prostate 
cancer in males (25.1% and 13.6% respectively) and breast and lung cancer in females 
(24.9%  and 14.1% respectively) exceeded it in terms o f incidence (3). It is therefore 
appropriate that such common diseases are being targeted by research, health promotion 
and population screening in an effort to reduce the incidence and improve upon current 
survival rates. This is indeed the case with colorectal cancer but as yet there has been no 
significant impact on survival rates.
Colorectal cancer is a multifactorial disease with several genetic and environmental risk 
factors identified (4). At one end o f  the spectrum are the inherited forms o f  the disease, 
Familial Adenomatous Polyposis (FAP) and Hereditary Non-Polyposis Colorectal Cancer 
(HNPCC)(5), which account for 1% and 5 to 15% o f  all colorectal cancers respectively
(2). Familial Adenomatous Polyposis is inherited in an autosomal dominant fashion. 
Affected individuals exhibit a phenotypic marker in the form o f hundreds, often thousands, 
o f benign colorectal adenomatous polyps developing in their teens, which invariably go on 
to develop malignant change in the second or third decades. The mutated gene
23
Figure 1 - The ten most frequently diagnosed cancers in 
Scotland in 1993
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responsible, named APC (abbreviation for Adenomatous Polyposis Coli), is a tum our 
suppressor gene and has been identified on the long arm o f chromosome 5 and it is now 
possible to  screen for this genetically. Unlike Familial Adenomatous Polyposis, 
Hereditary Non-Polyposis Colorectal Cancer does not have any phenotypic marker and 
diagnosis o f  this condition is based on family history, for which a list o f  criteria, known as 
the Amsterdam criteria, have been laid out (6). These stipulate that at least three 
members o f  the family within tw o generations be affected; that at least tw o o f  the affected 
individuals be first degree relatives o f the other; and that at least one o f  the affected 
individuals have developed the disease before the age o f  fifty. Four genes, hM LH 1, 
hM SH 2, on the short arms o f  chromosome 2 and 3 respectively and hPMS 1 (long arm o f 
chromosome 2) and hPMS2 (short arm o f chromosome 7) have subsequently been 
identified (7,8). These are mismatch repair genes and germline mutations o f  these have 
been identified in such families. Both these forms o f  colorectal cancer exhibit an “all or 
none” effect with those family members inheriting the mutated genes invariably going on 
to develop the disease.
“ Sporadic” colorectal cancer accounts for the remaining 85% o f cases. Even here, genetic 
predisposition to  the disease is thought to play an important role, as a number o f  mutated 
genes have been frequently identified in those sporadic tumours studied (9). These 
include the APC gene responsible for Familial Adenomatous Polyposis as described 
above, and others such as DCC (abbreviation for Deleted in Colorectal Cancer), K-ras and 
p53 (9). Furthermore, within this group, familial clustering o f the disease is evident, and 
those with an affected first degree relative run a substantially increasd risk, o f  the order o f 
two to four-fold, over the general population o f  developing bowel cancer, suggesting an 
underlying genetic aetiology (5). Environmental factors undoubtedly also have a role to 
play. For instance, it has been shown that immigrants from a region with low disease
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incidence settling in an area o f relatively high incidence, acquire an increased risk for the 
disease (10,11). Strong associations exist for a number o f environmental factors (4). 
Increased risk is seen in association with obesity, sedentary lifestyle and lack o f  physical 
exercise (4) as well as high consumption o f animal fat, protein and red meat (12-14). An 
inverse association exists for increased consumption o f dietaiy fibre, fruit and vegetables 
(15). A number o f chemicals in the diet are also thought to be protective against 
colorectal neoplasia, among them being calcium (4), folic acid (16) and vitamins A (16), C 
(4) and E (16). Also, there is evidence to suggest that aspirin and Non-Steroidal Anti- 
Inflammatory Drugs (NSAIDS) such as piroxicam and sulindac have an anti-neoplastic 
action on the colorectal mucosa (17-19).
It has long been recognised that a marked survival benefit to the patient accompanies the 
earlier the stage o f disease at presentation, diagnosis and treatment. Indeed, treatment o f  
the earliest stages o f colorectal cancer can in some cases be confidently predicted to be 
curative. The Dukes’ classification, first described in 1932 for cancers o f the rectum, but 
now applied to all adenocarcinomas o f the large bowel, bears this out (20). Dukes defined 
three stages o f the disease, namely stage A, stage B and stage C. D ukes’ A  lesions, the 
earliest stage, are limited to the wall o f the bowel. Dukes’ B tumours traverse the bowel 
wall completely, either through to serosa or perirectal tissue, but no regional lymph node 
metastases are present. D ukes’ C disease is that in which there is involvement o f  the 
draining mesenteric lymph nodes with metastatic disease. Dukes later sub-divided stage C 
into Ci and C2, the latter describing metastatic nodes at the level o f  ligature o f  the main 
arterial supply to the diseased segment o f  bowel (21). Quoted five-year survival figures 
for each o f these respective pathological stages o f disease after “curative” surgical 
resection are as follows : 80-100%, 45-78%  and 25-60% (2,22-24). Although not one o f  
Dukes’ originally described stages, D ukes’ D is now often used to describe metastatic
spread to the liver and beyond, which has a dismal prognosis. Modifications to  D ukes’ 
original classification, such as those o f Astler and Coller (25), Kirklin (26) and Turnbull 
(27), have not superceded its use, as none have been shown to be any more beneficial in 
predicting outcome (28,29). As a result o f this, and also its simplicity o f  use, D ukes’ 
staging system remains the gold standard against which all other prognostic classifications 
should be assessed (30), although a significant number o f  workers in the field have 
adopted and now apply the universal Tumour : Node : Metastasis (TNM) classification o f 
cancer to the disease (31).
Surgical resection remains the mainstay o f treatment for colorectal cancer. Despite 
intensive research and an ever increasing understanding o f the disease over the years, it is 
somewhat depressing to realise that the survival figures quoted above have changed little 
over several previous decades (32). As outlined above, and as with most malignancies, 
colorectal cancer is a multifactorial disease with multiple genetic and environmental 
factors cited in its aetiology. As such there exists the potential to modify the disease at 
several levels, from the intranuclear genetic makeup o f an individual to the risk factors to 
which he or she may be exposed on a daily basis, such as dietary components and drugs.
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2. Peptic U lcer Disease - an overview
Peptic ulcer disease has afflicted mankind for many centuries. For instance, the well 
preserved corpse o f  a Chinese man who died in 167 B.C. demonstrated that the cause o f  
death was peritonitis as a result o f a perforated pre-pyloric ulcer (33). The first 
documented reports o f gastric and duodenal ulcer in the medical literature were in 1586 
(34) and 1688 (35) respectively. Until the beginning o f this century, duodenal ulcer was 
considered to be a relatively rare disease, with gastric ulcer being the commoner o f  the 
two, and the latter being more prevalent in females (34). However, in the first half o f  the 
twentieth century, the incidence o f doudenal ulcer was seen to markedly increase, 
predominantly among the male population (36). Since 1950 onwards however, a definite 
decline in the natural incidence o f  the disease has been evident, which has pre-dated any o f  
the therapeutic advances introduced during this period (37). Analysis o f  birth cohorts has 
shown that those born around the turn o f the century had the highest risk for the disease 
and in all subsequent birth cohorts this risk has steadily decreased (38). It has been 
postulated that the death and senescence o f that particular group may be responsible for 
the now observed decline and that exposure o f this cohort o f  patients to some 
evironmental risk factor at the time o f  their birth and early life was responsible for the 
initial increase in frequency o f  the disease (37,38). Despite this natural decline, the 
incidence o f complications o f peptic ulcer, such as perforation and haemorrhage, and the 
mortality rates attendant upon them, have remained relatively constant, although the latter 
now tend to affect more aged patients (39,40). If  one also considers that peptic ulcer has 
an estimated incidence o f 2 to 3 per 1000, a one year prevalence o f  17 per 1000, and a 
lifetime prevalence o f  5-10% (39), and that present day treatment also confers a 
considerable financial burden on the economy (for instance, prescriptions for anti-ulcer
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drugs cost an estimated two billion dollars per year in the United States) (41), then it can 
be appreciated that it continues to represent a significant portion o f  both general 
practicioner and specialist gastroenterologist physicians and surgeons workloads.
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3. Pathophysiology o f Peptic Ulcer
In order to understand why treatment for peptic ulcer may adversely affect patients by 
increasing their propensity to develop colorectal cancer and other malignancies, it is 
necessary to know the main underlying mechanisms for ulcerogenesis, and the 
physiological alterations that occur with various forms o f treatment.
Ulceration in the stomach or duodenum occurs when the physiological balance between 
protective mucosal defence mechanisms and the potential for damage by intraluminal acid 
and pepsin is disrupted (42). Several aetiological factors are implicated.
3.1. Mucosal Protection
Protective mechanisms include the secretion o f mucus by the epithelium, which forms an 
unstirred layer adjacent to it and is resistant to the action o f pepsin (42). There is also 
continuous secretion o f  bicarbonate which creates a pH gradient across the unstirred 
mucus layer, so that when luminal pH is as low as 1.5, the fluid bathing the surface o f  the 
epithelial cells is pH 6 or greater (43). In addition, tight apical cellular junctions prevent 
back-diffusion o f  acid through the gastric mucosa (44). Rapid epithelial turnover and 
adequate mucosal blood flow are also thought to contribute to the defence o f the 
gastroduodenal mucosa (42). The “aggressors” against these protective features o f  the 
gastroduodenal mucosa include the acid and pepsin secreted by the body o f  the stomach 
for the purposes o f digestion o f luminal food contents. It is not necessary for these 
secretions to be in excess o f  their “normal” physiological range to  lead to  mucosal damage 
and subsequent ulceration (42). Although duodenal ulcer sufferers as a whole are known 
to have elevated acid secretion relative to the general population, in fact this difference 
occurs in only one third o f such patients, the so called “true hypersecretors” (45). It is
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also noteworthy that 10% o f Zollinger-Ellison syndrome patients (characterised by 
significantly excessive acid and pepsin secretion, secondary to a gastrin producing 
tum our) do not develop the typical ulceration so characteristic o f the condition (45). 
Furthermore, the majority o f gastric ulcers, unlike duodenal ulcers, develop in conditions 
o f  relative acid lack (hypochlorhydria) (45). However, in stating this, it should be 
appreciated that acid must be present to some degree for ulceration to occur, as it has 
been shown that ulceration does not develop in conditions o f complete absence o f acid 
(achlorhydria) (46). It follows from this that factors which exert a deleterious action on 
the mucosal protective mechanisms outlined above, must have a significant bearing on 
disease development. It is by this mechanism that the two most commonly implicated 
ulcerogenic agents, the spiral bacterium, Helicobacter pylori, and aspirin and the related 
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), are believed to act.
3.2. Helicobacter pylori.
Helicobacter pylori has generated a plethora o f research and literature since its description 
in 1983 by Marshall and Warren in association with histologically confirmed active 
inflammation o f  the gastric mucosa (47). However colonisation o f  the human stomach by 
such organisms had been reported previously by others, as early as 1896 (48-50). It is 
now known that Helicobacter is present in virtually all cases o f  chronic active gastritis, 
which usually affects the antral mucosa o f the stomach, but can occasionally affect the 
entire stomach (pangastritis) (51). It is not implicated in autoimmune chronic atrophic 
gastritis, which targets the acid-secreting parietal cells o f  the body o f the stomach, and is 
characterised by production o f auto-antibodies to the parietal cells, leading to their 
destruction, and resultant achlorhydria (52). It has also been widely shown that the 
majority o f patients, approximately 95%, with duodenal ulcer, harbour the organism, as
31
do about 70% o f  those with gastric ulcer (excluding those with NSAID-induced gastric 
ulcers) (42). The means by which the organism exerts its pathogenic action has not been 
fully identified, although a number o f hypotheses have been proposed. Production o f 
ammonia from urea by the organism’s characteristic urease enzyme may interfere with the 
passage o f hydrogen ions from the secretory canaliculi, and ultimately lead to their back 
diffusion through the gastric mucosa, with resultant mucosal injury (52). Similar injury 
may also result from damage to the mucus barrier, again leading to its increased 
permeability to hydrogen ions, and this may be mediated by protease enzymes produced 
by the bacterium (53). Direct cytotoxic activity o f a protein produced by Helicobacter 
organisms, has been demonstrated in mammalian cells in vitro (54). The gene which 
encodes for this cytotoxin has been identified and is known as the cag-A gene (cytotoxin 
associated gene) (55). Infection with the organism leads to chronic elevation o f 
endogenous gastrin levels (56), possibly due to the alkalisation o f the mucosal surface by 
ammonia produced by it’s urease enzyme (57), or by interference with local mucosal anti- 
secretory mechanisms such as somatostatin release (58). This results in significantly 
increased basal and maximal gastric acid output compared to non-infected persons, a 
difference which resolves after eradication o f the organism (58). Whatever the mechanism 
of injury, and although the association o f the organism to peptic ulceration is very strong, 
on current evidence, it cannot be conclusively stated that Helicobacter pylori is the sole 
cause o f such ulceration as there are many more asymptomatic and disease free 
Helicobacter positive individuals who will never develop the disease, than there are peptic 
ulcer sufferers (52). Furthermore, it cannot be implicated in Helicobacter negative 
patients with ulceration secondary to Zollinger-Ellison syndrome or aspirin/NSAID use 
(41). The organism’s pivotal role in peptic ulcer disease is inferred from the observation 
of dramatically reduced recurrent ulceration rates after its eradication by appropriate
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antibiotic therapy in conjunction with acid secretory inhibitors, as opposed to those 
patients treated by acid-suppresing agents alone (52,59).
3.3. Aspirin and Non-Steroidal Anti-inflammatorv Drugs (NSAIDs)
The association between the use o f aspirin and non-steroidal anti-inflammatory drugs and 
peptic ulcer, particularly its complications o f perforation and haemorrhage, is now widely 
recognised (60). A positive correlation exists between the use o f such agents and the 
incidence o f  complicated ulcer disease, and it is perhaps not surprising that the elderly 
population, who are afflicted by chronic inflammatory disorders such as arthritis and who 
therefore are prescribed the bulk o f  such agents, are the group predominantly affected. 
Treatm ent is associated with two distinct macroscopic forms o f mucosal injury which are 
the result o f  direct and systemic effects o f these agents respectively (60). Direct injury 
results in small mucosal haemorrhages and erosions and is due to topical solubility o f  the 
drug into the gastric epithelium. More important are the systemic effects o f  such agents, 
which lead to the development o f ulceration. This occurs as a result o f  inhibition o f 
mucosal prostaglandin synthesis, which are necessary for maintenance o f mucosal 
protective functions including mucus production, bicarbonate secretion and mucosal blood 
flow. Indeed, concurrent treatment with the prostaglandin analogue, misoprostil, results 
in significantly fewer NSAID ulcers (61), and has been commercially available, both alone 
and in combination with anti-inflammatory agents, for the past few years.
3.4. Zollinger-Ellison Syndrome
Less common than the previous two forms o f peptic ulceration are those cases o f peptic 
ulceration occuring in the setting o f the Zollinger-Ellison syndrome, briefly referred to 
earlier. This uncommon disease is characterised by massive hypersecretion o f  gastric acid
33
in response to autonomous production o f the peptide hormone, gastrin, by a neuro­
endocrine cell tumour, most commonly situated in the head o f  the pancreas. Gastrin, 
which is the major stimulant to post-prandial gastric acid secretion, will be discussed in 
m ore detail later. It is normally secreted from neuro-endocrine G-cells situated in the 
mucosa o f  the gastric antrum and proximal duodenum. Its secretion is subject to a 
negative feedback mechanism, whereby further release is inhibited as intraluminal acid 
increases and gastric pH falls. Tumour gastrin production is not under such physiologic 
control and as a result, in response to the chronic circulating hypergastrinaemia so 
produced, there occurs excessive acid and pepsin secretion. This results in peptic 
ulceration in the stomach, duodenum and proximal jejunum. N ot only is the amount o f  
acid secretion increased by maximal stimulation o f  existing parietal cells, but the capacity 
for the stomach to produce more acid is increased due to an expansion in the gastric 
parietal cell mass (62), secondary to the trophic action o f  gastrin on the gastro-intestinal 
tract mucosa. The syndrome takes its name from the clinicians who first described it in 
tw o o f their patients (63). They correctly postulated that the clinical features were the 
result o f a circulating humoral factor produced from the pancreatic tumour, although it 
was to take another twelve years before that factor was definitely confirmed as gastrin 
(64). A complete resume o f the disorder is outwith the scope o f  this thesis, but a number 
o f salient features are presented to summarise (65-67). It is a relatively rare condition 
with reported incidence rates o f between 0.2 to 0.4 cases per million o f  the general 
population per year, and accounts for an estimated 0.1 to 1% o f all peptic ulcer patients. 
Twenty five percent o f all cases occur within the spectrum o f the hereditary, autosomal 
dominant, Multiple Endocrine Neoplasia (MEN) Type I syndrome with adenomas 
elsewhere, most commonly o f the parathyroid glands, but also in the pituitary, adrenals, 
and rarely, thyroid. Gastrinomas in this group are commonly multifocal. The remaining
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75%  are termed “sporadic” and are usually solitary. They are usually slow growing 
lesions, but up to  50% o f  gastrinomas are locally invasive and metastasise. Often such 
behaviour only becomes apparent retrospectively as it is notoriously difficult to  ascertain 
histologically, benign from malignant lesions. Treatment is aimed at both control o f  acid 
hypersecretion and removal o f the primary problem itself. Latterly the former was 
performed by subtotal gastrectomy to excise the parietal cell mass, but with the advent o f  
powerful anti-secretory agents such as omeprazole, this has largely become obsolete. As 
these tum ours can often be only a few millimetres in diameter, attempts are made to 
accurately localise them pre-operatively and intra-operatively using modalities such as 
ultrasound, computerised tomography, magnetic resonance imaging, selective mesenteric 
angiography and selective portal venous tributary blood sampling. These techniques 
combined with careful and complete inspection and palpation at laparotomy, have varying 
degrees o f  specificity, sensitivity and success. Despite this, even in the hands o f  the most 
experienced surgeons, up to 50% o f laparotomies fail to identify the tumour. Apart from 
pre-operative tum our localisation, it is also useful to attempt to identify the presence o f  
inoperable metastases as, already mentioned, adequate control o f  acid secretion can now 
be obtained with safe and simple medication and furthermore, the patient avoids an 
unnecessary operation. Where surgery is possible and the tum our is identified, local 
enucleation o f the tumour is the usual method o f  removal, and more extensive procedures 
such as excision o f  the entire pancreatic head by way o f a Whipple’s procedure are not 
advocated. Treatment o f non-resectable and metastatic gastrinoma by cytotoxic 
chemotherapy and also the somatostatin analogue, octreotide, have been reported with 
varying results. At present, control o f acid secretion by omeprazole and related 
compounds remains the therapeutic mainstay. Overall survival figures for Zollinger- 
Ellison syndrome vary from 62 to 75% at five years and 47 to 53% at ten years.
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3.5. Associated factors
Finally, mention must be made o f  other factors which are associated with peptic ulcer 
disease. These include familial propensity, possession o f blood group O, seasonal and 
geographic variability, smoking, alcohol, diet, stress and the psychological profile o f  the 
individual patient (42,45).
3.6. Summary
In summary, peptic ulcer disease clearly has a multifactorial aetiology, with strong 
associations to  a number o f factors. Since the latter part o f  the nineteenth century until 
very recently, therapeutic intervention, for the most part, has been aimed at ways o f 
reducing the secretion o f  acid. However, it should now be clear from the foregoing 
discussion that the disorder is not solely caused by its excess secretion. A  discussion o f 
the various forms o f  treatment for peptic ulcer now follows, with particular attention to 
surgical therapy. It is the latter that has been conflictingly reported as rendering its 
recipients at increased risk for developing malignant disease in the years following 
surgery. However, in order to appreciate the rationale behind the various surgical and 
pharmacological manoeuvres which have been developed for the purposes o f  reducing 
gastric acid secretion, it is appropriate to first summarise the major physiological 
mechanisms which are responsible for stimulating acid secretion by the stomach.
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4. Regulation of Gastric Acid Secretion
Establishment o f the “acid” nature o f gastric secretion dates back to the 1820’s, from the 
w ork o f Thomas Beaumonte, who demonstrated its presence in the effluent o f  a post- 
traumatic enterogastric fistula in one o f his patients, Alexis St. Martin (68). At the same 
time, reports from Germany and France, by Tiedemann & Gmelin (69) and William Prout 
(70) respectively, confirmed it as being hydrochloric acid. The mechanisms by which acid 
release was regulated were only to become apparent at the beginning o f  the twentieth 
century, with the famous work o f Pavlov, who demonstrated stimulation o f  gastric acid 
secretion secondary to the sight and smell o f food (71), and that such neurally stimulated 
secretion was abolished by section o f the vagus nerves (72). Edkins, in 1905, showed 
there to be a powerful stimulant to gastric secretion in extracts o f  canine gastric antrum 
when injected into dogs (73). He called this unidentified substance, gastrin. This 
hypothetical hormone’s existence was ultimately confirmed some sixty years later, isolated 
from porcine antral mucosa, by Gregory and his associates (74). W e now know these 
observations as being two o f the main regulatory pathways o f  gastric acid secretion, 
namely neural and hormonal. The third is the paracrine, due to local secretion o f 
histamine from mucosal mast cells and enterochromaffin cells. Histamine’s action as a 
potent stimulant to gastric acid secretion was shown by Popielski in 1920 (75).
All three o f the major pathways interact to produce and self-regulate acid output, and 
their effects have been shown to be synergistic (76). Ultimately, they act to stimulate 
production o f acid from the gastric parietal cell, and the latter possesses specific 
membrane receptors for acetyl choline (the neurotransmitter released from post-synaptic 
parasympathetic neurones in the gastric wall), gastrin, and histamine (76). In addition, 
gastrin release is itself stimulated by neuronal influences; indirectly, by vagally mediated
inhibition o f somatostatin release, another o f the gastrointestinal peptides which acts upon 
both the parietal and gastrin-producing G-cells in an inhibitory fashion; and directly, by 
release o f another peptide, bombesin (also known as gastrin releasing peptide - GRP), 
from post-synaptic neurones in the gastric antrum. Furthermore, histamine release is 
enhanced by direct action o f acetyl choline and gastrin on the mast cell (76).
As acid secretion increases in response to these stimuli, the fall in intra-luminal pH leads 
to reflex inhibition o f  further acid output. This is the result o f  acid-stimulated release o f 
somatostatin from cells in the mucosa o f the gastric antrum and duodenum, which lie in 
close proximity to G-cells, and which are directly inhibited by the peptide (76). As will be 
discussed later, it is the loss o f this inhibitory feedback mechanism, and the resultant 
chronic elevation o f circulating levels o f  gastrin that attends surgically or 
pharmacologically induced abolition o f gastric acid secretion, that may be a critical factor 
in the future development o f colorectal and other cancers.
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5. Evolution o f Surgery for Peptic Ulcer
The surgical treatment o f peptic ulcer disease initially stemmed from operations devised 
for resection o f  gastric cancer. However, as the understanding o f the physiology o f 
gastric secretion improved, new procedures were developed and others refined to 
specifically target the stimuli to gastric acid secretion.
5.1. Distal Gastric Resection (Antrectomy) - Bilroth I and Bilroth II Partial Gastrectomy. 
Gastroenterostom y and Pyloroplasty
5.1.1. Antrectomy
The first successful distal gastric resection for gastric cancer in man was performed by 
Professor Theodor Bilroth o f Vienna in 1881, with restoration o f continuity by 
gastroduodenal anastomosis (77). The procedure bears his name to the present day as the 
Bilroth I partial gastrectomy. The operation was devised in 1874 in dogs by two o f his 
students, Gussenbauer and Winiwarter (78). However, the idea o f such a procedure for 
gastric cancer pre-dates this by almost a century and is attributed to Michaelis in 1786 
(79), whose student Merrem successfully performed pylorectomy in dogs in 1810 (80). 
Its potential application to humans was decried by Langanbeck, a leading surgeon o f the 
time, and as a result no progress was to be made until its resurrection later that century 
(79). Although Bilroth is attributed with the first “successful” partial gastrectomy (his 
patient died four months later from recurrent disease), unsucessfiil attempts on humans 
had been made by others, namely Pean (France) in 1879 (81) and Rydygier (Poland) in 
1880 (82). It was the latter who first applied it successfully to a patient with peptic ulcer 
disease in 1882, in order to excise a benign pyloric ulcer (83).
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Bilroth subsequently restored gastrointestinal continuity after gastric resection by means 
o f a gastrojejunal anastomosis in 1885 and o f course this is now known as the Bilroth II, 
or Polya, partial gastrectomy. Bilroth’s assistant at that operation, Viktor von Hacker, 
reported the technique to the German Surgical Society (84). The alternative name is 
derived from Eugen Polya, a distinguished Hungarian surgeon who helped popularise 
gastric resection for peptic ulcer disease in America in the first half o f  the twentieth 
century, with the help o f other leading proponents o f the method such as Finsterer and 
Mayo (75). Despite Bilroth being credited historically with the technique, like the Bilroth 
I procedure, this form o f gastroenteric anastomosis was first applied by one o f  B ilroth’s 
associates, Wolfler, in September 1881, to bypass an obstructing and unresectable distal 
gastric tumour (85). It is said that it was in fact the first assistant at that operation, Karl 
Nicoladoni, who suggested the maneouvre to Wolfler (75).
5.1.2. Gastroenterostomy
Gastroenterostomy without gastric resection for uncomplicated chronic duodenal ulcer 
was subsequently undertaken by Codivilla in 1893, on the basis that bypassing the 
duodenum would rest the part and allow ulcer healing (86). By the end o f  the nineteenth 
century, gastroenterostomy alone was popularised by others such as Moynihan and Mayo 
and became the most commonly performed procedure for benign peptic ulcer for the first 
half o f  the twentieth century (87).
5.1.3. Pyloroplasty
The first pyloroplasty was performed by Heineke in 1881, to overcome a gastric outlet 
obstruction secondary to a large duodenal ulcer penetrating into the pancreas (87). It was 
only described in the literature some years later by one o f his students, Fronmuller, in
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1886 (88). Soon afterwards, Mikulicz described an identical procedure to allow access to 
cauterise a bleeding ulcer (89). This was in 1887, and due to the close temporal relation 
o f  these descriptions, both surgeons are immortalised by the term, Heineke-Mikulicz 
pyloroplasty. Various modifications to this procedure have been described by others, but 
it is in its original form that it was most widely performed.
As already mentioned, gastroenterostomy on its own was the most widely practiced 
surgical treatment for peptic ulcer in the United States o f  America (87). This was because 
it was a widely held view that gastric resection, more widely practised in Europe, was 
accompanied by significantly higher morbidity and mortality than the former (87). With 
time, however, it became increasingly apparent that gastroenterostomy was accompanied 
by a high incidence o f recurrent ulceration, with rates o f  30-50% quoted in some studies 
(87). Clearly, gastroenterostomy was, on its own, an inadequate treatment in effecting 
long-term cure o f  the ulcer diathesis and its popularity declined in favour o f  gastric 
resection by the mid-1930s (87). Exponents o f gastric resection also realised from 
retrospective review, and the acceptance that the antrum produced a potent acid 
secretagogue, as demonstrated by Edkins (73), that at least two-thirds gastrectomy was 
required to lead to resolution o f the ulcer and avoid recurrence (79). Furthermore, a 
higher recurrent ulcer rate after Bilroth I gastrectomy led to its relative unpopularity 
compared to Bilroth II (79). This was probably due to food-stimulated release o f 
duodenal gastrin occurring in the former, as was to be demonstrated many years later
(90). Gastric resection, with its low incidence o f  recurrent ulceration, but significant 
incidence o f side-effects, was thus established as the surgical mainstay o f  treatm ent for 
both gastric and duodenal ulcer by the middle o f the century. Its position, however, was
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soon to be challenged by the introduction o f a new approach to reduce gastric acid 
secretion.
5.2. Vagotomy
5.2.1. Truncal Vagotomy
In 1944, Lester Dragstedt and Frederick Owens from Chicago reported the effect o f 
division o f  the vagus nerves above the diaphragm on gastric secretion in two patients with 
symptomatic duodenal ulcer (91). In each case, the vagi were approached through a left 
thoracotomy with removal o f the eighth rib, and after mobilisation o f the lower ten 
centimetres o f the oesophagus, the vagal fibres were separated from it and lengths o f three 
to four centimetres excised. They observed a 70% reduction in the volume o f  nocturnal 
acid secretion in early post-operative measurements compared to pre-operative values
(91). Furthermore, the acidity o f these post-vagotomy secretions was considerably 
reduced compared to pre-operative levels, with pH values o f 2.70-2.73 and 1.25-1.50 
respectively. Similar measurements made tw o to three months later, confirmed that these 
changes were maintained. M ost importantly, both patients were rendered asymptomatic 
and no difficulty with eating or swallowing was reported after the operation. In view o f 
the small patient number and the brevity o f  the post-operative follow-up period, the 
authors cautiously concluded that although both the patients studied had appeared to 
benefit from the procedure, they could not recommend its introduction into clinical 
practice for treatment o f  duodenal ulcer.
Dragstedt had simply applied long recognised physiological knowledge in the 
development o f  his operation. Benjamin Brodie, in 1814, had demonstrated that dividing 
the vagi below the diaphragm significantly reduced gastric secretion induced by arsenic in
dogs (92). At the turn o f the century, Pavlov and co-workers demonstrated long-standing 
inhibition o f  gastric secretion by both supra- and subdiaphragmatic vagotomy in dogs 
(72,93). In the early part o f the 20th century, sub-diaphragmatic vagotomy was employed 
by a number o f clinicians, for a variety o f gastric maladies (94). Exner was probably the 
first to employ the technique in humans in 1911, for cure o f gastric symptoms o f  tabes 
dorsalis (94). Bircher reported using the technique in twenty patients in 1920 (95). Two 
years later, Latarjet reported its use in twenty-four patients, six o f whom had duodenal 
ulcer (96). He recognised that vagotomy, apart from denervating the secretory parietal 
cell mass, also led to gastric stasis and he feared that this would aggravate or induce 
ulceration in the stomach. He therefore employed a gastroenterostomy in all cases, and 
indeed attributed the success o f his procedures more to the latter than to vagal 
transection. He hypothesised that vagotomy might be used to  complement 
gastroenterostomy for the treatment o f ulcer. Several other reports o f  varying success 
with vagotomy were to follow. Dragstedt’s advocacy o f  complete division o f  all vagal 
fibres arose from his conclusion that many o f the failed operations that had been 
performed previously were the result o f incomplete vagotomy (94). His initial avoidance 
o f a complementary drainage procedure on the stomach was to ensure that the latter 
would not be attributed as the major factor in the success o f the operation, as Lataijet had 
thought. Despite his initial successes, he soon came to realise the need for an adequate 
gastric drainage procedure in conjunction with truncal vagotomy, and in order to  perform 
both, subdiaphragmatic vagotomy from an abdominal approach led largely to  the 
abandonment o f his initial intrathoracic vagotomy (94).
43
5.2.2. Selective Gastric Vagotomy
Shortly after the introduction o f  vagotomy, refinements to the procedure were advocated. 
These were prompted by the recognition o f unwanted extragastric side-effects 
accompanying the operation. Jackson (97) and Franksson (98), working in separate 
centres, questioned the need for complete transection o f all vagal fibres, which included 
those running to the hepato-biliary system and small bowel, when the sole aim was to 
denervate the stomach alone. Thus the operation o f  selective gastric vagotomy was to 
become established in clinical practice. In fact, the technique o f  selective gastric 
denervation was probably employed by the earliest proponents o f vagotomy, such as 
Bircher (95) and Latarjet (96), but it was to this incomplete form o f  vagotomy that 
Dragstedt attributed the generally poor results o f these early operations (94). Despite the 
selectivity o f denervation, all nerves to the stomach were divided, including the m otor 
branches to the antrum, and hence it soon became apparent that an accompanying 
drainage procedure was still required, just as with truncal vagotomy. Because o f  this, and 
the fact that it was technically more demanding to perform, without any convincing 
evidence o f  physiological superiority to the truncal form, it did not become universally 
popular (40,99).
For the next twenty to thirty years, vagotomy, either truncal or selective, became the most 
popular procedure for peptic ulcer. It was combined with either pyloroplasty, 
gastroenterostomy or antrectomy. The preference for the accompanying drainage 
procedure, or incorporation o f antral resection, was very much dependant on the 
mortality, morbidity and rate o f recurrent ulceration experienced by individual surgeons 
for each type o f operation.
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5.2.3. Highly Selective Vagotomy
In an effort to reduce the unwanted sequelae o f  truncal or selective vagotomy, which were 
largely the result o f the drainage procedure required to overcome gastric stasis, the next 
refinement to the procedure was conceived in 1957 by Griffiths and Harkins, who 
performed selective denervation o f the vagal fibres supplying the acid-secreting parietal 
cell mass only, preserving the hepatic, coeliac and gastric antral fibres (100). This was 
performed in ten dogs with good results (100). Such highly selective vagotomy (H.S.V.), 
also known as proximal gastric vagotomy, parietal cell vagotomy or selective proximal 
vagotomy, was performed in humans by Ferguson in 1960 (101), and Holle in 1961 (102). 
However, in each case, they combined the vagotomy with gastric resection and 
pyloroplasty respectively. The first reports o f highly selective vagotomy w ithout a 
combined drainage procedure or gastric resection were first published in 1970 by Amdrup 
& Jensen (103) and Johnston & Wilkinson (104), almost three decades after D ragstedt’s 
initial description o f vagotomy in man (91). Whilst the morbidity and mortality associated 
with this procedure was appreciably lower than with previous forms o f  anti-ulcer surgery 
(105), it was attended by a higher ulcer recurrence rate (106). Its widespread use was 
hindered by the tedious and time-consuming nature o f the surgery, as well as the technical 
expertise required to achieve good results. Ultimately, the latest modifications to the 
technique were introduced in the 1980’s, to overcome this. This comprised posterior 
truncal vagotomy combined with anterior lesser curve seromyotomy (107,108). This 
procedure has been shown to achieve similar results in terms o f  ulcer cure and post­
operative sequelae as highly selective vagotomy (109). It also avoids the rare, but 
commonly fatal, complication o f lesser curve necrosis which is peculiar to highly selective 
vagotomy, and is due to interruption o f the blood supply to the lesser curvature o f  the 
stomach during the dissection and section o f the nerve branches (105). The newer
operation avoids this by preserving all the posterior lesser curve blood vessels, since this 
area is left undisturbed at operation. Whilst the myotomy achieves compete transection o f  
all nerve branches, if performed properly it should avoid division o f  the accompanying 
blood vessels which run more deeply in the stomach wall than the nerves (107).
Finally, gastric surgery has not escaped the revolution o f laparoscopic surgery and truncal 
vagotomy (with pyloric stretch), highly selective vagotomy, and the latest techniques with 
lesser curve myotomy, as well as simple closure o f perforated ulcers in the emergency 
setting, have all been performed using minimal access techniques (110).
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6. M edical Therapy for Peptic Ulcer
Elective surgery for peptic ulcer has witnessed a tenfold decrease over the past thirty 
years (111). This, in part, is due to the decline in the natural incidence o f  the disease (37). 
However, a large proportion o f  that decrease, especially in recent years, must be 
attributed to  the rapid evolution o f  powerful anti-ulcer drugs dating from the introduction 
into clinical practice o f the first histamine receptor antagonist, cimetidine, in 1977. Prior 
to that time, the mainstays o f medical therapy before the histamine receptor antagonist era 
o f the seventies, were prescribed diets, antacids and anti-cholinergic drugs. Over recent 
years, newer, more potent antagonists o f acid secretion have been developed, including 
those with the same mode o f action as cimetidine, and others such as the proton pump 
inhibitors. Omeprazole, the first o f these proton pump inhibitors, is central to the 
experimental studies which are to be presented later. Other agents which do not affect 
gastric acid secretion in any way, but which are thought to stimulate the protective 
mechanisms o f the gastroduodenal mucosa, so-called cytoprotective agents, have also 
been introduced over this period and are widely used. The latest development in medical 
therapy for peptic ulcer has been the introduction o f specific antibacterial regimes in 
conjunction with anti-ulcer drugs to eradicate Helicobacter pylori infection in the presence 
o f peptic ulcer. A brief summary o f these drugs now follows.
6.1. Restrictive Diets
From the turn o f the century until the 1970’s, the prescription o f  bland diets for peptic 
ulcer sufferers was commonplace. The best known o f these was the Sippy diet (112). 
This consisted o f a prolonged period o f hospitalisation, sedation and bedrest, often up to 
six weeks, in combination with hourly administration o f small amounts o f food, in the
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form o f milk, cream or eggs along with “Sippy powders” which were combinations o f 
antacid salts such as sodium bicarbonate, calcium carbonate and magnesium oxide. 
Sedation was provided by administration o f phenobarbitol. Even before the advent o f 
modern therapeutic agents, the requirement for such restricted diets were questioned, and 
a number o f investigators showed there to be little difference in healing rates in patients 
taking unrestricted diets (112). The milk-based diets, based on their acid-buffering 
capacity, may have done more harm than good, and indeed milk, with its high protein 
content, actually increases gastric acid secretion (112). The impact o f  such diets on the 
risk o f cardiovascular disease also led to their condemnation.
6.2. Antacids
Antacids have been used for centuries for the treatment o f dyspeptic symptoms. John 
Abercrombie o f Edinburgh, in 1828, recommended milk for relief o f ulcer symptoms
(113), and ancient physicians reported the efficacy o f crushed coral (calcium carbonate) in 
patients with dyspepsia, as long ago as the 1st century A.D. (43). Even now, their 
widespread availability as “over-the-counter” formulations, with patients treating their 
dyspeptic symptoms themselves, causes some concern that in a proportion o f  such cases, 
more sinister upper gastrointestinal lesions are escaping early diagnosis.
The commonest formulations in present day use are oxide and hydroxide salts o f 
aluminium and magnesium, or combinations thereof. The basis o f  antacid therapy was, 
until recently, to administer enough o f the compound to buffer all free acid in the stomach 
(41,45). As gastric secretion is a continual process, albeit with meal-stimulated peaks, 
this results in a regime o f  frequently repeated daily doses result in large total doses, up to 
1,000 millimoles per day. Maximal buffering capacity o f meal-stimulated acid is achieved 
if the antacid is taken approximately thirty minutes after food, with continued action for
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up to two to three hours thereafter (114). However, recent studies have shown that low 
dose antacid therapy, that is, o f 120millimoles per day, has comparable healing rates to  the 
traditional regimes (41,46,114). This calls into question whether their action is purely the 
result o f  neutralisation o f  acid. This dose is clearly inadequate to buffer the acid produced 
over a twenty-four hour period, and it is suggested that cytoprotective effects such as 
stimulation o f prostaglandin release, mucus and bicarbonate secretion, mucosal 
regeneration and mucosal blood flow, may be the mechanism responsible for this 
protection (45). Such low dose regimes will reduce the side-effects commonly seen in up 
to 60% o f patients with the more traditional schedules, and include constipation with 
aluminium salts and diarrhoea with magnesium(41). Hypophosphateaemia may also occur 
with aluminium compounds, due to formation o f insoluble precipitates in the gut, with 
resultant symptoms o f fatigue, anorexia and skeletal pain (114). Both aluminium and 
magnesium are absorbed as chloride salts, and toxicity may occur in the patient with 
chronic renal failure (41,114). Even in health, there are concerns as to the effect o f  tissue 
deposition o f  aluminium in prolonged therapy, as a contributor to osteoporosis and 
osteomalacia, and possibly Alzheimer’s disease (46).
Calcium carbonate and sodium bicarbonate have also been used for their ability to buffer 
gastric acid secretion, but they have fallen from favour for a number o f  reasons. Sodium 
bicarbonate is highly soluble, hence apart from having a short duration o f action, it is also 
promptly absorbed from the small intestine and repeated dosage may result in a metabolic 
alkalosis, especially in the renally impaired (45,114). Calcium carbonate is not 
recommended due to the significant absorption o f calcium that occurs and which may lead 
to the symptoms o f hypercalcaemia, with precipitation o f  renal stones (45). Indeed, 
excessive dosing with combinations o f these two agents can lead to the potentially 
dangerous milk-alkali syndrome, characterised by metabolic alkalosis and transient renal
49
insufficiency (112,114). In most cases, normality resumes with discontinuation o f 
therapy, but in some cases, a more chronic form o f the syndrome ensues. This is 
characterised by hypercalcaemia with bone pain, anorexia and metastatic deposition o f 
calcium in soft tissues such as the eye. A further reason to avoid calcium-containing 
antacid formulations is that residual calcium left after acid neutralisation has occurred 
actually stimulates gastric acid secretion, possibly by increasing gastrin release and also by 
a more direct action on the parietal cell. This is known as the “acid-rebound” effect (45).
6.3. Anticholinergic drugs
Such agents act by blocking the M l muscarinic acetyl choline receptors on the parietal cell 
to abolish vagally stimulated acid secretion. However, their absorption is low and erratic, 
and they reduce both basal and meal-stimulated acid secretion only by about 30 to  50%
(41,114). The classical “atropine-like” agents, such as propantheline, hyoscine and 
butylscopolamine, act on both types o f muscarinic receptors, M l and M2, and at 
therapeutic doses, this results in a number o f  troublesome side effects such as dry mouth, 
blurred vision, tachycardia, constipation and urinary retention (41). Newer selective M l 
receptor antagonists, pirenzepine and telenzepine, have been developed, but like their 
forebears, have no advantage over the new types o f anti-secretory agent available, and as 
such, the use o f  anticholinergic drugs in peptic ulcer disease is largely now o f historical 
interest only.
6.4. Carbenoxolone
For the purpose o f completeness, mention must be made o f this compound derived from 
liquorice, which was used briefly in the 1970’s in the treatment o f  gastric, and to a lesser 
extent, duodenal ulcers. It has no activity against acid secretion and exerts a
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cytoprotective effect, possibly by reducing prostaglandin breakdown in the mucosa
(41,114). Its side effects stem from its corticosteroid-like activity, leading to  salt and fluid 
retention and hypokalaemia, which may precipitate or exacerbate congestive heart failure 
in susceptible individuals. For this reason and its lack o f  obvious benefits over other 
agents, its vogue was shortlived.
6.5. Fb-Histamine Receptor Antagonists
When Sir Andrew Watt Kay, in 1953, described the augmented histamine stimulation test 
for the purposes o f investigating gastric acid output, he observed that histamine’s 
secretory action, and the associated facial flushing which occured with its administration, 
were not abolished by the administration o f the standard antihistamine type drugs available 
at the time (115). In 1966, Ash and Schild showed that histamine acted on more than one 
form o f receptor (116), and this prompted an intensive search for novel drugs capable o f 
blocking these so-named H 2 receptors. By 1972, three such agents had been developed 
and tested on both animals and humans, by Sir James Black and his team at the Smith- 
Kline & French laboratories (117). Their rapid, sustained and marked inhibition o f  
maximally stimulated acid secretion, assessed by administering pentagastrin to a Zollinger- 
Ellison patient with pre-existing supernormal basal levels, was profound (118). The 
extremely low incidence o f side effects was also a prominent feature. O f these original 
three compounds, cimetidine was found to be the most potent with the highest safety 
profile and was subsequently introduced to the market in 1976. It is still one o f  the most 
commonly used agents in its class today.
Since then, the group has expanded with the subsequent introduction o f  ranitidine, 
famotidine, nizatidine and roxatidine, which on a dose equivalent basis, are more potent 
than cimetidine (46). Apart from the smaller dose requirements which stems from this, the
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superiority o f the newer agents compared with cimetidine is questionable and at best 
modest (41,46).
The H2 receptor antagonists competitively inhibit such receptors on the gastric parietal 
cell. Because o f  the synergy between the three main stimulatory pathways o f  acid 
secretion, they also significantly reduce vagal and gastrin stimulated acid secretion. They 
therefore inhibit up to 90% o f daily acid output, but do not abolish meal-stimulated peaks
(114). The realisation that ulcer healing rates were positively correlated with reduction o f 
nocturnal acid output rather than daytime or total daily output is evidence that the 
persistence o f meal-stimulated acid output while being treated with such agents does not 
detract from their efficacy (45). Indeed, such observations have led to alterations in the 
dosing schedules o f such agents, from three or four divided doses daily to single nocturnal 
or twice daily dosing. Ulcer healing rates on these agents are o f  the order o f  75% and 
95% at four and eight weeks respectively, for duodenal ulcer. Healing rates for gastric 
ulcer are slightly lower at approximately 60% and 85% at four and eight weeks 
respectively (45). These drugs have an excellent safety profile with less than 3% o f 
patients reporting adverse effects (45), which include minor gastrointestinal and central 
nervous system disturbances, such as diarrhoea, nausea, headache and drowsiness. 
Gynaecomastia and impotence are rare but well known side effects o f  cimetidine, and are 
due to an anti-androgenic action o f  the drug with displacement o f  dihydrotestosterone 
from peripheral receptors (45).
The significant medical advance that Black’s discovery produced was recognised by his 
peers, being awarded the Nobel prize in 1988 for his work. Despite the introduction o f  an 
even more powerful class o f gastric acid inhibitor since his discovery, the place o f  H2 
receptor antagonists in the treatment o f peptic ulcer disease seems assured at the present 
time.
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6.6. Proton Pump Inhibitors
The final common pathway by which hydrogen ions are secreted from the parietal cell in 
response to vagal, gastrin and histamine mediated stimulation, occurs at a cell membrane 
enzyme, Hydrogen Potassium Adenosine Triphosphatase, also known as the proton pump 
(41). When active, it excretes a hydrogen ion in exchange for a potassium. It is abundant 
on the invaginated cell surface that forms the secretory canaliculus on the mucosal surface 
o f  the parietal cell. It is by the selective and irreversible inhibition o f this enzyme that the 
latest class o f acid inhibitory drugs exert their powerful action.
The first o f these agents, omeprazole, became available for clinical use in the late 1980’s. 
It is in fact an inactive pro-drug, and as a weak base, is rapidly degraded in the stomach 
unless administered with a protective enteric coating. Intestinal absorption is rapid and 
the drug distributes widely throughout the body, initially to the extracellular space (45). It 
ultimately diffuses through the parietal cell to reach the acidic milieu o f  the secretory 
canaliculus, and within four hours o f dosing, it has been demonstrated that the majority o f 
the administered drug comes to be concentrated in this area (41). Here, it becomes 
protonated, which prevents the drug from passing through the mucus surface barrier into 
the lumen o f the stomach. High concentrations o f the drug accumulate in the canaliculus 
as a result. Protonation also leads to a configurational change in the molecule to its active 
sulphenamide form, and it binds irreversibly to the H+/K+ ATPase enzyme by covalent 
disulphide bonds (41). As a result, enzymatic activity only returns when sufficient new 
enzyme is synthesised and it is for this reason that the action o f the proton pump inhibitors 
is so marked and prolonged. Hence, complete abolition o f total daily gastric acid output 
is achieved with once daily dosing o f sufficient strength, and unlike the H2 receptor 
antagonists, meal stimulated acid peaks are also abolished (41). Rapid healing o f  ulcers 
ensues, with rates at two and four weeks comparable to those achieved by H 2 antagonists
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at four and eight weeks (114). Due to its administration as a pro-drug, and rapid and 
almost complete convergence at its site o f action, its adverse reaction profile is minimal. 
Omeprazole does however interact with certain members o f the drug-metabolising family 
o f  cytochrome P450 enzymes, situated predominantly in the liver (as do the H 2 
antagonists) and this can lead to potentiation o f effects o f  drugs such as phenytoin and 
warfarin, if administered concurrently (114). As will be discussed later, this action may 
also be important when considering a possible protective role in the development o f 
experimental colonic tumours, which constitutes a large portion o f  the study in this thesis. 
O f more concern are the potential sequelae o f the physiological changes which accompany 
the profound and complete acid suppression afforded by these agents, and this too will be 
discussed in more detail later in this chapter.
6.7. Cvtoprotective Agents
With the growing realisation o f  the significance o f mucosal defence mechanisms in the 
pathophysiology o f peptic ulcer, a number o f drugs which do not exert any action on acid 
secretion have also become established in the past twenty years.
6.7.1. Sucralfate (41.45.46.114)
This compound is a complex sugar molecule with bound aluminium hydroxide residues. 
In the presence o f  acid, the aluminium hydroxide dissociates, leaving negatively charged 
sulphate groups which bind electrostatically to proteins and mucins on the ulcer base. 
This binding is thought to inhibit penetration o f aggressors such as acid, pepsin and bile 
salts. It is possible that it further enhances mucosal protection by stimulating 
prostaglandin synthesis, mucus and bicarbonate secretion, and exerting a trophic effect on 
gastric mucosa. Very little o f the drug is absorbed, most o f  an oral dose subsequently
54
being recovered in the faeces, and as such is virtually devoid o f side-effects. Similar rates 
o f ulcer healing to those with H2 antagonists have been shown.
6.7.2. Bismuth (41.45.46.114)
Bismuth-containing compounds, such as colloidal bismuth subcitrate and bismuth 
subsalicylate, have been used to treat peptic ulcer since the mid-1970’s. In the presence 
o f acid, crystals o f bismuth oxychloride and bismuth citrate precipitate out o f  solution and 
bind preferentially to the base o f ulcer craters, producing an impenetratable barrier to 
further damage from luminal acid and pepsin. They also stimulate prostaglandin synthesis 
and bicarbonate secretion in the mucosa. One further striking feature o f  the drug is its 
ability to eradicate Helicobacter pylori in up to 30% o f cases, and ulcer recurrence rates 
after treatment are significantly lower than with H2 antagonists. Part o f  its success in 
healing peptic ulcer may be due to this antibacterial action, by inhibition o f its urease 
enzyme and death o f individual organisms due to coating with bismuth salts (51). As with 
sucralfate, systemic absorption is minimal and reports o f adverse effects are low, though 
blackening o f the tongue and darkening o f the faeces are commonly seen with treatment 
and patients should be warned to expect this.
6.7.3. Prostaglandin Analogues (41.45.46.114)
A number o f  synthetic prostaglandins have been manufactured for use in peptic ulcer 
disease, in an attempt to confer the protective effects o f their natural derivatives upon the 
gastroduodenal mucosa. O f these, misoprostil has been licensed for use in most countries, 
including Great Britain and North America. They increase mucosal bicarbonate and 
mucus production, enhance mucosal blood flow and exert a small, but direct, inhibition o f 
gastric acid secretion. Even at therapeutic doses, they do produce troublesome side
55
effects such as diarrhoea and abdominal pain. In view o f this, and because o f  their 
absence o f obvious benefits over the other commonly used anti-ulcer drugs, they are not 
widely used as first line therapy in peptic ulcer disease. Their commonest indication for 
use is as prophylaxis against NSAID-induced ulceration, and indeed are to be found 
combined with such agents as single formulations, for instance Arthrotec, which is 
misoprostil combined with diclofenac.
6.8. Therapy aimed at eradication o f Helicobacter pylori (51)
In the past few years, with the recognition o f the dramatic reduction in ulcer recurrence 
rates that accompany successful eradication o f  Helicobacter pylori, a multitude o f  drug 
regimes have been studied in an attempt to identify the most effective at attaining this 
ideal. Initially, single agent therapy, using either bismuth formulations alone, or single 
antibiotic agents, was tried. It soon became apparent that no significant impact on ulcer 
recurrence was achieved by such monotherapy, and recrudescence o f  infection occurred 
frequently. Helicobacter also soon developed resistance to many o f the antibiotics to 
which it was initially shown to be sensitive in vitro. Attempts at dual therapy, either with 
bismuth or an acid secretory inhibitor in combination with an antibiotic, or double 
antibiotic therapy alone, were, with few exceptions, also disappointing, and development 
o f antibiotic resistance was still a common feature. This ultimately led to triple therapy 
regimes, and in view o f the high success rates achieved with them, they are now the 
recommended form o f therapy to heal ulcers, eradicate Helicobacter infection, and thus 
significantly reduce ulcer recurrence. A number o f  combinations have shown to be 
equally efficacious, and usually consist o f either bismuth, an H2 antagonist, or a proton 
pump inhibitor, in combination with amoxycillin or clarithromycin and metronidazole. 
Such regimes achieve 80 to 100% eradication o f the organism (41,51), and resultant
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recurrence rates o f approximately 20% as compared to around 90% or more, with single 
agent acid reduction therapy (41,52,59).
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7. Effect of Gastric Surgery and Drug Therapy on Gastrointestinal Physiology
A number o f  pathophysiological changes occur in response to ulcer treatment and are 
presented below. It is these changes that may be the cause o f the described association 
between such treatment and subsequent cancer development in the gastrointestinal tract.
7.1. Inhibition o f Gastric Acid Secretion
It is clear from the foregoing that the commonest and indeed, the desired, physiological 
change that accompanies most forms o f surgical or medical treatment for peptic ulcer is a 
reduction in the “normal” amount o f gastric acid produced. Dependant on the nature o f 
surgery performed or degree o f pharmacological acid inhibition achieved, this may result 
in partial acid reduction - hypochlorhydria ; or complete abolition o f  its secretion - 
achlorhydria. Clearly, this does not apply to treatment with agents that have no inhibitory 
effect on gastric acid production, nor to operations that do not significantly interfere with 
the acid-secreting parietal cell mass or its stimulatory influences.
The extent to which various surgical procedures reduce acid output have been widely 
studied in patients. Two parameters are usually measured, basal and maximal acid output. 
Basal acid output (BAO) measures the amount o f acid secreted whilst the stomach is in 
the fasting state, whereas maximal acid output (MAO) is that occurring in response to 
parenteral administration o f a potent secretagogue, either histamine or pentagastrin. 
Pentagastrin is a synthetic analogue o f gastrin, consisting o f the five amino acids chain 
peptide present at the C-terminus o f the natural hormone which confers its physiological 
activity. Both BAO and MAO are usually expressed as milliequivalents per hour, as the 
acid present in the collected gastric aspirate is indirectly measured by titration with a 
strong alkali such as sodium hydroxide until neutral pH is reached.
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As one might expect, neither gastroenterostomy nor pyloroplasty, when performed alone, 
significantly alter the acid output o f  the stomach (119,120). On the other hand, 
antrectomy resulted in a mean reduction o f acid output o f 82% from pre-operative levels 
in one study o f forty-nine patients (121). Professor Kay’s observed value in 
gastrectomised individuals was slightly lower at 70% (122). Broome and colleagues 
observed a mean 50% reduction in maximal acid output in thirteen post-antrectomy 
subjects (123).
Truncal vagotomy and drainage procedures have been shown to reduce acid secretion to  a 
similar degree to partial gastrectomy. Measured reductions o f acid output for vagotomy 
and gastroenterostomy include a mean o f 68.4% and an 80% reduction in M AO in 
response to histamine (121,124). Similar results are achieved with vagotomy and 
pyloroplasty. For example, 78% and 64% reductions occured in basal and maximal 
output respectively, in one study (125), and 67% and 78% decrease in these parameters in 
another (126). The type o f vagotomy performed, whether truncal, selective or proximal, 
do not have quantitively different effects on the degree o f acid reduction obtained (127- 
129). In their presentation o f  twenty-five patients treated by highly selective vagotomy, 
Johnston and Wilkinson observed maximal acid output to be reduced by 70% (104).
As one may have predicted, the combination o f  antrectomy with vagotomy and hence 
removal o f  the two main stimuli to gastric secretion, cause even greater acid reduction. 
Over 90% decreases in both BAO and MAO from pre-operative values have been 
demonstrated in one study and 76% and 85% respectively, in another (126). 
Furthermore, the magnitude o f  acid reduction was increased by a further 33% after the 
addition o f  vagotomy in Broome’s thirteen previously antrectomised patients (123). N ot 
surprisingly, this form o f surgery is associated with the lowest disease recurrence rate o f
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all the classical peptic ulcer operations, with quoted figures o f 2% or less in most series 
(40).
Medical therapy with histamine receptor antagonists results in up to 90% reduction in 
total 24-hour acid output in a linear dose dependant fashion (45). Complete inhibition is 
not seen, and in particular, daytime meal-stimulated peaks o f  secretion still occur (45). 
The proton pump inhibitors, such as omeprazole, however, are capable o f  rendering the 
patient completely achlorhydric, even by once daily pharmacological dosage (45).
A number o f  pathophysiological sequelae occur as a result o f  iatrogenic hypochlorhydria. 
That which has attracted much interest, for reasons that will be discussed fully later, is the 
uninhibited secretion o f gastrin into the circulation, due to loss o f  the negative feedback 
mechanism already described. Serum gastrin levels have been measured for all the main 
types o f  ulcer operation in concert with acid secretion, in most o f the studies quoted 
above.
7.2. Effect on Circulating Gastrin Levels
Although both antrectomy and vagotomy result in similar degrees o f hypochlorhydria, the 
post-operative gastrin concentrations differ markedly. Resection o f the antrum is 
performed to abolish gastrin-stimulated acid secretion, by removing the main source o f  
that stimulus. As a result, gastrin concentrations after distal gastrectomy either drop or 
remain unchanged from normal physiological values as measured pre-operatively. For 
instance, McGuigan observed a 77% reduction in mean fasting gastrin levels from 114 
pg/ml to 26 pg/ml in four patients who underwent antrectomy in addition to vagotomy 
(125). W hether these patients underwent Bilroth I or Bilroth II anastomosis was not 
specified. In another study o f  seven patients examined before and after antrectomy with 
Bilroth I anastomosis, mean fasting gastrin values were slightly less post-operatively, at
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128 and 109 pg/ml respectively (126). Circulating gastrin is not completely abolished by 
antrectomy as G-cells in the proximal duodenum continue to secrete the hormone, albeit 
to a lesser extent than the gastric antrum. This was demonstrated by Stern and Walsh 
who observed that patients who had undergone Bilroth I antrectomy, where continuity is 
restored by gastro-duodenal anastomosis, had meal stimulated release o f  gastrin due to the 
presence o f food entering the duodenum (90). This response to food was not seen in 
patients with a Bilroth II anastomosis, where no food enters the defunctioned duodenum 
but empties further down the small bowel via the gastrojejunostomy. For the same reason, 
basal gastrin values after the Bilroth I procedure were modestly and insignificantly 
reduced compared to pre-operative levels whereas the Bilroth II patients had significant 
reductions in these measurements. This probably explains the differing magnitude o f  the 
reduced gastrin levels seen between the first two studies quoted above.
Vagotomy without any concomitant gastric resection causes elevation o f circulating 
gastrin concentrations, due to the G-cells o f the intact antrum being continually stimulated 
to secrete hormone in response to the persistently elevated luminal pH to which they are 
exposed. M ost measurements have been performed on subjects having undergone 
vagotomy with pyloroplasty as the drainage procedure. McGuigan and Trudeau (125) 
observed an increase in mean basal values from 98 to 123 pg/ml, which was not 
statistically significant, but most other studies have shown the elevation to be significant, 
with increase from pre-operative values o f 29% (126), 98% (130), 137% (90), 435% 
(131), and even 800% (131) in one group o f patients. The nature o f the vagotomy, 
whether truncal, selective or highly selective, all have the same effect o f  increasing 
circulating gastrin (132,133).
Gastric acid suppression by histamine receptor antagonists or proton pump inhibitors also 
result in elevation o f gastrin levels. Twenty-four hour profiles o f  intragastric acidity and
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plasma gastrin concentrations for all the available histamine receptor antagonists and 
proton pump inhibitors have been measured in humans, and all show a consistent elevation 
in mean gastrin levels compared to pre-treatment values (134). Gastrin concentrations 
have an inverse linear relationship to the degree o f acid inhibition, which in turn varies 
directly in a dose dependant fashion to the amount, and potency, o f the drug administered 
(134). Thus, the increase in gastrin levels is modest with the standard doses o f  histamine 
receptor blockers, for instance, approximately 25% increase with cimetidine 800 mgs 
nocte and ranitidine 150 mgs nocte, but in excess o f 300% with Omeprazole 20 mgs once 
daily (134).
7.3. Effect on the Bacterial Population o f the Upper Gastrointestinal Tract
A nother consequence o f reduced or absent gastric acid secretion is bacterial colonisation 
o f the stomach and upper small intestine. Acid reduction by whatever means, surgical, 
medical, or secondary to disease such as atrophic gastritis, leads to the survival and 
proliferation o f swallowed bacterial organisms from the oropharynx and nasopharynx, 
which are normally destroyed in the acidic gastric milieu (135-137). “Faecal” organisms 
such as faecal streptococci, faecal bacteroides, enterobacteriae and klebsiellae, normally 
found in the colon, are also encountered in the stomach in such conditions. Significantly 
increased amounts o f  bacteria have been recovered from gastric aspirates after even short 
periods o f acid suppression (138-141). The potential pathological consequences o f this 
will be discussed later.
7.4. Sequelae peculiar to Gastric Surgery - the Postgastrectomy Syndromes
A number o f  clinico-pathological entities occuring after ulcer surgery are well recognised. 
For the  purpose o f completeness, they are briefly summarised in the following pages.
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Although not confined to gastric resection procedures alone, they are commonly referred 
to as the postgastrectomy syndromes. They occur in approximately 20% o f  all operated 
patients to a varying degree and fortunately most cases are mild, self-limiting and transient 
(111). O f those that are not, the majority will respond to simple dietary manipulation and 
hence only a minority o f  patients are sufficiently disabled to require some form o f 
revisional surgery (111). These syndromes occur as a result o f  interference with the 
normal motor function o f the stomach and alteration in its rate o f emptying. In normality, 
two vagally mediated reflex mechanisms occur to increase the reservoir capacity o f  the 
stomach (111). The first o f these is receptive relaxation o f the proximal stomach in 
response to swallowing, and further relaxation and distension o f  the stomach occurs as 
food accumulates within it. The latter is known as accomodation. Thereafter, the ingesta 
is reduced into small amounts o f semi-digested foodstuffs (chyme) by peristaltic waves in 
the stomach wall. This is then expelled in metered amounts onwards into the duodenum 
for further digestion. An anatomically and physiologically normal pylorus is a pre­
requisite for this and it is evident that, with the exception o f  highly selective vagotomy, 
this is disrupted or bypassed by the operations devised for peptic ulcer.
7.4.1. Dumping (111.142.1431
This syndrome has been long recognised and indeed the term “dumping” was coined by 
Mix in 1922, who observed the rapidity with which radiological contrast passed from the 
stomach to the small intestine, through a gastroenterostomy stoma (144). The arrival o f  a 
large amount o f hyperosmolar contents into the proximal small bowel leads to its 
distension with reflex increase in its activity. There also occurs the release o f  a variety o f 
vasoactive peptides from the gut, for instance, serotonin and vasoactive intestinal peptide 
(VIP). Furthermore, an extracellular fluid shift into the lumen o f  the intestine with a
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corresponding decrease in the circulating intravascular volume ensues. These responses 
result in a variety o f  vasomotor and gastrointestinal symptoms. These include sweating, 
acute weakness, flushing and palpitations in combination with nausea, abdominal cramps 
and profuse diarrhoea. Such symptoms usually occur within half to one hour o f  ingestion 
o f  a meal and affected individuals can avoid their onset by altering their eating pattern to 
eating smaller, more frequent, less carbohydrate-rich meals, a short period o f  recumbency, 
and liberal fluid intake after eating.
7.4.2. Post-Prandial Hvpoglvcaemia (Late Dumping) (111.142.143)
This problem is often referred to as “late dumping”, to differentiate it from true “early” 
dumping, but it is best labelled as above as it is causally and temporally distinct from the 
latter. As a result o f an excessive carbohydrate load being delivered to the small bowel, 
there occurs release o f enteroglucagon, which in turn sensitizes the insulin-secreting 15- 
cells o f  the pancreatic islets to respond to the excessive carbohydrate load being absorbed. 
The insulin response is more than sufficient to  redistribute it to intracellular sites, either 
for storage as glycogen in hepatocytes, or for metabolism in active organs, and a relative 
hyperinsulinaemia ensues. This results in symptomatic hypoglycaemia, manifesting 
clinically with acute lethargy, sweating, tremor, confusion and in some cases, collapse. 
The similarity o f the symptoms to those occuring in the dumping syndrome have led to  its 
alternative label; the “lateness” o f their onset referring to the fact that they usually occur 
some three to four hours post-prandially. Unlike the dumping syndrome, gastrointestinal 
symptoms are not a feature. Once again, alteration in dietary habits is the mainstay o f 
treatment, with avoidance o f excessive amounts o f carbohydrate-rich food, and educating 
affected individuals to recognise symptoms early in their onset, so that hypoglycaemia can 
be avoided by self-administration o f a glucose-rich snack or drink.
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7.4.3. Post-Vagotom v Diarrhoea 011.142.143)
For reasons similar to those in the dumping syndrome, namely the fast delivery o f 
hyperosmolar contents to the small bowel, and the resultant intra-luminal fluid shift that 
occurs in response to it, this can manifest itself as an increase in the frequency o f  bowel 
habit, with the passage o f loose, watery motions. As a result, this can be reported after 
either partial gastrectomy or vagotomy, but a distinctive form is recognised after the 
latter, hence the term “post-vagotomy” diarrhoea. It can be distinguished from the 
diarrhoea that accompanies dumping in that the latter only occurs in response to  a meal 
and is usually accompanied by other symptoms o f the syndrome. Post-vagotom y 
diarrhoea is unrelated to eating, is often episodic and can result in the passage o f up to 
twenty or more loose stools in a day. Its exact atiology remains unknown but denervation 
o f  the gut and biliary tract, as occurs in truncal vagotomy, but not the more selective 
forms o f the procedure, is thought to play a role in its pathophysiology.
7.4.4. Alkaline Reflux Gastritis (111.142.143)
The formation o f a non-anatomical communication between the stomach and intestine, as 
is the case in gastrojejunal anastomosis, is inevitably associated with the regurgitation o f  
enteric contents into the stomach, to a varying degree. Even loss o f the normal pyloric 
sphincter mechanism, as occurs in pyloroplasty, leads to increased retrograde passage o f  
bile and pancreatico-duodenal secretions into the stomach. In most cases, such reflux is 
asymptomatic, though the alkaline fluid is irritant to the gastric mucosa and sub-clinical 
gastritis occurs in most patients. The gastritis may manifest itself clinically with dyspeptic 
symptoms similar to those for which the patient was treated in the first place. In severe 
cases, distressing bile vomiting occurs. A number o f such cases may be the result o f  
surgical inattention, due either to an excessively large stoma, or one created at a non­
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dependant position, too high on the greater curvature o f the stomach. The large majority 
o f  cases,however, occur in the absence o f any identifiable surgical cause. Symptomatic 
control may be attempted with administration o f cytoprotective drugs such as sucralfate 
or agents which bind bile salts, such as cholestyramine, but a minority o f  troublesome 
cases may require some form o f revisional surgery, designed to transfer the flow o f  bile 
away from the stomach. These will be described shortly, as a few patients in the clinical 
study have undergone such procedures.
7.4.5. Small Stomach Syndrome (111.142.143)
This can be seen after gastric resection, where the natural reservoir function o f  the 
stomach is altered, simply by a decrease in the volume o f the viscus. However, it is more 
common after vagotomy without gastric resection, and is the result o f  gastric atony 
consequent upon denervation o f the gastric musculature. This abolishes the normal 
physiological responses o f  the stomach described earlier, to distend in response to food 
and to  empty its contents distally in a graded fashion. Clinically, such patients complain o f 
early satiety during meals and vomiting o f  foodstuffs shortly after their ingestion. As with 
dumping, re-education o f  the patient’s eating regime is the usual treatment, advising the 
intake o f  small, but frequent meals.
A number o f other syndromes are associated with specific types o f  surgery.
7.4.6. Afferent Loop Syndrome and Blind Loop Syndrome (111)
This occurs in a minority o f  patients who possess a gastroenterostomy stoma, whether or 
not fashioned to an intact or antrectomised stomach. Narrowing o f the afferent loop o f  
jejunum at the stoma, usually the result o f kinking or twisting, leads to the build-up o f  
biliary, pancreatic and enteric secretions proximal to the obstruction. Intermittently, this
partial obstruction is overcome, either once the volume and pressure in the loop reach a 
critical level, or patient movement results in temporary unkinking o f  the bowel. This 
sequence o f  events is manifest clinically by intermittent episodes o f  worsening, crampy 
epigastric pain which is relieved completely by an episode o f  profuse bile vomiting. 
Treatment is usually by surgery, to overcome the site o f obstruction (see later). Afferent 
loop syndrome may be further complicated by “blind loop” syndrome, where stasis in the 
obstructed afferent limb results in bacterial overgrowth with deconjugation o f  bile acids 
and resultant fat malabsorption and steatorrhoea
7.4.7. Efferent Loop Syndrome (111)
Mechanical obstruction o f the distal limb can also occur at or near the gastro-enteric 
anastomosis. Symptoms may be similar to those o f afferent loop obstruction and contrast 
radiology may be required to differentiate the two. Treatment is surgical but may vary, 
dependant on the cause o f obstruction found, from division o f adhesions to reconstruction 
o f the gastroenterostomy.
7.5. Remedial Surgery for Postgastrectomy Syndromes
A brief mention should be made o f the surgical maneouvres employed in an attempt to 
correct the above problems, as a minority o f  the clinical study cohort have undergone such 
procedures. The commonest o f  these is creation o f a Roux-en-Y gastroenterostomy, most 
often used to overcome troublesome symptoms o f bile reflux through a gastroenterostomy 
stoma. The afferent limb o f the gastroenterostomy stoma is divided where it meets the 
stomach and then sutured end-to-side to the small bowel at a distance o f  40 to 60 
centimetres from the gastroenterostomy. This diverts hepato-biliary secretions away from 
the stomach. It is also employed for afferent loop syndrome and severe dumping. Its
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success in the latter problem is due to alterations in the neuro-muscular activity o f  the 
efferent limb which occur as a result o f jejunal transection during construction o f  the Roux 
loop (111,142). Contractions which normally propogate from the duodenum and 
proximal jejunum distally, are prevented from travelling to the efferent limb. In addition, 
ectopic contractions also occur and travel proximally towards the stomach. The 
combined result is slowed gastric emptying and propulsion o f chyme in the efferent limb. 
Unfortunately, this may itself result in the Roux stasis syndrome with symptoms secondary 
to markedly reduced or absent gastric emptying which necessitate take-down o f  the loop. 
Nine o f  the patients in the cohort studied in this thesis also went on to have a jejunal 
interposition whereby a short (10cm) segment o f  proximal jejunum is sutured 
isoperistaltically between the gastric outlet and duodenum in an attempt to slow gastric 
emptying and relieve the symptoms o f dumping.
7.6. Nutritional Sequelae o f Gastric Surgery
Gastrectomised patients have long been recognised to suffer from varying degrees o f  
malnutrition and malabsorption with resultant weight loss (143). M uch o f  this may be 
simply the result o f reduced dietary intake owing to symptoms induced by the surgery 
itself, such as early satiety. Reduction in dietary intake may also occur in the unfortunate 
patient who does so deliberately to avoid the onset o f  symptoms o f one o f  the 
postgastrectomy syndromes. Decreased absorption o f  nutrients may result from a number 
o f post-operative factors, including the rapid delivery o f large food boluses to the small 
intestine, poor mixing o f  these with the digestive secretions o f the upper gastrointestinal 
tract, delayed or reduced pancreatico-biliary secretion secondary to  denervation by truncal 
vagotomy, bacterial colonisation o f the proximal small bowel and increased small bowel 
transit. M ore specific nutritional defects, described below, are also seen.
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7.6.1. Anaemia
Iron deficiency anaemia has long been recognised to be a common late sequel to partial 
gastrectomy (145-147). A significantly high incidence (43.5%) was also seen in 255 
patients reviewed 15 years after vagotomy and gastroenterostomy (148). Although some 
cases will reflect a generally inadequate dietary intake, it is known that most dietary iron is 
in the ferric form, which is poorly dissociated from food in the absence o f  acid, and also 
more poorly absorbed than when in the ferrous state (149). Such conversion is normally 
accomodated in the acid milieu o f the stomach, which is, o f course, lost or markedly 
reduced after surgery for peptic ulcer.
Megaloblastic anaemia secondary to malabsorption o f  vitamin B12, can occur where there 
has been excessive resection o f the parietal cell mass o f the stomach (150). The latter is 
the site o f  production o f Intrinsic Factor, a glycoprotein which binds the vitamin and 
allows its absorption by receptor-mediated endocytosis through the mucosa o f  the distal 
small bowel (151).
7.6.2. Osteomalacia
Reduced mineral bone mass has been demonstrated in up to 25% o f gastrectomised 
subjects and is secondary to decreased absorption o f  calcium and vitamin D (152,153). 
Calcium is solubilised in the presence o f acid to allow optimum absorption and absorption 
o f vitamin D may suffer as a result o f fat malabsorption (154).
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7.7. Other documented sequelae o f Peptic Ulcer Surgery
1.1.1. Cholelithiasis following Truncal Vagotomy
Truncal vagotomy not only denervates the stomach, but also transects the 
parasympathetic supply to the liver, biliary tree, pancreas, small bowel and proximal half 
o f the colon. The recognition that the incidence o f post-vagotomy diarrhoea is 
significantly less with the more specific forms o f  gastric vagotomy is strongly suggestive 
that denervation o f  these extra-gastric sites plays an important role in its aetiology (111). 
Distension and decreased contractility o f the gallbladder has been observed in humans 
after truncal vagotomy (155-157). This in turn may be partly responsible for the reported 
increased incidence o f gallstones following truncal vagotomy (158,159), secondary to 
biliary stasis. Increased lithogenicity o f bile due to a reduction in bile salts is also seen 
after vagotomy and this may be equally, if not more, important in this phenomenon 
(160,161).
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8. The Association between Ulcer Surgery and Development of M alignancy, with  
particular reference to Colorectal Cancer
The last o f the recognised sequelae o f peptic ulcer surgery has been one o f  the most 
widely studied post-surgical phenomena in the past forty years; the development o f 
malignant disease in the years following surgery for benign peptic ulcer. This is at the 
core o f the work to be presented in this thesis and a review o f the many previous studies 
follows.
Since Balfour, in 1922 (162) and Beatson, in 1926 (163) described carcinoma in the post- 
surgical stomach, there have been a plethora o f reports regarding this phenomenon in the 
worldwide medical literature. Until the 1950’s this was thought to be a relatively rare 
occurrence when the paucity o f reported cases was reviewed (164). Since then however, 
the number o f reported cases has become more frequent. Studies began comparing the 
observed disease rates with expected values derived from the general population or from 
the numbers seen in control groups such as forensic autopsy subjects. M ost o f  these 
studies reported statistically significant excess numbers o f  gastric cancers in patients 
previously having undergone surgery for peptic ulcer disease. The number o f  studies o f  a 
similar nature have flourished in the literature to the present day. The vast majority o f 
studies have concentrated on gastric cancer, which is perhaps not surprising as the 
patients under study have initially had some form o f operation on this viscus and if  there 
are to be any ill-effects o f that surgery, then the obvious place for it to  occur would be in 
close proximity to the operation itself. As such, appropriate time and length will be given 
to review the literature regarding this important observation. However, as it is the 
possible association between peptic ulcer treatment and colorectal cancer which is the
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subject o f this thesis, then the somewhat comparatively smaller volume o f work, on the 
association between gastric surgery for benign ulcer disease and subsequent colorectal 
cancer development, which has only accumulated in the past 15 years, will be discussed 
first.
8.1. Gastric Surgery and Colorectal Cancer
The first observation o f a significant excess o f colorectal cancers in patients previously 
operated on for peptic ulcer was made by McLean Ross and colleagues from Edinburgh in 
1982 (165). In order to test the suggested hypothesis that people previously subjected to 
peptic ulcer surgery are poor life insurance risks, they examined the mortality in a group 
o f 779 men who had undergone such surgery a minimum o f 15 years previously. Eighty 
six per cent o f  the cohort had undergone gastrectomy, the exact nature o f  which was not 
specified. The remainder had vagotomy with or without a drainage procedure. The 
relative proportions o f  doudenal to gastric ulcers was not presented. A total o f  16 deaths 
from colorectal cancer were observed in the study cohort, compared to the expected value 
o f 8.9, calculated from mortality statistics for Scotland. This difference was significant, 
with a probability value o f less than 0.01.
In a study o f similar design and purpose to that above, W att and colleagues from Belfast 
(166) examined the mortality in a group o f 735 patients who had undergone vagotomy 
and drainage only, between 15 and 25 years previously. Seventy eight per cent o f  the 
patients were male and 22% females. As was their intention, this was the first study to 
look at mortality after vagotomy, as all previous series, M cLean R oss’s included, had 
dealt mostly, or exclusively, with antrectomised patients. They correctly pointed out that 
it was important to identify any unusually common diseases in vagotomised subjects, so 
they could be specifically looked for in the post-operative follow-up period. Like McLean
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R oss’s group o f predominantly antrectomised men, a significant excess o f  colorectal 
cancer deaths were found in the vagotomy patients. Twelve were observed as compared 
to 5.2 expected, giving an observed to expected ratio o f 2.3 with probability value less 
than 0.05.
Following soon after these two observations, further evidence for an association between 
previous peptic ulcer surgery and colorectal cancer came from a matched case control 
study performed by Bundred in Edinburgh (167). Two hundred and eighty nine patients 
presenting with colorectal carcinoma between 1979 and 1983 formed the study group. 
The sexes were represented approximately equally, with 151 females and 138 males. 
Control subjects, chosen from hospital admission records, were matched for age, sex and 
admission date. Twenty seven patients (9.3%) in the colorectal carcinoma group had 
undergone previous surgery for peptic ulcer, compared to 13 patients (4.5%) in the 
control group, which was a statistically significant difference (P<0.05). Within the group 
o f  27 colorectal cancer patients identified as previously having had peptic ulcer surgery, 
15 had undergone partial gastrectomy and the remaining 12, vagotomy. In the 13 control 
group patients, 9 had previously undergone partial gastrectomy and 4 a vagotomy. The 
excess in the study group was mostly accounted for by males; the mean time from surgery 
to diagnosis o f colorectal carcinoma was 16 years (range 3 to 40 years); and no difference 
existed for site, Dukes' stage or histological grade o f tumour compared to the population 
as a whole.
The evidence for a link between bowel cancer and previous gastric surgery grew, when in 
1987, Caygill reported a small (1.6-fold), but significant, excess mortality from colorectal 
carcinoma in a group o f  5,018 patients operated on some 25 or more years previously 
(168). The majority o f patients had undergone partial gastrectomy. This increased risk 
only became apparent 20 years post-operatively. Indeed, within the first 20 years from
gastric surgery, the risk was slightly, but significantly, less than that o f the general 
population with relative risk equal to 0.7, with probability value o f  less than 0.05. 
Interestingly, both o f these observations occured only in patients whose original pathology 
was gastric ulcer rather than duodenal ulcer, with relative risks equal to  3.0 and 0.8 
respectively. Furthermore, the reduced risk within 20 years o f  operation was only evident 
in men, and the excess thereafter was mainly accounted for by women.
Findings from a study from Denmark, also published in 1987, were however, to  be 
contradictory to the evidence which had accumulated up until then (169). Toftgaard 
reviewed the incidence o f colorectal carcinoma in a cohort o f  3,919 patients followed up 
for 22 to 27 years post-operatively or until death, and compared it with national incidence 
rates. As had been the rule, with the exception o f W att’s group, the majority o f  subjects 
had undergone partial gastrectomy in the form o f Bilroth II (69.1%) or Bilroth I (10.8%) 
resection. The remainder o f the group comprised : simple closure o f  perforated ulcer 
(14.5%), gastrojejunostomy alone (2.7%) and only 0.9% had a vagotomy & drainage 
procedure. There was a 2 to 1 prevalence o f  duodenal to gastric ulcer in the group. 
Eighty four cases o f  large bowel cancer were observed, differing little from the 85.9 
expected. No difference existed between the sexes nor did any operation type exhibit an 
excess risk, though it is plain from looking at the breakdown o f the group by operation 
type, that the conclusion drawn from this study has little relevance to vagotomised 
patients, as indeed the authors admitted. Furthermore, unlike Caygill’s study (168), 
relative risk between gastric ulcer and duodenal ulcer patients had not been presented, and 
it was not therefore possible to determine the prevalence o f  each in those patients 
subsequently developing colorectal cancer. I f  the majority o f such patients had been 
operated upon for duodenal rather than gastric ulcer, then if Caygill's observations applied
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to the population under scrutiny, one would not expect to see an excessive risk for cancer 
o f  the colorectum.
Not since Watt's series in 1984, had a study looked exclusively at outcome following 
vagotomy, but in 1989, Ditlevsen attempted to do just that (170). He presented the 
mortality o f  824 patients from Aarhus County in Denmark who had undergone various 
forms o f  vagotomy procedure. The series comprised : selective gastric vagotomy and 
drainage (384 patients), selective gastric vagotomy and antrectomy (60 patients) and 
parietal cell vagotomy with or without drainage (380 patients). The operative diagnosis 
was duodenal ulcer in 588 patients, pyloric or pre-pyloric ulcer in 208 patients, or a 
combination o f  the two (28 patients). In stark contrast to the results o f  W att (166), the 
ratio o f deaths from colorectal cancer between cases and controls was 0.3. However, 
despite both o f these "vagotomy" studies being o f similar magnitude, the follow-up period 
in the Danish study was short in comparison to others, including that o f  W att’s, being in 
the order o f only 8 to 13 years. This may be insufficient time from surgery to see the true 
long-term sequelae o f the procedure.
In 1990, a prospective screening study by Mullan, compared the prevalence o f  large bowel 
neoplasms in 100 asymptomatic patients who had undergone truncal vagotomy some 10 
years or more previously, with that o f  age and sex-matched forensic autopsy subjects
(171). The former agreed to undergo investigation by both barium enema and 
colonoscopy. Fourteen per cent o f  the vagotomy group, (which also represents 14 
patients, by virtue o f the convenient cohort size) were found to  have colorectal neoplasms 
compared to only 3% o f  the control group (P = 0.01). O f these, 11 patients had 
adenomas, 3 (all male) had carcinomas, one o f whom had 2 cancers and 3 adenomas. 
Stemmerman, in a study o f 432 Hawaiian Japanese men who had undergone subtotal 
gastrectomy for peptic ulcer, were next to show a positive association between gastric
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surgery and bowel cancer (172). They demonstrated a 1.9-times relative risk for 
gastrectomised individuals to develop colonic carcinoma (4.9% v 2.6%, P = 0.008). The 
risk for cancer o f the rectum, though still increased at 1.4, did not reach significance. 
Once adjustment was made for the possible contributory factors, cigarettes and alcohol, 
the increased risk o f developing colonic cancer remained significant.
Also reported in 1990, by Lundegardh, was the incidence o f large bowel cancer in a 
cohort o f  6,459 patients (173). Within this group o f  patients, whose follow-up spanned 
25 to 33 years, an overall total o f 131 cases o f colorectal cancer were identified, 
compared to an expected 150.3 cases (relative risk = 0.87). On further scrutiny, it was 
noted that the relative risk in such patients was lower in the first nineteen years post- 
operatively, for instance (x0.75, x0.58, x0.96 for each six year time band) and slightly 
higher thereafter (xl .02, x0.79, xl .29). Though the latter show a degree o f  variability, it 
is apparent that those patients who are in the group with longest follow-up, and hence 
have been longest exposed to the carcinogenic factors and/or environment postulated to 
occur after gastric surgery, do indeed have an increased risk o f developing bowel cancer. 
Neither operation type (Bilroth II 73%, Bilroth I 27%), nor original pathology (duodenal 
ulcer 61%, gastric ulcer 27%, other 12%) were shown to confer any significant difference 
on outcome.
The most recent study to present mortality data following gastric surgery came from 
Edinburgh, by Macintyre and O ’Brien in 1994 (174) and observed the outcome o f 2,241 
patients who had undergone surgery for duodenal ulcer, with a post-operative follow-up 
period o f  20 to 40 years. Although slightly higher than that in the general population, the 
death rate from cancer o f colon and rectum was not shown to be significantly different, 
with an observed to expected ratio o f  1.25. As with most o f  the previous studies, the
76
results reflect mainly on a gastrectomised population (Bilroth II 59.9%, vagotomy +/- 
drainage 29.1%) and no sub-analysis by operation was presented.
8.2. Gastric Surgery and Gastric Cancer
As already mentioned in the introduction to this section, cancer developing in stomach 
following surgery for peptic ulcer disease was recognised as long ago as the 1920’s 
(162,163). For the first 30 years or so following these initial observations, the scarcity o f  
similar reported cases in the literature reinforced the opinion that such an event was a 
relatively rare occurrence and therefore o f  little relevance clinically.
However, a number o f reports from Scandinavia appeared in the 1950’s and their findings 
were contradictory to the views held until then. One o f  the first studies to  examine 
specifically the late outcome o f patients operated upon for peptic ulcer was that by Urban 
Krause, published in 1957 (146). As he pointed out, there had been a plethora o f  series in 
the preceding 30 years examining the morbidity and mortality from such surgery and from 
these were identified the sequelae which we know so well today, such as dumping, 
diarrhoea, anaemia etc., and which have already been discussed earlier in this chapter. 
However, the length o f follow-up in these studies was relatively short, usually in the order 
o f 5 to 15 years, rarely longer. Krause therefore reviewed a total o f 361 patients in whom 
Bilroth II gastrectomy had been performed some 23 to 50 years previously. The principal 
cause o f  death in the group was found to be from an excessive number o f  cases o f  gastric 
carcinoma, with 28 deaths compared to an expected 11.3. Interestingly, he also noted 
there to have been 11 deaths from carcinoma o f the alimentary tract and 9 from carcinoma 
"elsewhere", but no further definition o f these cases or statistical analysis was presented. 
One can only wonder whether he inadvertently overlooked an excessive death rate from 
colorectal cancer in his group o f patients.
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K rause’s findings were consistent with those o f Helsingen and Hilstadt (175) who had 
presented data from 229 gastrectomised patients. They found a 3 to 1 excess o f  gastric 
cancers in their patients, but however noticed that all o f the 11 cancers developed in 
patients operated on for gastric ulcer rather than doudenal ulcer, which led them to 
suggest that the increased chance o f developing gastric cancer may be related to the 
original diagnosis rather than the surgical procedure itself.
These findings prompted a number o f other workers to see if such an occurence was 
identifiable in other cohorts o f  gastrectomised patients. Liavaag (164) found that 25 
patients (2.6%) from a total o f 934 diagnosed as having gastric cancer over a 20 year 
period between 1940 and 1960 had undergone previous ulcer surgery, either 
gastroenterostomy alone (11 cases) or partial gastrectomy (14 cases). The average 
latency from surgery to diagnosis o f  cancer was 29 years and 16 years in these respective 
operative groups. However, both o f  these groups developed their cancer at a similar age 
o f  62 years, which was no different from the average age in the whole group and they 
were unable to show any significant increase in risk in those previously operated on for 
peptic ulcer, even when examined by diagnostic category o f gastric or duodenal ulcer. 
The same conclusion was reached by De Jode (176) in a similar study. He reported a 2% 
incidence (19 patients) o f previous gastric surgery in a series o f  1,000 diagnosed with 
gastric cancer in a 10 year period. Twelve o f these 19 patients had undergone 
gastroenterostomy only and 7, partial gastrectomy.
Stalsberg (177) studied a total o f 17,070 patients who underwent necropsy over a 10 year 
period, in which 630 were confirmed as having a gastric cancer. When compared to age 
and sex-matched control autopsy subjects, the incidence o f previous surgery for peptic 
ulcer was 3 times more common in the gastric cancer group than in controls (P<0.0005). 
The pattern was identical in both sexes. No specific form o f operation nor underlying
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ulcer type, whether duodenal or gastric, appeared in relative abundance to any other, in 
the patients identified as having developed gastric cancer post-operatively. The length o f 
time after such surgery was shown to be o f  significance and the excess o f  patients with 
previous surgery in the carcinoma group was 6 times that o f the control group when such 
surgery had been performed 25 years or more before death. Domellof (178) observed a 
significant excess o f gastric cancers in patients having undergone both Bilroth I and 
Bilroth II gastrectomy, with observed to expected ratios o f 4 to 1.6 and 10 to 6.6 
respectively. There was no significant difference in risk when these were compared and 
therefore further analysis o f the group was performed with both operative groups 
combined. As was now becoming commonly recognised, there was a demonstrable latent 
period between surgery and cancer development, and in this study, no significant increase 
in risk was seen until 12 years or more had elapsed. Furthermore, unlike Helsingen (175), 
they could not find any difference in risk dependant on the type o f  ulcer for which surgery 
was undertaken.
In the study o f  Mclean Ross (165), already discussed in the previous section on colorectal 
cancer, no increased risk from gastric cancer was demonstrated, with observed and 
expected values o f  8 and 10.4 respectively. These findings were consistent with two 
others reported at the same time. Fischer (179) did not find any notable increase in 
incidence in a group o f 1,000 patients who had undergone Bilroth II gastrectomy for 
duodenal ulcer, with the 13 cases observed being slightly, but insignificantly greater than 
the 10.6 expected. This was also found to be the case in a study o f  338 patients who had 
undergone various forms o f anti-ulcer surgery, mostly Bilroth II, between 1935 and 1959, 
for duodenal ulcer, by Schafer and colleagues (180). They reported no increased risk o f 
malignancy in the gastric remnant, with an observed to expected ratio o f  2.0 to 2.6, and 
although not specifying any further particular disease state, they did note that "the cohort
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did not appear to be at unusual risk o f death from other causes, either". Presumably 
colorectal cancer is included in the "other causes" category.
In 1983, a study from the Western Infirmary in Glasgow was reported by Totten and 
colleagues (181). In this series, 40 out o f 1,092 patients diagnosed as having gastric 
carcinoma over a 22 year period (1956 to 1978) were found to have previously undergone 
surgery for duodenal ulcer. Thirteen patients had undergone truncal vagotomy with or 
w ithout drainage and 27 had partial gastrectomy. No significant difference existed 
between the two groups as regards age at operation or duration o f dyspeptic symptoms 
prior to surgery. Whilst the prime aim o f the study was not concerned with comparison o f 
the disease rate with unoperated subjects, their findings are worthy o f  note. The mean 
time between surgery and diagnosis o f malignancy was 8.5 years for the vagotomy group 
compared to 24 years in the gastrectomy group (P<0.001). Indeed, 12 o f the 13 
vagotomised patients were diagnosed within 15 years o f  the original operation. This 
differed markedly from the gastrectomy patients, in whom all, with the exception o f  one, 
were diagnosed 15 years or later, from time o f surgery. In addition, age at diagnosis o f 
cancer was significantly lower in the vagotomy group, at 55 years, as compared to 64 
years in the gastrectomy group (P<0.05). The resectability o f the tumours, determined by 
the extent o f local and distant spread, in the previously vagotomised group was found to 
be in the order o f  48% versus 67% in gastrectomised individuals, though this difference 
did not reach statistical significance. The authors concluded that when gastric cancer 
developed in patients post-vagotomy, it did so after a shorter latent period when 
compared with patients who had undergone partial gastrectomy. The study also 
suggested that tum ours developing in post-vagotomy patients were more aggressive and 
less likely to be amenable to resection than in their gastrectomised counterparts. Whilst 
the study was not designed to assess whether vagotomised patients were at a similar
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increased risk o f gastric cancer as was being noted for gastrectomised individuals in some 
earlier studies, it was one o f the first to suggest that if indeed such a risk existed for 
vagotomy, then it may be associated with tumours o f a more aggressive nature than seen 
after gastrectomy.
Shortly after the publication o f the above observation on vagotomised patients, W att and 
colleagues presented the mortality statistics o f their 735 patients, all o f  whom had 
exclusively undergone vagotomy and drainage. A significantly greater number o f  deaths 
from gastric cancers than expected were seen, with 16 observed as opposed to an 
expected 4.8 (166).
The emphasis in other studies, however, continued to be with post-gastrectomy patients. 
Pickford (182), in 1984, reported a threefold excess o f gastric cancers over that expected 
in 307 patients who had Bilroth II gastrectomy 20 to 30 years previously. The risk was 
significantly, but not exclusively, greater in those operated on for gastric ulcer compared 
to duodenal ulcer. These results were at odds with a much larger group o f 3,827 patients, 
also published in 1984, by Tokudome, who had undergone either Bilroth I or Bilroth II 
gastrectomy in the preceding 11 to 33 years. In this study, a significantly lower number o f 
cancers were observed than that expected over the period o f  follow-up, with 11 versus 
52.85 respectively, P<0.01 (183). This report, however, was the exception to the rule. 
Viste (184) detected a twofold excess o f observed to expected gastric cancers in a cohort 
o f 3,470 Norwegian patients who had predominantly undergone Bilroth II resection. This 
increased risk became apparent 10 years after operation and increased with length o f  post­
operative follow-up, such that the relative risk was 7.3 after 40 to 45 years o f  follow-up. 
No difference in risk was demonstrated between the sexes, nor was risk affected by ulcer 
or operation type. Caygill (185) also found a 4.5 excess o f  observed over expected 
gastric cancer deaths in their cohort o f 4,466 patients. Like most series, however, the
number who had undergone vagotomy and drainage was relatively small at 534 patients 
(11.6% ) when compared with the proportion who had had Bilroth I or Bilroth II 
gastrectomy, which constituted 29% and 59.1% o f  the total, respectively. Again, the risk 
only became apparent after a latent period, and in this study it was 20 years for the group 
as a whole. This was true for both duodenal and gastric ulcer subjects, but these groups 
differed in that the former exhibited a significantly lower risk prior to that time (0.43), 
whereas for gastric ulcer patients, their propensity to develop cancer post-operatively was 
apparent even before 20 years had elapsed, with a cumulative risk o f 2.67 for this period. 
It is also notable that when the duodenal ulcer patients were analysed according to 
operation type, the risk for vagotomy subjects was much greater than that for 
gastrectomised subjects, being 7.8 and 2.8 respectively. In the gastric ulcer group, both 
types o f  gastrectomy were associated with an increased risk, though it was greater for 
Bilroth II than Bilroth I, at 8.6 and 4.0 respectively. Women with duodenal ulcer were 
consistently seen to inherit the greatest risk, irrespective o f operation performed, but no 
difference between the sexes existed in the gastric ulcer group.
The concerns regarding post-operative incidence of, and mortality from, gastric carcinoma 
continued to dominate the literature, with the publication o f three large post-gastrectomy 
patient series in 1988, by Offerhaus (186), Arnthorsson (187) and Lundegardh (188). 
Cohort sizes ranged from 1,795 to 6,459 patients with length o f  post-operative follow-up 
from 25 to 45 years. All three studies showed there to be an increased risk o f gastric 
cancer post-operatively, after a latent period o f  15 to 25 years. No sub-analysis by ulcer 
site or type o f gastrectomy was presented by Offerhaus (186) or Arnthorsson (187), but 
Lundegardh (188) found that Bilroth I patients ran a significantly lower risk o f developing 
gastric cancer post-operatively. Indeed, relative risk was less than one, both in “less than 
20 year” and “greater than 20 year” post-operative time periods, when compared to
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Bilroth II patients, which was partly at odds with the findings o f Domellof (178) and 
Caygill (185), where both forms o f  gastrectomy were associated with an increased risk. 
In addition, those undergoing surgery for gastric ulcer had an increased risk relative to 
duodenal ulcer cases. This finding concurs with those o f  Helsingen (175) and Caygill 
(185).
It is clear from the foregoing, that despite the increasing number o f  studies, there was a 
lack o f  consistency in their findings. The minority showed no increased risk at all, and o f 
those that did, such risks were or were not shown to vary with the original nature o f  the 
ulcer and/or type o f  surgery performed. In an attempt to define which, if any, specific 
sub-groups o f  post-operative ulcer patients were at significant risk o f  gastric cancer, 
Tersmette (189) performed a meta-analysis o f  20 such studies combined. There was a 
significant overall relative risk o f  gastric cancer, to the order o f 1.6. This increase in risk 
only became apparent 15 years or more after operation, relative risk for this period being 
1.48, with that in the first 15 years being only 0.91. Patients whose pre-existing diagnosis 
was gastric ulcer were seen to be the ones who inherited such an increased risk, with a 
relative risk o f  2.12 as opposed to duodenal ulcer patients, where it was 0.84. Analysis by 
sex and operation type, Bilroth I or Bilroth II gastrectomy, did not show any significant 
difference in risk, although it was slightly higher in females and after Bilroth II.
Thereafter, Ditlevsen’s vagotomy study (170) concurred with the findings o f  the only 
previous vagotomy group. He reported an increased gastric cancer mortality, at 2.7 times 
greater than expected. However, in the largest study o f  vagotomised patients to date, by 
Lundegardh (190), with 7,198 patients in total, a higher, but insignificant, incidence o f 
gastric carcinoma was shown. There were 34 cases diagnosed compared with 25.6 
expected, constituting a relative risk o f 1.33. This risk was unaffected by any o f the 
following factors: age at operation, sex, diagnosis (gastric ulcer 17%, duodenal ulcer
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67%, other 16%), operation type (vagotomy and drainage 26%, vagotomy only 74%) or 
length o f  follow-up. However, the follow-up was relatively short, at 9 to 17 years, and as 
the authors concluded, a longer period is required before any firm conclusion on cancer 
risk following vagotomy can be drawn. Clearly, this large cohort o f  vagotomised patients, 
if re-examined in years to come, will provide important information on the long-term 
cancer risk, not only o f stomach, but o f colorectum and other sites, o f  this surgical 
procedure. Unlike the previous “vagotomy” study o f  Ditlevsen (170), that o f  Lundegardh 
(190) excluded all patients who underwent antrectomy in addition to vagotomy, and, 
arguably, therefore gives a more accurate reflection o f the cancer risk attendant with the 
latter acid-reducing procedure, with retention o f  the gastric antrum.
Finally, in Macintyre’s cohort o f  2,241 patients who had undergone surgery for duodenal 
ulcer only (174), between 20 to 40 years previously, no significant excess o f  gastric 
cancers was found.
8.3. Carcinoma at other sites and Morbidity and Mortality in general after Ulcer Surgery 
Although it can be seen from the above that reports o f gastric cancer risk, and to a lesser 
extent, colorectal cancer, have dominated most research in the field, some degree o f 
perspective should be put on the relative importance o f these to other diseases which 
occur in patients after ulcer surgery. An overall increased mortality for such patients has 
been consistently shown in many o f these studies and much o f it can be attributed to 
lifestyle factors, ranging from the psychological profile o f peptic ulcer sufferers, to their 
consumption o f  tobacco and alcohol. For instance, in Krause’s study (146), the mortality 
o f the group as a whole was excessive with 210 observed deaths in comparison to  the 
163.1 expected. As with gastric cancer, deaths from tuberculosis and suicide were also 
seen to be unduly common (146). When deaths from gastric carcinoma and tuberculosis
were excluded, although not reaching statistical significance, the mortality was still greater 
in the gastrectomy group under study (161 observed deaths compared to 143.1 expected), 
suggesting that deaths from other causes were also increased in gastrectomy patients. 
Cardiovascular disease was the commonest cause o f death in the group, with seventy 
fatalities, and as noted earlier, eleven deaths from carcinoma o f the alimentary tract and 
nine from carcinoma "elsewhere", but without further definition o f  these cases or 
statistical analysis being presented.
Despite this evidence, in a symposium on peptic ulcer presented to  the Edinburgh Medico- 
chirurgical Society in 1963 (121), M ess’rs Small and Sircus o f  the Gastro-intestinal Unit 
at the Western General Hospital suggested that there was no justifiable reason for marking 
up such patients in terms o f life insurance risk, especially if three to four years from 
gastrectomy had elapsed without any significant sequelae o f  the operation occuring. 
However, in a long term follow-up study o f  1,679 such patients from the same unit (191), 
they, like Krause, came to realise their longer term decreased life expectancy. This was 
the result o f  an excessive number o f  deaths from lung cancer and ischaemic heart disease, 
which they logically attributed to the use o f tobacco and alcohol in such patients, rather 
than any direct consequence o f the surgery itself. Later studies confirmed such a scenario, 
with Mclean Ross (165) reporting an overall excess mortality from all causes o f  death in 
their patients under scrutiny that persisted within each age-group division (20-29 years, 
30-39 years, 40-49 years, 50-59 years), with a tendency to premature death and a 
decreased life expectancy o f  approximately 9 years. Statistically significant excess 
mortality was seen in smoking-associated diseases (192) when assessed as a whole but not 
individually. This far outnumbered any other causes o f  death, including gastric cancer, 
which was no more common than in the general population. Like Krause many years 
before, a statistically proven excess o f deaths by suicide was evident in this group o f
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patients (10 observed : 3 expected, P<0.05) as was death from liver cirrhosis (7 observed 
: 2.2 expected, P<0.05), both strongly associated with chronic alcohol abuse.
W att’s group o f  735 patients (166), all o f whom had exclusively undergone vagotomy & 
drainage procedures in a 10 year period from 1957 to 1967, were also seen to have an 
excessive mortality compared to the general population with an observed 281 deaths in 
comparison to a calculated 184 expected, constituting a relative risk o f 1.53 (P<0.0001). 
This was consistent for both sexes and within each sub-group divided by age. 
Significantly excessive death rates were noted from the following causes : lung carcinoma, 
gastric carcinoma, cerebrovascular accident, bronchopneumonia and as previously 
discussed, colorectal carcinoma. The latter accounted for 12 deaths in the group and was 
o f  similar magnitude to the 16 observed deaths from gastric cancer, but both o f  these are 
small in comparison to the 46 deaths from lung carcinoma. The authors therefore 
concluded that smoking-associated diseases were still the most important factor in deaths 
following surgery for peptic ulcer, despite the move from gastric resection to vagotomy. 
Ditlevsen’s group o f  824 vagotomy patients (170) were also seen to be at increased risk 
o f  death compared to their age and sex-matched controls with statistically significant risks 
o f 1.3 and 1.5 in males and females respectively. With the exception o f gastric cancer, no 
other cancers were significantly more common, although there was a small excess o f 
pancreatic and lung cancers in the study group, the relative risks being 2.0 and 1.5 
respectively. In addition, no excessive mortality from respiratory or cardiovascular 
disease was evident from this study, though one must bear in mind its relatively short 
period o f  post-operative follow-up. Once again, however, deaths from suicide and liver 
cirrhosis were significantly raised.
The most recent study to present mortality data following gastric surgery is that o f 
Macintyre and O ’Brien (174) in which 2,241 patients who had undergone surgery for
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duodenal ulcer only, were reviewed 20 to 40 years post-operatively. The death rate o f  the 
cohort was shown to be significantly excessive to that o f  the general population (observed 
: expected = 1.13), which in turn was due to a significant excess o f  deaths from neoplasia 
(observed : expected = 1.25) and digestive disease (observed : expected = 1.71). The 
former was also shown to be due to higher mortality from carcinoma o f  lung (observed : 
expected = 1.37) and from other smoking-associated cancers (lung, oesophagus, pancreas, 
rectum and bladder) (192) when assessed as a whole (observed : expected = 1.32). When 
examined individually however, with the exception o f lung cancer, none reached statistical 
significance, though it is noteworthy that all have relative risk ratios greater than unity. 
As in most previous series, the only significant excess mortality was seen 20 years or more 
post-operatively, again predominantly because o f  smoking-related cancers and respiratory 
disease. Also in concordance with previous studies, the death rate from liver cirrhosis was 
more than twice that to be expected.
Other groups results are similar with respect to the predominance o f  lung cancer with 
increased rates o f  the disease also reported by Caygill (168) : times 3.9 ; Stemmerman
(172) : times 2.1 and Lundegardh (193): times 1.5.
Pancreatic cancer was initially observed to be significantly more frequent in 
gastrectomised patients in the same study that first observed a similar scenario for 
colorectal cancer, namely that o f  McLean Small in 1982 (165), where 11 deaths from the 
disease occured in the cohort compared to an expected 3.9 (P<0.01). Caygill (168) also 
found there to be a highly significant excess o f pancreatic cancers in her group o f  patients, 
with a relative risk o f  times 4. Modestly elevated rates have also been shown in the 
vagotomy subjects o f  Watt (166) : times 2; and Ditlevsen (170) : times 2, but are 
insignificant due to the small numbers o f cases involved in computing these risks. Similar
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analyses have been reported by Stemmerman (172) : times 1.5 and McIntyre (174) : times
1 . 2 .
Oesophageal cancer is another disease that has been mentioned in a few studies, but with 
little evidence to suggest any increase in risk for this disease in the years after peptic ulcer 
surgery. Shearman (194) reported that 9% o f  92 patients with squamous carcinoma o f  the 
oesophagus were found to have undergone previous surgery for peptic ulcer, which 
exceeded reported values o f  the 3 to 8% incidence for achalasia o f the cardia, a condition 
accepted as conferring an increased risk for this cancer. However, in a similar but slightly 
larger scale study o f  203 oesophageal cancer patients, presented by M acDonald (195), 
there was only a history o f previous ulcer surgery in 2%. These observations were 
corroborated in a necropsy case-control study by Stalsberg (196) where the incidence o f  
previous surgery in the oesophageal cancer group o f 185 was a little over 1%, which was 
less than that in controls (3%). Since these early studies, the evidence from the larger 
series would tend to endorse there being no significant excess o f this tum our after ulcer 
surgery.
Finally, mention must be made o f the remainder o f Caygill’s study (168), where an 
increased risk o f  cancer at multiple sites was found after a latency o f 15 to 20 years post- 
operatively. In addition to those sites already discussed, malignancy at the following sites 
were also increased : biliary tract (times 9.1), bladder (times 2.4), female breast (times 
4.0); and the overall cancer risk was times 3.3. These finding are not, however, as 
alarming as they may initially appear as they tended to be offset by decreased risk ratios 
during the first two post-operative decades to such a degree that the overall post­
operative risk was not significantly different from the general population. The two later 
patient series o f  Lundegardh (193) and McIntyre (174), which also assessed risk at all 
sites, showed no overall risk for the majority o f cancers, lung cancer excepted, although
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small excesses o f biliary tract and oesophageal cancer in specific sub-groups when divided 
by sex and original type o f peptic ulcer, were reported by Lundegardh (193).
It would therefore appear that the social habits and personality o f  the peptic ulcer sufferer 
probably play a large part in creating the morbidity and mortality statistics seen in the 
years following their surgery. However, the frequency with which diseases such as gastric 
and colorectal cancer, which have much less o f  an association with tobacco and alcohol 
use, have been reported in such patients, does implicate some effect o f the surgery itself 
on influencing their development.
The hypotheses as to what mechanism(s) may lead to their development, some with strong 
experimental evidence to back them up, others less so, are explored in the following 
section. As before, as the main subject o f this thesis is colorectal cancer, appropriate 
length will be given to work specifically dealing with that disease entity.
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9. Possible causes for the association between Ulcer Surgery and Cancer 
Development
The physiological change that is common to both antrectomy and vagotomy, and is shared 
with the H2 receptor antagonists and proton pump inhibitors, is a significant reduction, or 
complete abolition, o f gastric acid output. Concerns as to the dangers o f  prolonged acid 
suppression stem from the recognition that individuals with type A auto-immune atrophic 
gastritis, better known as pernicious anaemia, and which results in achlorhydria, have an 
increased incidence o f gastric cancer. That risk is in the magnitude o f 3 to 4 times that o f 
the general population (197-199). Small, but statistically insignificant increases in 
colorectal cancer incidence have been observed in such patients in two studies (199,200). 
As already seen, hypochlorhydria leads to a number o f pathophysiological sequelae 
including bacterial colonisation o f the stomach and upper small bowel. In addition, where 
acid reduction occurs in an intact stomach; for example, as occurs in vagotomy and 
pharmacological acid blockade, but not antral resection, there is a reflex increase in 
circulating levels o f gastrin originating from the antrum o f the stomach. N ot surprisingly, 
therefore, much o f the research that has been undertaken in an attempt to identify a causal 
link between ulcer surgery and subsequent tum our development has concentrated on the 
above phenomena.
9.1. Gastric Cancer
9.1.1. Pre-malignant histological mucosal changes
Microscopically discernable alterations in the gastric mucosa have been shown to be 
commonplace in the post-operative stomach. These vary from acute gastritis to chronic 
gastritis o f varying severity and also intestinal metaplasia and dysplasia. All may co-exist
in the same stomach. For instance, Domellof (201) performed gastroscopy on 214 
patients still alive 20 years or more after Bilroth II gastrectomy and performed 6 biopsies 
each from the region o f the gastroenteric anastamosis and also from the fundic region o f 
the stomach. This revealed that 97% o f these patients had changes o f  chronic gastritis, o f 
mild, moderate or severe degree. In addition, 33% o f patients biopsied had intestinal 
metaplasia o f the gastric epithelium and 70% cystic dilatation o f mucosal glands. These 
findings are similar to those o f Pickford and colleagues (182) who endoscopically 
examined and biopsied 54 patients 31 to 39 years after Bilroth II gastrectomy. In addition 
to changes o f gastritis, they reported 35% o f stomachs as containing mild to moderate 
degrees o f  mucosal dysplasia. Although never conclusively proven, nor universally 
accepted, all o f these histological changes have been implicated as possible precursors to 
cancer development in a number o f animal and human studies (201-205). Hypotheses as 
to why they occur include hypochlorhydria per se, withdrawal o f the trophic effects o f 
gastrin (see later), and as a consequence o f  bile reflux through the gastroenterostomy 
stoma. As regards the latter, in the above studies, 77 to 100% o f patients had bile reflux 
at endoscopy, but this did not correlate with the severity o f  gastritis demonstrated at 
biopsy.
9.1.2. Bacterial Colonisation
The confirmation o f significant bacterial colonisation o f the hypochlorhydric stomach has 
already been presented (135). The main concern arising from this observation has been 
the production o f potentially carcinogenic N-nitroso compounds from nitrites. The latter 
are formed from dietary nitrates and refluxed bile salts by the action o f  bacteria possessing 
the nitrate reductase enzyme, aptly named nitrate reducing bacteria (206). Increased 
numbers o f such strains o f organisms have been confirmed in studies showing the
91
generalised increase in bacterial numbers in the stomach rendered hypo/achlorhydric, 
w hether by disease, medical or surgical means (138,139,141,143,207). N-nitroso 
com pounds such as nitrosamines, nitrosamides and nitrosoureas are carcinogenic in 
experimental animals (208-210) and significantly raised concentrations o f such compounds 
have been demonstrated in the human stomach during treatment with cimetidine 
(211,212), omeprazole (140) and after peptic ulcer surgery (213). It must be stated 
however, that comparable studies with omeprazole (141), cimetidine (214), and also 
ranitidine (139), as well as in vagotomised and gastrectomised patients (139,215) have 
been unable to demonstrate excessive amounts o f N-nitroso compounds, despite most o f  
them confirming the presence o f increased numbers o f  nitrate reducing bacteria and nitrite 
concentrations in the stomach (139,141,215). Differences in the techniques used for 
measuring these relatively unstable substances (141,214), contamination during sampling 
(141), and indeed what represents “normal” levels o f these compounds (141) have been 
cited as possible reasons for the discrepancies in the results o f  these studies. Delivery o f 
such bacterially metabolised compounds distally to the mucosa o f the colorectum has also 
been suggested as a cause for the increased incidence o f tumours in this organ after ulcer 
surgery (166,167).
9.1.3. Gastrin and Gastric Carcinoma
The confirmation o f  gastrin’s second major physiological function as a trophic factor for 
gastro-intestinal mucosa subsequently led investigators to ask whether the same trophic 
effects would be conferred on the growth o f neoplasms arising from it. Gastrin binds to 
gastric adenocarcinoma cells (216) and stimulates their growth in vitro (217,218). 
Administration o f gastrin or pentagastrin increases the incidence o f  chemically induced 
(219) and transplanted (220) gastric cancers in rats, and vagotomy enhances the growth o f
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such tumours in dogs (221) and rats (222). However, from the literature review earlier, it 
is clear that the greatest number o f post-surgical gastric cancers have arisen in 
antrectomised stomachs, where the major source o f endogenous gastrin has been 
removed. Although conditions such as pernicious anaemia and atrophic gastritis, both 
characterised by hypergastrinaemia secondary to hypo/achlorhydria, do have an 
established strong association with development o f  gastric adenocarcinoma (198- 
199,205), it seems more likely that the events leading to mucosal carcinogenesis are a 
result o f  the decreased acid milieu at local mucosal level, which is common to 
antrectomy, vagotomy and the above maladies, rather than circulating hypergastrinaemia. 
Despite it being unlikely that gastrin is the initiating factor in gastric carcinogenesis, it is 
still possible that in the presence o f chronic hypergastrinaemia, gastric cancer, once 
established, may behave in a more aggressive fashion. The observations o f Totten (181) 
lend support to this hypothesis. In that study, discussed in detail earlier, gastric cancers 
arose significantly earlier in vagotomy patients compared to those who had undergone 
antrectomy, and the lesions were histologically and clinically more aggressive; further 
advanced and less likely to be resectable.
9.1.4. Helicobacter pylori
The presence o f the above organism, discussed in detail earlier in the chapter, is now 
recognised as a possible risk factor for the future development o f  gastric cancer (223), 
with several studies demonstrating a significant excess o f cancers in H. pylori positive 
subjects compared to those who do not possess the organism (224-226). Furthermore, 
there is evidence to suggest that one specific phenotype o f  the organism, the so-called 
CagA H.pylori, named after the cytotoxic protein which it produces, may be the specific 
type which confers such a risk (227). The mechanism is postulated to be due to atrophy
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developing in gastric mucosa chronically inflamed as a result o f infestation with the 
organism. These observations are based on cancer developing in the intact stomach. It is 
unknown what influence the organism may have in the development o f  stomach cancer 
after peptic ulcer surgery, though it is interesting to note that the vast majority o f 
duodenal ulcer sufferers, a condition long recognised to have a strong inverse relationship 
with gastric cancer development (227,228), are H.pylori positive (42). Differences in 
phenotypes o f the infecting organisms as described above, may partly explain this 
paradox, but clearly much more research is required in this area.
9.2. Colorectal Cancer
A number o f hypotheses have been postulated as to the excess o f  colorectal neoplasia seen 
after peptic ulcer treatment. By far, most interest has focused on the relationship between 
gastrin and colorectal tumour growth and hence this will be discussed first, beginning with 
a brief resume o f the salient features o f the hormone itself.
9.2.1. Gastrin and Colorectal Cancer
In 1906, Edkins proposed the existence o f a hormone that influenced gastric acid 
secretion (73). The hypothesised hormone, "gastrin", was only isolated over half a century 
later from the gastric antrum o f the pig (75). It was shown to be a heptadecapeptide 
existing in two microheterogeneic forms, that is, differing only by the presence, or not, o f 
a sulphated tyrosine in the sixth position from the C-terminus o f  the molecule (75). Soon 
afterwards came the development o f useful antibodies against gastrin (229), which 
allowed demonstration o f  gastrin as also existing in various macroheterogeneic forms, that 
is, varying in amino-acid chain length, namely Gastrin-34, Gastrin-17 and G astrin-14 
(230). The biological activity o f  gastrin is confined to the constant C-terminal
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tetrapeptide o f all these variants which, however, is shared by the other major gut 
hormone, cholecystokinin (231). The latter, however, differs from gastrin in that it 
contains tyrosine in the seventh position, not the sixth, from the C-terminus and this is 
likely to account for the difference in their respective biological actions (232).
9.2.1 .(i) Physiological Function o f  Gastrin
Gastrin is the major stimulus to secretion o f acid and pepsin from the body o f  the stomach 
(233). It originates from the G-cells o f the gastric antrum (234) and is released in 
response to a number o f  stimuli including presence o f  intraluminal peptides and amino- 
acids, acetyl choline and gastrin-releasing peptide from post-ganglionic neurones. 
Consequent upon such stimuli, gastrin is released into the circulation and induces acid 
secretion by direct action on the parietal cell (76,233), and indirectly by stimulating 
release o f histamine, which in turn also causes release o f acid from the parietal cell 
(76,233).
9.2.1 .(ifi Evidence for the trophic action o f Gastrin
The first indication that gastrin was involved in mucosal growth was the observation that 
the remaining gastric mucosa atrophied following antrectomy (235,236). Conversely, 
patients with Zollinger-Ellison syndrome, who have chronic and persistent elevation o f 
circulating gastrin due to secretion o f  the latter by a tumour, have gastric mucosal 
hyperplasia (237).
The earliest experimental evidence o f  gastrin's trophic function was observed when both 
pentagastrin and gastrin were shown to stimulate protein synthesis in gastric and duodenal
mucosa o f  rats, as measured by incorporation o f ^C -labelled  leucine, both in-vitro (238) 
and in-vivo (239). This growth-promoting effect was further substantiated by
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demonstration o f significantly increased mitotic rates and protein content o f  both human 
and rat gastric mucosal cells cultured and maintained in-vitro, when treated with 
pentagastrin compared to saline-treated controls (240). Similarly, in further work from 
the same centre, rat duodenal mucosal cells in vitro, when treated with pentagastrin, 
showed a significant reduction in doubling time versus saline-treated controls (241).
These same cells also demonstrated increased uptake o f tritiated thymidine (J H- 
thymidine) which occurs during active DNA synthesis and is indicative o f cells in 
proliferative phase (241). DNA synthesis was also shown to markedly and significantly 
rise in the oxyntic, duodenal and ileal mucosa o f rats after a single intraperitoneal injection 
o f  pentagastrin (250 micrograms/kg) with sacrifice and collection o f  tissue for analysis 
sixteen hours later (44-100%, 62-81%, 58% increase over control values, respectively) 
(242). Furthermore, atrophy o f oxyntic and duodenal mucosa has been demonstrated in 
animal models where circulating levels o f endogenous gastrin have been lowered from 
physiological values, by antrectomy or starvation with or without intravenous feeding, and 
that such atrophy can be prevented or reversed by administration o f pentagastrin 
(243,244).
9.2.1 .(in) Gastrin as a growth factor for Colorectal Mucosa
In a series o f experiments along similar lines to those on gastro-duodenal mucosa, tritiated 
thymidine incorporation and total DNA content o f  colonic mucosa were found to be 
significantly elevated in rats which had received 6 equally spaced injections o f  pentagastrin 
250micrograms/kg over 48 hours (and sacrificed 8 hours after the final dose), compared 
to saline-treated controls (245). Identical results were obtained for administration o f  the 
natural porcine gastrins G-17 I, G-17 II and G-34 II in equivalent experiments, with no 
significant differences in the degree o f stimulation by one particular form o f  gastrin over
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another (245). This constituted the first published evidence o f  a trophic effect o f gastrin, 
in a variety o f physiological forms, on colorectal mucosa.
Dembinski (246) then demonstrated that endogenous antral gastrin was also trophic for 
colorectal mucosa, by observing that antrectomy in rats significantly reduced colonic 
weight and DNA synthesis in comparison to normogastrinaemic controls. Significantly 
reduced blood gastrin levels were confirmed in the antrectomised animals. A group o f 
antrectomised rats then received 1 week’s treatment with 6-hourly intraperitoneal 
injection o f  pentagastrin 250pg/kg, while a control group received an equivalent amount 
o f  saline. Pentagastrin treatment resulted in stimulation o f colonic DNA synthesis to  75% 
above control values. This observation, along with the fact that antrectomy caused a 
greater reduction in weight and DNA synthesis o f  colon than any other tissue (acinar 
pancreas behaved similarly), prompted the authors to conclude that colonic mucosa was 
the most sensitive gastrointestinal tissue for gastrin, due to the marked changes caused by 
interference with levels o f the hormone. Furthermore, in observing that both RNA and 
DNA content both responded similarly to the alterations in gastrin stimulus, and thus the 
RNA to DNA ratio did not change, they concluded that true hyperplasia o f  the mucosa 
was occuring, rather than hypertrophy, where RNA synthesis tends to increase without a 
concomitant rise in DNA.
Sirinek (247) also confirmed a trophic response o f  5 different human colonic mucosal cell 
lines maintained in tissue culture, to treatment with pentagastrin 5pg/ml. Saline treated 
control cells showed a mean threefold increase in number over a 72 hour incubation 
period, but those with pentagastrin in culture increased fivefold over the same period, a 
mean increase o f 65% (range 40 to 80%) compared to controls (P<0.05).
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9.2.1 (iv) Gastrin as a growth factor for colorectal neoplasms
Somewhat inevitably, in light o f these observations, questions were raised as to what 
influence gastrin may have on neoplasms arising from such a responsive tissue. Indeed, in 
Sirinek’s in-vitro study (247), the authors also studied the response o f  5 human colonic 
adenocarcinoma cell lines to the same concentration o f  pentagastrin in the culture 
medium. A stimulatory effect similar to that observed in the non-neoplastic colonic 
mucosal cells was evident. The pentagastrin treated carcinoma cells increased in number 
by approximately sevenfold as compared to saline treated controls which increased to  4.5 
times their initial number (P<0.05).
Other workers confirmed this effect for natural gastrin in vitro. Kusyk and colleagues
(248) studied the action o f physiological doses o f gastrin-17 on in vitro grow th o f  the 
human colonic adenocarcinoma cell line, LoVo. They confirmed a significant increase in 
DNA synthesis in gastrin treated cells, as measured by incorporation o f  tritiated 
thymidine, and also in cell numbers, with increases o f  over 200% and 50% o f  control 
values, respectively. They also noted that such measurements were maximal in cells 
supplemented with either feotal bovine serum or “conditioned medium”, the latter 
prepared from medium which had been used to maintain LoVo cells for the previous 48 
hours. They concluded that the enhanced effect on growth by cells supplemented with the 
above was a result o f  small amounts o f gastrin and other growth factors present in serum 
and in the “conditioned medium”, suggesting the presence o f autocrine grow th factors 
released by the cancer cells themselves. Palmer Smith (249) also found significantly 
increased values o f tritiated thymidine incorporation and cell counts in HT29 human colon 
cancer cells in vitro in response to a wide dose range o f  gastrin-17, varying from 0.4 to 
400 picomoles per litre. Since these early observations, gastrin’s trophic action on
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colorectal cancer cells in vitro has been confirmed in a substantial number o f  cell lines 
studied (250).
The results o f  a number o f in vivo studies also served to lend weight to gastrin being an 
important factor in colorectal tumour growth. One o f the first o f these was by M cGregor 
(251), who observed significant increases in chemically induced colonic tum our synthesis 
and concentrations o f  DNA, RNA and protein in rats rendered endogenously 
hypergastrinaemic by surgical antral exclusion. Similar results were observed in animals 
that were administered exogenous pentagastrin, compared to antrectomised or sham 
operated animals in whom gastrin levels did not differ significantly. Similarly, W insett and 
collleagues (252) studied the effect o f varying doses o f pentagastrin on growth o f  an 
implanted colonic tum our xenograft (MC-26) in Balb/c mice. Significant increases in 
tumour weight and DNA content were confirmed in all pentagastrin treated animals who 
received the hormone for 14 days at a dose o f either 125, 250 or 500pg/kg 8-hourly. 
Maximal stimulation o f  tumour growth appeared to be present at the lowest dose o f 
pentagastrin as no significant difference in the measured parameters was evident between 
any o f the 3 different dosage groups. Thus, in a second experiment utilising this dose o f 
pentagastrin, they measured the survival o f mice bearing the colonic tum our after an initial 
7 or 14 days treatment with pentagastrin or saline placebo. Compared to control animals, 
all pentagastrin treated animals had a significantly reduced survival as a result o f  excessive 
tumour growth. For instance, at day 35, 90% o f control mice were alive as compared to 
55% o f  those treated with pentagastrin. By day 55, all o f  the latter group were dead 
whereas 80% o f the controls were still alive. In a study o f similar design, Palmer Smith
(249) also found that pentagastrin-treated nude mice bearing xenografts o f  2 human 
colonic adenocarcinomas, CXI or X56, had significantly increased tum our volumes, 
weights, protein and DNA content compared to control animals. Similar results were
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reported by Alonso (253), who utilised Balb C mice inoculated with CT26 human 
adenocarcinoma o f  the colon, and observed a significant reduction in the survival time o f 
animals so treated. Chu (254), observed similar effects o f  endogenous gastrin on a human 
colon carcinoma xenograft implanted in the colon o f athymic Lewis rats. Those rendered 
hypergastrinaemic by fiindectomy (excision o f the entire oxyntic gland bearing area o f the 
stomach) had increased proliferation o f tumour, as measured by metaphase arrest index. 
The tumours in this group o f animals were also more aggressive, with direct local 
extension o f tumour outwith the bowel evident in all hypergastrinaemic rats and liver 
metastases in 20%, findings which were absent in sham-operated controls.
Like most hormones, gastrin’s action on colorectal cancer cells was presumed to be due 
to its interaction with a specific receptor on the effector cell. Specific gastrin receptors 
had already been identified and characterised on gastric parietal cells o f  the rat (255) and 
dog (256). In the light o f gastrin’s apparent action on colorectal mucosal and tum our 
growth, the search for a similar receptor on such cells began and gastrin receptors were 
indeed identified in normal mammalian colonic mucosa (257). Subsequently, high affinity 
gastrin receptors were also identified on a substantial proportion (38 o f  67, 56.7%) o f 
human colorectal carcinomas tested in one study, suggesting that some, but not all, such 
tumours were under the influence o f gastrin (258). Furthermore, specific pharmacological 
gastrin receptor antagonists have been developed and shown to inhibit the trophic effects 
o f both natural and synthetic gastrins on susceptible tumours in vitro and in vivo (259- 
262), introducing the exciting possibility o f hormonal manipulation in the treatment o f  the 
disease, as already occurs in breast and prostate cancer.
Most o f the above information has been obtained from laboratory based experiments, 
either in cell culture or small mammal based studies. To date, there is little substantial 
clinical evidence to suggest that gastrin significantly influences the development and
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growth o f colorectal cancer in man. In 2 studies o f patients with pernicious anaemia and 
its associated chronic hypergastrinaemia, the incidence o f  colorectal cancer was 
unchanged (199) and slightly, but insignificantly, higher (200) than in the general 
population. In a study o f patients with longstanding medically controlled Zollinger-Ellison 
syndrome, also characterised by persistently elevated circulating gastrin levels, the number 
o f colonic crypt cells in the proliferative S-phase o f  the cell cycle, measured by labelling o f  
single stranded DNA with the thymidine analogue, 5’-Bromodeoxyuridine, was noted to 
be significantly higher than in control subjects (263). Despite this, the total number o f cells 
in the colonic crypts was not significantly different in the 2 groups and thus no resultant 
mucosal hyperplasia ensued. In the 23 Zollinger-Ellison patients studied, 5 were found to 
have adenomas at colonoscopy, and 1 o f these patients also had a neuroendocrine tum our 
at the splenic flexure. None o f  the control subjects had any such lesions because a normal 
colonoscopy was one o f the criteria for admission to the control group. The authors 
concluded that the prevalence o f adenomas in their small study group was probably no 
greater than that found in the general population and that the results o f a study o f  this size 
could not accurately compare their relative prevalence anyway. However, their results are 
almost identical to those o f a larger study o f  97 Zollinger-Ellison patients, in whom the 
prevalence o f asymptomatic colonic polyps found at colonoscopy was 18% (264). 
Finally, in a study o f 7 patients who had undergone hepatic resection o f  colorectal liver 
metastases and then had augmentation o f their chemotherapy with the gastrin receptor 
antagonist, proglumide 1200mgs/day for 2 years, only one (14%) had recurrence after a 
median follow-up o f 39 months in comparison to 24 o f 46 (52%) control individuals who 
had chemotherapy only (265). Despite the impressive percentage difference here, one 
must appreciate the very small size o f the treatment group.
Further evidence o f  an association between hypergastrinaemia and human colorectal 
cancer was suggested by the studies o f Palmer-Smith (266) and Seitz (267), who found 
significantly elevated circulating gastrin levels in patients with colorectal cancer. Charnley 
(268) also confirmed significantly elevated gastrin levels in their subjects, but also 
questioned whether the measured gastrin was being produced by the tumours themselves, 
as gastrin-like immunoreactivity (269) in colorectal tumour cells and secretion o f  a 
gastrin-like protein (270) from them had previously been detected by other workers. 
Charnley (268) therefore measured gastrin levels in draining mesenteric vein blood intra- 
operatively. No significant difference between portal or peripheral venous gastrin levels 
was found, and a further tw o studies (271,272), which did not show any significant 
elevation o f pre-operative gastrin values in colorectal cancer patients, also confirmed that 
these measurements were not altered after the tumour had been resected, further evidence 
against a significant production o f  gastrin by the tumours. However, these findings are at 
odds with those o f  Wong (273) and Seitz (274) who both found that serum gastrin levels 
fell after apparent curative tum our resection. However, it is still possible that any 
autocrine gastrin production by the tumours is either too small in amount or is completely 
utilised at the local cellular level to be detected by the above methods, as both gastrin 
mRNA (275-278) and protein products thereof, including immature precursor gastrins 
(277-280) such as preprogastrin, progastrin, glycine-extended gastrin as well as the 
physiologically active, mature carboxyamidated form (279-281), have been identified in 
human colorectal carcinomas.
Gastrin’s exact role in growth o f  normal colorectal mucosa and in colorectal 
carcinogenesis remains controversial however, as the results o f an equally substantial 
number o f  studies have been unable to corroborate the findings reported above. Thus, in 
a number o f in vivo studies with rats, alterations o f  endogenous gastrin levels induced by
102
surgical procedures such as fiindectomy and antrectomy (282,283), treatment with proton 
pump inhibitors (284,285) or H2-antagonists (285) and administration o f  exogenous 
pentagastrin (286) or physiological gastrin-17 via osmotic mini-pumps (287) have not 
shown any significant effect on growth o f normal colonic mucosa or o f chemically induced 
colorectal tumours. Also, not all human colorectal tumours studied have been found to 
contain gastrin receptors (288), though this does not rule out the hormone as having a 
significant action on those that do possess such receptors. Finally, as already mentioned, a 
number o f studies have not shown any elevation o f  gastrin levels in patients with 
colorectal cancer compared to controls (271,272,289,290).
9.2.2. Other potential mechanisms for Colorectal Carcinogenesis after surgical or medical 
treatment o f  Peptic Ulcer
Although the majority o f work has concentrated on the potential role o f  gastrin in 
colorectal tum our growth, a number o f  other hypotheses have been forwarded to explain 
the increased incidence o f the disease seen in some studies. Indeed, hypergastrinaemia 
cannot be implicated in those tumours seen after procedures such as antrectomy, and thus 
it is possible that the consequences o f some factor shared by antrectomy, vagotomy and 
drug treatment, such as hypochlorhydria, may be responsible for their development. 
Alterations o f  bile acid metabolism following gastric surgery have been suggested as a 
possible cause for the increased incidence o f  colorectal cancer (166,167,171). The 
constitution o f bile reaching the distal gastrointestinal tract is known to be altered 
following both partial gastrectomy (291) and vagotomy (171,292). This may be the result 
o f metabolism by the bacteria shown to colonise the stomach and upper small bowel in the 
presence o f hypochlorhydria, with an increased ratio o f secondary to  primary bile acids 
being the predominant feature (171,292). Similar ratios have been found in the faeces o f
patients with colorectal neoplasms (293,294) and in those at high risk o f developing 
colorectal cancer (295,296). These changes also occur after cholecystectomy (297,298) 
which itself has been associated with an increased risk o f colorectal cancer (298-301). 
Cholelithiasis too, has been associated with an increase risk o f bowel cancer (302,303), 
and the lithogenicity o f  bile is known to increase after gastric surgery (158-161,304). 
Secondary bile acids have been shown to promote experimental colorectal carcinogenesis 
in rodents (305-307) and cytosolic receptors for such have been demonstrated in 
colorectal cancer cells (308).
Stemmerman (172) proposed that the nutritional sequelae that occur after gastric surgery, 
which have been discussed earlier, may lead to the increased incidence o f  bowel cancer 
after operation. His group o f  432 gastrectomised patients were lighter and had lower 
serum lipid levels than their normal counterparts, suggesting that undernutrition may be 
the common thread. They also had reduced calcium intake, a further risk factor for 
colorectal cancer development.
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10. Omeprazole - an Inhibitor o f Colorectal Carcinogenesis?
10.1. The Evidence
Despite the concerns o f  prolonged acid suppression and hypergastrinaemia on colorectal 
mucosa, the few experimental studies using omeprazole to evoke this state have not 
shown any stimulatory action on the growth o f  chemically-induced or transplanted colonic 
tum ours in rats (284,285). Existing studies o f  long term acid suppresion by omeprazole in 
the treatment o f  gastro-oesophageal reflux or peptic ulcer in humans, usually in the order 
o f  5 years or less (309,310), cannot be compared to the much longer periods o f  follow-up 
in the studies o f  operated patients presented earlier, and are at present unlikely to yield 
any useful information regarding the long-ranging effects o f  chronic hypochlorhydria or 
hypergastrinaemia secondary to acid-inhibitory drugs.
The results o f a study by Penman (311), designed to assess the effect o f omeprazole- 
induced hypergastrinaemia on chemically-induced colonic tumour growth in rats, actually 
found that in omeprazole treated rats, despite significant hypergastrinaemia (and one 
therefore presumes, achlorhydria), as confirmed by blood sampling, there was a 
significantly reduced tum our incidence compared to normogastrinaemic control animals, 
with 12 out o f  19 animals affected (63%) in the omeprazole-treated group compared to 
19 out o f  20 (95%) in the control group (P<0.02). In addition, in the treatment group o f 
animals, the total number o f tumours and the median number o f tumours per rat were also 
significantly less than in controls (28 versus 59, median (range) 1(0-5) versus 3(0-10) 
respectively ; P = 0.02). This unique finding was unexpected, and to date, remains 
unexplained. Only one other study (312), looking at the in vitro action o f  omeprazole on 
the growth o f  3 carcinomas derived from human colorectal mucosa, has suggested that the 
drug may have an inhibitory effect on the growth o f  such tumours. The growth o f  1 o f
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the 3 cell lines tested was inhibited by omeprazole, irrespective o f  whether gastrin was 
present in the growth medium. These two isolated reports o f  a potential anti-proliferative 
action o f  omeprazole on colorectal cancer are the stimulus to the laboratory based work 
to be presented in this thesis.
10.2. Omeprazole - Pharmacokinetics (313)
Omeprazole, (5 -methoxy-2- {4-methoxy-3,5 -dimethyl-2-pyridinyl)methyl] sulphinyl} -1H- 
benzimidazole) exerts its powerful acid inhibitory action by selective and non-competitive 
binding to the H+/K+ Adenosine Triphosphatase enzyme which is situated in the 
membrane o f  the intracellular canaliculus o f the gastric parietal cell. This enzyme is 
presently thought to be exclusive to this cell, although a similar potassium-dependant 
pump has been identified in rabbit colon (314). The drug is rapidly absorbed, with 
maximum plasma concentrations being seen within 25 minutes or less o f  a standard oral 
dose in humans. It distributes rapidly to extravascular sites with its volume o f distribution 
being similar to that o f  the extracellular fluid compartment. In rats, within half an hour o f 
dosage, the highest concentrations o f the drug, as assessed by measured radioactivity after 
ingestion o f 14C-labelled drug, are found in the stomach, liver, kidneys and duodenum. 
This reflects the concentration o f the drug at its specific site o f action and its routes o f 
excretion via bile and urine. Its high concentration at the latter sites, occuring within half 
an hour o f dosing also indicate its rapid first-pass metabolism through the liver and rapid 
elimination. The average plasma half-life o f the drug in humans is approximately 60 
minutes. All o f the administered dose is biotransformed to inactive metabolites in the 
liver, as no unchanged drug is recoverable in the urine or faeces. In humans, 
approximately 70% o f  the metabolites are renally excreted, with the remainder excreted in 
the bile and ultimately in the faeces. The principal metabolites are hydroxy-omeprazole
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and its carboxylic acid, with much lesser amounts o f omeprazole sulphone and sulphide 
identified in human plasma. None o f  the metabolites are considered to play any part in the 
inhibition o f acid secretion, and the prolonged effect o f a single dose reflects the non­
competitive and irreversible nature o f the binding to the proton pump, by formation o f  a 
disulphide bond between the proton pump and the active sulfenamide form o f the drug.
10.3. Proposed mechanisms for Omeprazole’s anti-neoplastic action 
Penman (311) proposed 2 hypotheses for the apparent anti-neoplastic action o f 
omeprazole. The first o f these was to suggest that alterations in the bacterial milieu o f  the 
colon, in response to the profound acid suppression upstream, may lead to increased 
bacterial metabolism o f the administered carcinogen, azoxymethane, to inactive 
metabolites, with a resultant decrease in tumour development.
The second hypothesis suggested that omeprazole may interfere with some stage o f  the 
body’s metabolism o f the carcinogen. Azoxymethane is itself a procarcinogen, which 
requires to undergo a series o f metabolic reactions before the active carcinogen, the 
alkylating methyldiazonium ion, is generated (315). It is site specific with the vast 
majority o f tumours arising in the colorectum. This is why no tum our growth occurs at 
the site o f subcutaneous injection o f  the drug and the animal model o f  azoxymethane- 
induced colorectal cancer is now widely utilised in the investigation o f the disease. M ost 
known carcinogens to which the average human body is exposed, like azoxymethane, 
exist as procarcinogens and require metabolism, usually hydroxylation, to their active 
genotoxic form (316). Such metabolism usually occurs in the liver, primarily by a large 
and heterogenous family o f microsomal hepatic enzymes, the cytochrome P450s (317). 
The metabolic activation o f most o f these carcinogenic compounds, or xenobiotics, such 
as heterocyclic amines found in cooked food, is mainly undertaken by two specific types
o f  these enzymes, cytochromes P450-1A1 and -1A2 (318). Omeprazole has been found 
to  induce production and increase activity o f both these specific enzymes in the liver 
(319) and in other extrahepatic sites such as duodenal and colonic mucosa (320). This has 
raised concerns that this may in turn lead to increased production o f  carcinogens from 
ingested dietary xenobiotics. Somewhat paradoxically, it has been shown that induction 
o f  cytochromes P450 1A1 and 1A2 actually leads to reduced activity o f administered 
carcinogens in vivo, thus increased enzymatic activity does not necessarily correlate with 
increased mutagenicity (321,322). The exact number and type o f cytochromes which are 
involved in the conversion o f azoxymethane to its active metabolite are not fully known, 
with only one, cytochrome P450IIE1, having been identified as an intermediary enzyme in 
its metabolism (323). However, the activity o f  this particular enzyme has not been shown 
to be affected by omeprazole (319).
Defining where omeprazole acted in the carcinogenesis process would be beneficial in 
elucidating the drug’s mode o f action. The process o f chemical carcinogenesis can be 
broadly divided into two separate stages : initiation and promotion (324). Initiation 
occurs by a direct action o f the carcinogen on the DNA genome o f  the cell, and 
consequently that altered cell replicates by mitosis. Initiation is an irreversible process and 
results in the development o f a population o f  such “initiated” cells. These cells, however, 
will only go on to develop cancer if they are further exposed to a promoting agent, which 
in most cases is the continuing presence o f  the initiating carcinogen. The exact number o f 
steps involved in the promotion phase is not known, but the latter is usually a prolonged 
process, as the latency with which lung cancer appears after many years o f  cigarette 
smoking displays. Furthermore, unlike initiation, promotion can be considered a 
reversible process. For instance, not all smokers will develop lung cancer and those who 
discontinue the habit will enjoy a progressive reduction in their risk o f developing the
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disease with increasing time. Furthermore, areas o f tissue hyperplasia and dysplasia which 
are regarded as early pre-malignant changes, do not all inevitably progress to become 
cancerous.
From the design o f  Penman’s study (311), it cannot be identified at which o f these 2 main 
stages o f  the carcinogenesis process omeprazole exerted its effect, as the drug was given 
throughout the duration o f the study. The animals were therefore exposed to omeprazole 
both during carcinogen administration (initiation) and thereafter (promotion). The 
experimental work described in this thesis was designed to clarify the influence o f  
omeprazole on the initiation and promotion phases o f colorectal carcinogenesis and on in 
vitro colorectal cancer cell proliferation.
<
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11. Summary
Peptic ulcer disease and colorectal cancer remain two o f  the most prevalent diseases 
worldwide.
With the advent o f new, powerful acid inhibitory drugs, the management o f all but the 
most resistant cases o f peptic ulcer is medical. These drugs have largely superceded 
effective acid reducing surgery which was popular up until about 20 years ago. A legacy 
o f  such surgery has been the recognition o f a decreased life expectancy and a propensity 
for development o f malignancy, usually occuring 15 to  20 years post-operatively. Gastric 
cancer and lung cancer have frequently been seen as the commonest malignancies to occur 
in such patients, but so too has colorectal cancer. Potential explanations for the 
mechanism leading to its development include alterations in the bacterial milieu o f the 
gastrointestinal tract secondary to the surgically produced hypo/achlorhydria, leading to 
increased production and delivery o f carcinogens to the colorectal mucosa, and dietary 
changes in response to such surgery.
The vast majority o f  patients studied have undergone partial gastrectomy as opposed to  
vagotomy and drainage. Studies o f post-vagotomy patients have either had small patient 
numbers or too brief a follow-up period in comparison to their gastrectomised 
counterparts to give a true picture o f the mortality/cancer risk attendant with this 
procedure. The risk following vagotomy is important to establish for a number o f  
reasons. Firstly, we are presently at a time approximately 25 years on from when 
vagotomy was the commonest procedure employed in the surgical treatment o f peptic 
ulcer. If there is a latent period for vagotomy patients similar to that for gastrectomised 
individuals, then we may now just begin to see an increased incidence o f  colorectal cancer 
and other malignancies as a consequence o f  the operation. Furthermore, vagotomy,
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unlike gastrectomy, leads to chronic elevation o f circulating levels o f  the antral hormone, 
gastrin. Gastrin has been shown to be trophic for colorectal carcinoma both in vitro and 
in vivo, and blockade o f  gastrin receptors found on such tumours by specific antagonists 
leads to their reduced growth. Despite this evidence, the association between 
hypergastrinaemia and tumour growth remains controversial. If  such an association is 
true, however, it is possible that persons with chronically elevated gastrin levels, such as 
those previously vagotomised, may have a substantially increased risk for development o f 
colorectal cancer, and may benefit from screening for the disease in the long-term post­
operative period. Finally, if patients with long term acid suppression and 
hypergastrinaemia, do have an increased incidence o f colorectal cancer, this may have 
safety implications for the long-term prescription o f agents such as omeprazole and other 
proton pump inhibitors.
In view o f these concerns, Penman and colleagues designed an in vivo study to  assess the 
effect o f omeprazole induced hypergastrinaemia on the yield and growth o f chemically- 
induced colorectal cancers in rats. Unexpectedly, and to their surprise, they found that the 
drug treated animals had a significantly lower yield o f such tumours, compared to control 
animals, despite confirmation o f significant elevation o f gastrin levels in the former group. 
This finding remains unique and similar studies looking at omeprazole-induced 
hypergastrinaemia on colorectal carcinogenesis have shown no significant effect, 
inhibitory or otherwise, on tumour development. The mechanism for such an inhibitory 
action o f omeprazole on tumour growth, if real, remains unknown. The design o f  their 
study does not allow identification o f the possible time at which omeprazole exerted its 
action on the carcinogenesis process. One further isolated report exists for omeprazole 
inhibiting the growth o f a human carcinoma cell line o f  colorectal origin in vitro, 
suggesting a direct action o f the drug at cellular level.
I l l
The treatment o f  colorectal cancer remains primarily surgical, and despite increases in our 
knowledge o f  the genetic defects that occur early in its genesis, survival after treatment 
has changed little in the past 20 or 30 years. Identification o f  potential high-risk groups 
for the disease, such as those with a history o f previous ulcer surgery, may lead to  earlier 
diagnosis, treatment, and hopefully, improved survival. The possibility that some tumours 
may be influenced by the hormone, gastrin, whose action can be blocked by specific 
antagonist drugs, opens an exciting new avenue in potential treatment o f  the disease. So 
too, does the potential use o f a widely used drug with minimal adverse reactions, for 
reducing colorectal tumourigenesis, if isolated reports o f such an action can be 
substantiated. These constitute the reasons for the work contained in the following pages.
12. Statement of Aims
The aims o f the studies undertaken for this thesis are therefore :
1. To identify whether patients previously treated surgically for peptic ulcer disease, 
predominantly by vagotomy and drainage, run an increased risk for the development o f 
malignancy, in particular colorectal cancer, in the long-term post-operative period.
2. To investigate further, a possible inhibitory action o f the gastric acid-suppressing agent, 
omeprazole, on growth o f colorectal tumours in vivo and in vitro, despite the production 
o f endogenous hypergastrinaemia which occurs during treatment with the drug, and which 
itself may promote growth o f such tumours.
3. If such an action o f omeprazole is confirmed, to attempt to identify at which stage o f 
the carcinogenesis process this effect occurs, and assess whether the drug acts directly on 
the cancer cell, by investigation o f its effect on human colorectal cancer cells in vitro.
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Chapter 2 - Materials and Methods
1. Prospective Study o f Cancer Incidence following Surgery for Benign Peptic 
Ulcer, with particular reference to Colorectal Neoplasia after Vagotomy.
1.1. Introduction
A specialist clinic dedicated to the investigation and treatment o f  peptic ulcer ran for 
approximately 20 years, from the mid 1960’s to 1983, at the Western Infirmary, Glasgow. 
Apart from serving the population o f Glasgow and the surrounding towns, its catchment 
o f  patients extended from the Western Isles in the north to Dumfries and Galloway in the 
south, thus covering the whole o f  the West o f Scotland.
Each patient attending this clinic had details o f their medical history, examination findings 
and treatment, recorded on standardised proforma. Despite the clinic being disbanded in 
1983, these files were retained. Thus, there existed an ideal and untapped patient 
database that would address the issue o f cancer incidence in the years following surgery 
for benign peptic ulcer disease.
1.2. Selection o f  Study Cohort
Four thousand, five hundred and thirty three (4,533) patients attended the clinic between 
1965 and 1983. Patients who received no operative treatment and those in whom data 
was incomplete were excluded from further study. Similarly, a small number in whom it 
was felt co-incident factors may significantly alter their cancer risk or affect their 
endogenous gastrin status (for instance: one patient with hereditary polyposis coli, one
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patient who had an extensive small bowel resection for volvulus) were also excluded. 
This left a total o f  1,992 patients for analysis.
In contrast to previous studies o f a similar nature, there were no further exclusion criteria. 
Therefore, patients who had more than one operative procedure, whether for recurrent 
ulcer or for treatment o f  sequelae or complications o f the initial procedure such as bile 
vomiting, small stomach syndrome or dumping, were not excluded. Neither were those 
who had simple suture o f a perforated ulcer, whether followed or not by a more definitive 
anti-ulcer procedure. Nor were patients who had underwent cholecystectomy in addition 
to ulcer surgery, the former also being associated with an increased risk o f  colorectal 
carcinoma (298-301). This was thought appropriate as such select sub-groups have either 
been totally excluded or had relatively little attention paid to them by previous workers, 
and therefore little, if anything, is known o f the cancer risk attendant with multiple gastric 
procedures or gastric surgery and cholecystectomy combined.
1.3. Characteristics o f  the Cohort
1.3.1. Distribution by Aue and Sex (Figure 1)
Patients age at operation, which was also their age at entry into the study, followed a 
normal distribution for the whole cohort and this was also the case when the male and 
female populations were examined seperately. The majority o f patients were operated 
upon between the ages o f  25 and 55. Males predominated in the series 4-fold with 1,578 
males compared to 414 females, 79.2% and 20.8% o f the total cohort respectively.
1.3.2. Number o f Operations (Figure 2)
The 1,992 patients underwent a total o f  2,628 operative procedures, giving a mean value 
o f 1.32 procedures per patient. The median value was 1, and the range 1 to 5.
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One thousand, five hundred (1„5Q0) had only/ one o p era tio n  an d  a fu rth e r 3 71 had tw o , the 
latter usually accoun ted  fu r by simple repair o f a perfo ra ted  u lc e r  p reced ing  th e ir elective, 
definitive p rocedu re .
1.3.3. O perative D iagnosis ("Table 1 and  Figture 3)
The m ajority  o f  bo th  m ale and fem ale patiem ts had undergone  su rg e ry  fo r duo d en a l ulcer. 
This diagnosis accoun ted  for 80%  o f  all opperations perform ed. G astric  u lce r w a s  m ore  
frequ ent in the fem ale popula tion  but w as  stilll 5 tim es less com m on th an  duo d en a l u lce r in 
this group.
1.3 .4. Nat ure o f  S u rgery  p erfo rm ed  (T ab le  21 and Fi gure 4>
The types and frequency  o f  opera tions p erfo rm ed  is ou tlined  below . A s can  b e  seen, for 
definitive surgery  fo r p ep tic  u lcer, vagottormy, w ith  o r  w ith o u t an assoc ia ted  drainage 
procedure, p redom inates.
1.3.5. L ength o f  fo llow -up  (F igure  5)
Patients u n d erw en t su rg ery  o v er a period! o f  81 years, rang ing  from  1906 to  1987. 
Exclusions w ere  not m ade if  su rgery  w as pcerformed ou tw ith  th e  lifespan o f  th e  clinic as 
long as th e re  w as sufficiently acc u ra te  inforim ation on  p ro ced u res  perfo rm ed . D e sp ite  this 
relatively b ro ad  tim escale, 9(0% o f  all operattions w ere  p e rfo rm ed  w ith in  a 25 y ea r period , 
from 1954 to  1979, the 5th and  95 th  centiless occuriing in these  years respectively , w ith  the 
median in 1969.
The follow -up period  w as defined as tiimte from  first defin itive u lcer o p e ra tio n  until 
diagnosis o f  cancer, cancer-free survival tilll death  o r th e  end  o f  July 1995. D efin itive 
surgery w as  any  surgery  perform ed  in an ; attem pt to  cu re  the  u lcer diathesis,, such  as
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vagotomy and drainage or partial gastrectomy, as opposed to, for instance, repair o f  
perforated ulcer.
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Materials and Methods - Table 2
Peptic Ulcer Clinic Study Cohort - 
Operations Performed
(values in parentheses are percentages)
Operation type Frequency
Vagotomy and Pyloroplasty 918 (35.0)
Vagotomy and Gastroenterostomy 700 (26.6)
Vagotomy only 130 (5.0)
Bilroth Gastrectomy 138 (5.3)
Polya Gastrectomy 163 (6.2)
Gastroenterostomy only 63 (2.4)
Pyloroplasty only 30 (1.1)
Roux-en-Y 10 (0.4)
Jejunal Interposition 9 (0.3)
Repair of Perforation only 341 (13.0)
Cholecystectomy 68 (2.6)
*Other 58 (2.2)
Total 2628
* Other - a heterogeneous group o f  procedures, 
for instance : local excision o f  ulcer, segmental gastrectomy
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1.4 Data Collection
Patient files were individually examined and relevant information pertinent to the study 
noted on a form designed for that purpose (Appendix 1). This allowed the data on all 
patients to be collated on computer for collective analysis at a later date.
Sufficient information was also recorded to allow definite identification o f  patients from 
the records o f  the local Cancer Registry, including name, date o f  birth, hospital 
registration number, last recorded address and General Practitioner’s name and address.
1.5. Identification o f Patients subsequently developing Cancer
Once all the relevant data for the study cohort had been recorded, each patient’s details 
were checked against the files o f  the West o f  Scotland Cancer Surveillance Unit, based at 
Ruchill Hospital, Glasgow. The latter agency registers cancers from six Health Boards in 
the West o f Scotland, namely Greater Glasgow, Argyll and Clyde, Lanarkshire, Ayrshire 
and Arran, Dumfries and Galloway and Forth Valley. This population area mirrors closely 
the referral area o f  the peptic ulcer clinic at the Western Infirmary. Cancer registration in 
this region began in 1958 and became computerised in 1985. The estimated population o f 
the region in June 1985 was 2, 777, 715 (325).
A patient identification was considered positive when at least two or more o f  the 
following criteria concurred between the files o f  the Peptic Ulcer Clinic and the Cancer 
Registry : Name, Address, Date o f Birth, Hospital Unit Number. W here any doubt 
existed as to  the identification, that patient’s hospital casenotes were retrieved and 
perused.
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1.6. Data Analysis
By summating the length o f follow-up for each patient, this gave the person-years at risk 
for the cohort. When multiplied by the cancer incidence rates prevailing in the general 
population over the same calender period o f the study (see study end-points above), this 
gave the number o f cases that would be expected in that number o f  patients over that 
particular period o f time. This calculated figure was compared with the observed number 
o f  cancer cases in the cohort and an observed : expected relative risk ratio was derived. 
Significance was assessed by application o f the Poisson distribution. The “general 
population” referred to above, is the population o f the West o f Scotland, from which all 
the patients in the cohort originated and whose specific cancer rates were used to 
calculate the expected cancer numbers.
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2. In vitro experiments - Clonogenic Assays
2.1 Introduction
The following experiments utilise the method o f clonogenic assay, which measures the 
proportion o f  a known number o f cells surviving after a period o f  exposure to a range o f 
concentrations o f the drug under investigation. After the period o f drug exposure has 
ended, the cells are plated out onto petri dishes. Viable cells form colonies, a count o f 
which gives an index o f survival during the period o f  drug treatment. The method is 
widely utilised in the investigation o f  cytotoxic drugs.
2.2 Human Colorectal Carcinoma Cell Lines and Culture Medium employed (Appendix 2) 
Three well established and widely used human colonic adenocarcinoma cell lines were 
used : LoVo - derived from a colorectal tumour metastasis in a supraclavicular lymph 
node o f a 56 year old male (326); HT29 - from the ATCC (American Type Culture 
Collection) (327); and B E. (328). They grow as adherent cultures in a 50/50 mixture o f 
Ham’s F10 Nutrient Mixture (Integra Biosciences, Northumbria Biologicals, U.K) and 
Dubecco’s modified Eagles medium (Gibco BRL, LifeTechnologies Ltd, Paisley, 
Scotland, U.K.) containing glutamine 2mmol/L (GibcoBRL, Paisley) and 10% foetal calf 
serum (Globepharm Ltd, Esher, Surrey, U.K.).
2.3. Preparation o f Omeprazole and Pentagastrin
Omeprazole powder was donated by the manufacturers (Astra Hassle, Molndahl, 
Sweden). In accordance with their instructions for use o f the drug in vitro, and due to its 
poor solubility in water, an initial solution o f  O.Olmol/L was prepared by diluting 3.45 
mgs o f  omeprazole powder in an organic solvent, buffered dimethyl sulphoxide (DMSO).
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This solution was then serially diluted with culture medium, initially by a factor o f  50, to 
achieve the strongest concentration to be tested, 0.2mmol/L. Four mLs o f  the latter was 
then diluted by a factor o f 5 to achieve the second test concentration, 40pmol/L, as were 
all subsequent concentrations, giving a broad range o f  test concentrations down to 
12.8nmol/L. The therapeutic range and maximal plasma concentrations o f the drug as 
observed in animals and humans at various dosing regimes fall well within the above range 
(313,329), as do the concentrations used in previous in vitro studies (330,331). 
Pentagastrin was obtained from l.C.I Pharmaceuticals, Wilmslow, Cheshire, U.K., as 
Peptavlon, which is packaged in glass ampoules each containing 500pgs Pentagastrin 
B.P. in 2mLs solution (sodium chloride, ammonium chloride and water). This constitutes 
an initial concentration o f  0.3mmol/L. This was serially diluted with medium, as described 
above, to give a range o f test concentrations from 6pmol/L down to 15.4 picomol/L.
2.4. Assay Technique
Established monolayers o f each cell line were loosened from the flask surface and from 
one another by addition o f 2mLs o f 0.5% trypsin solution, which was left to bathe the 
cells for 1 minute. Once the cell monolayer was disrupted, 8mLs o f culture medium was 
then added to form a suspension o f the loosened cells. A sample o f this was taken and 
counted in a Coulter counter (Coulter Electronics Ltd., Luton, Bedfordshire, England), 
which calculates the number o f particles in a suspension by measurement o f  the scatter o f  
a beam o f electrons passed through it. After appropriate dilution o f the suspension, cells 
were plated out at a density o f  7.75 x 104 cells per 25cm2 flask in 5mLs o f  culture medium 
and allowed to attach and grow for 2 days in a humidified atmosphere o f  2% CO 2 in air. 
The medium was then removed from each o f the flasks and replaced with 4 mLs medium 
containing the drug under investigation, namely, omeprazole, pentagastrin or the drug
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vehicle only (DM SO), at varying concentrations. One flask was replenished with drug- 
free medium and served as the control.
Drug exposure lasted 24 hours after which medium was removed from each o f  the flasks. 
The cells were then trypsinised as before, and re-suspended in lOmLs o f medium. 
Following this, the resultant cell suspensions were transferred to universal containers and 
centrifuged for 5 minutes at 3,000 revolutions per minute. The supernatant was removed 
and the cell pellets re-suspended in 10 mLs fresh medium and cells from the untreated 
control flask only, were counted. This cell suspension was diluted to achieve a suspension 
o f  103 cells per mL and 1 mL o f  this suspension was then plated onto 6cm diameter petri 
dishes and a further 5mLs o f medium added. Therefore, the control plates contained 103 
cells per dish. The suspensions from all the drug treated flasks were then diluted and 
plated exactly as for the control flask. Therefore, if the drug had no effect on these cells 
during the period o f exposure, one would expect to be plating a similar number o f  cells 
and ultimately expect similar numbers o f cell colonies at the end o f  the experiment. Four 
dishes were set up from each flask. These were then returned to the incubator for 10 days 
to allow colonies to develop from surviving cells.
At the end o f this period, growth medium was discarded, colonies were fixed in methanol 
and stained with 0.1% crystal violet solution. Colonies were counted by means o f an 
Artek colony counter. Three counts o f each plate were taken.
For omeprazole, 2 such identical assays were performed on each o f the cell lines, LoVo 
and B.E., and 3 on HT29, giving a maximum o f 8 and 12 colony counts respectively, at 
each concentration tested. A single assay was performed with the drug vehicle for 
omeprazole; dimethyl sulphoxide; to ensure that the concentrations o f  this compound, 
present in the omeprazole medium, would have no effect on the cells. Finally, 2 assays
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addressed the potential growth promoting action o f  pentagastrin on colorectal cancer 
cells.
2.5 Statistical Analysis
The clonogenic assays were examined by non-parametric one way analysis o f  variance 
using the Kruskal-Wallis test. Where the latter suggested significant differences between 
treatment groups (control/drug concentrations) within an assay, individual pairs o f  groups 
were examined by the Mann-Whitney U test to identify them. Any potential trend in 
colony count as omeprazole concentration increased was assessed by the Wilcoxon-type 
non-parametric method devised by Cuzick (332) and described by Altman (333). 
Significance was taken at P = 0.05 or less.
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3. In vivo Study - Effect of Omeprazole treatment (and the resultant 
hypergastrinaemia so induced) on the Initiation and Promotion Phases o f  
chemically induced Colorectal Carcinogenesis in Rats.
3.1. Introduction
In order to ensure that comparisons could be made with the original work which was the 
stimulus to this study (311), it was designed to adhere as closely to the original 
experiment as possible, in terms o f  animal species, laboratory conditions, drug 
preparations and dosages.
3.2. Animal Species and Care
Seventy five, 5-week old, female Sprague Dawley rats (Harlan OLAC Ltd, UK) were 
housed and maintained under standard animal house conditions with a 12 hour light-dark 
cycle, with free access to water and rat chow. Animals were weighed on a weekly basis 
and examined daily for any signs o f ill health which could potentially lead to  early sacrifice 
and withdrawal from the study. Particular attention was paid to any signs suggestive o f  
colonic tumour development, for instance: diarrhoea or abdominal distension.
3.3. Drug Preparation (Appendix 3). Administration and Handling
Dependant on treatment group and phase, each rat received a single daily dose o f  either 
omeprazole suspension or inert drug vehicle. Omeprazole was given in a dose o f 
40pmol/kg/day at a volume o f 5mL/kg/day and inert vehicle at the same volume per 
kilogram o f body weight. Pure omeprazole powder (Astra Hassle) was suspended in a 
vehicle o f  0.25% methylcellulose, buffered with 0.2% sodium bicarbonate and adjusted to 
pH 9 with sodium hydroxide. This was kept refrigerated at 4°C for up to  5 days when in
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use, but stored at a temperature o f -20°C until required. Inert drug-free vehicle was 
treated similarly.
The proximate carcinogen, azoxymethane (Sigma Chemicals, Dorset, UK) was diluted 
with sterile normal saline to a concentration o f lOOmgs/mL and stored in a locked 
container at 4°C. Immediately prior to administration, it was further diluted with normal 
saline to 10 mgs/mL. In accordance with “Control o f Substances Hazardous to Health” 
(COSHH) guidelines, to avoid exposure to the chemical, all work with azoxymethane was 
performed inside a unidirectional airflow hood whilst wearing a mask with organic 
chemical filter and disposable gown and double gloves. Non-essential staff were excluded 
from the vicinity o f  the procedure room and the area used to house the animals. All 
contaminated materials including disposable overclothes and animal waste and bedding 
were double-bagged and destroyed by incineration.
3.4. Study Design (Table 3 and Figure 6)
After a settling-in period o f 1 week, the 75 rats were randomly allocated into 3 equally 
sized treatment groups o f 25, as shown below. The duration o f the experiment was 24 
weeks.
Omeprazole and placebo dosage were given by once daily oral gavage. Each animal was 
gently restrained in one hand in the proper fashion and a semi-rigid plastic catheter was 
passed perorally down the oesophagus into the stomach, at which point the appropriate 
amount o f drug was instilled from an attached syringe. This technique ensured that an 
exact dose was administered and received by the animal. It has clear advantages over 
other forms o f oral administration, such as addition o f drug to drinking w ater or food, 
where ingestion o f a specified amount varies and cannot be guaranteed.
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Table 3 
T rea tm en t Phase 
W e e k !  - 12 W eek 13-24
G ro u p  A : Omeprazole 40pmol/kg/day Inert drug vehicle 5mL/kg/day
G ro u p  B : Inert drug vehicle 5mL/kg/day Omeprazole 40pmol/kg/day
G ro u p  C  : Inert drug vehicle 5mL/kg/day Inert drug vehicle 5mL/kg/day
All animals received azoxymethane by once-weekly subcutaneous injection, in a dose o f 
lOmg/kg/week for 10 weeks (weeks 1 to 10 inclusive) resulting in a total dose per rat o f 
1 OOmg/kg.
Group A subjects received omeprazole during the initiation phase o f carcinogenesis; that 
is: in conjunction with administration o f carcinogen; and crossed over to placebo 
treatment in the promotion phase, after cessation o f exposure to carcinogen. Conversely, 
Group B animals only commenced active treatment with omeprazole after carcinogen 
exposure had ceased. The treatment cross-over point was delayed for 2 weeks after the 
final azoxymethane injection to ensure complete metabolism and clearance o f  the 
carcinogen from the animals prior to change in treatment. Group C received placebo for 
the duration o f the study and acted as the control group.
3.5. Assessment o f Endogenous Gastrin Response to Treatment
To assess endogenous gastrin levels in response to omeprazole treatment, samples o f  tail 
vein blood, up to a maximum o f lmL, were taken from each rat at 3 time points during 
the study. The first sample was collected in the week prior to commencement o f  
treatment (week 0), to obtain baseline fasting values o f plasma gastrin. A second sample 
was taken in week 6, representative o f  the first treatment phase o f the study, and the final
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sample was collected in week 24, representative o f the second treatment phase o f the 
study. All blood sampling was performed between 1200 - 1600 hours which, in the case 
o f the latter two sampling points, was within 2 to 4 hours o f  drug or placebo 
administration. Blood was collected into Eppendorf tubes containing 0.1 mL lithium- 
heparin solution, centrifuged and the plasma separated and pipetted into Nunc containers 
and stored at -70" C for analysis at a later date. As in Penman’s study, plasma gastrin was 
analysed by radioimmunoassay with R98 antibody (334).
3.6. Post-M ortem Analysis
At the end o f the study, all rats were killed by cervical dislocation, and post-mortem 
examination performed. The entire colorectum from caecum to anus was removed, 
opened longtitudinally, pinned flat on a cork board, cleaned and examined by naked eye. 
All visible mucosal lesions were noted, and their volume (product o f height x length x 
breadth) and distance from anal verge measured. Each tumour was assigned an 
identification code, then excised, fixed in 10% formalin and thereafter processed to 
paraffin, stained with haematoxylin and eosin and examined by light microscopy. The 
latter was performed by a pathologist who had no knowledge from which treatment group 
the specimens had originated.
Lesions were classified as adenocarcinomas or adenomas and in the case o f  
adenocarcinomas, depth o f  invasion o f  the bowel wall was classified by stage as either 
Dukes A or Dukes B, as described in Chapter 1.
Only macroscopic abnormalities were taken for analysis. Therefore, neither visibly or 
palpably normal mesocolon, was routinely submitted for microscopic examination and 
thus it is accepted that some o f  the lesions classified as Dukes stage B may in fact be
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Dukes C due to the presence o f microscopic metastases in the draining mesenteric lymph 
nodes, hence Dukes B lesions are referred to as Dukes B+.
3.7. Statistical Analysis
Tumour incidence, Dukes stage and carcinoma to adenoma ratio were analysed by Fishers 
exact test. Total tumour yield, tumour volume and distribution were assessed by the 
Mann Whitney U test. Plasma gastrin values in the different phases o f  the study were 
compared using Student’s paired T-test, and animal weight and growth rate by Student’s 
unpaired T-test. Correlation between tumour development and final animal weight and 
growth rate was examined by calculation o f  Spearman’s rank correlation co-efficient(rs). 
Significance in all tests was assumed at P = 0.05 or less.
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Chanter 3 - Results
1. Cancer Incidence following Surgery for Benign Peptic Ulcer
From the cohort o f  1,992 patients operated on for peptic ulcer, a total o f  352 cancers 
arising in 339 o f these patients were identified. Eleven patients developed 2 malignancies 
and one patient had 3. The latter unfortunate man had a skin cancer diagnosed 9 years 
after his ulcer operation and more significantly, developed colorectal cancer 15 years post- 
operatively, before succumbing to a gastric neoplasm within a year o f  this. Figure 1 
indicates the frequency o f  the most commonly encountered neoplasms. The observed and 
expected numbers o f the commonest neoplasms, with the observed: expected relative risk 
ratios (0 :E ) are summarised in Table 1. The results from analysis by specific operation 
type are summarised in Table 2. The category labelled “Other” in the results presented is 
a heterogenous group o f diagnoses which includes various types o f haematological and 
reticulo-endothelial malignancies; benign and in-situ neoplasms; secondary carcinomas 
with primary origin unspecified; and isolated cancers at a variety o f  sites, including cervix 
(1), ovary (4), testis (3), gall bladder (2), liver (1) etc ... In view o f  either the small 
numbers o f cases involved, or difficulty in accurately categorising many o f these 
diagnoses, analysis o f these was not performed.
Overall, the incidence o f malignant disease within the cohort was not excessive compared 
to the population from which the patients originated. Indeed, less malignancies than 
expected were seen (observed 352 : expected 412 ; RR = 0.85 ; P = 0.99). Carcinoma o f  
the lung was the most frequently observed cancer in the cohort and was slightly more 
prevalent than in the population from which the patients originated, though just outwith
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statistical significance (observed 119 : expected 106 ; RR = 1.13 ; P = 0.09). A 
significant excess for this disease was however evident in the vagotomised group o f 
patients (observed 95 : expected 79 ; RR = 1.20 ; P = 0.04).
Cancers o f the large bowel were the next most frequently observed neoplasm but were 
less than expected (observed 30 : expected 45 ; RR = 0.67 ; P = 0.9). This applied 
regardless o f operation type (vagotomy with or without drainage : observed 25 : expected 
33 ; RR = 0.76 ; P = 0.94 ; partial gastrectomy : observed 3 : expected 8 ; RR = 0.38 ; P 
= 0.99). The latent period between ulcer operation to diagnosis o f  colorectal cancer 
ranged from 5 to 29 years. The median period was 17 years and the median age at which 
cancer was diagnosed in these patients was 65 years (range 54 - 89years).
Carcinoma o f the stomach accounted for 27 cancers in the cohort and this was only 
slightly greater than the expected 20 (RR = 1.17 ; P = 0.23). These presented from as 
early as 2 years up to 31 years post-operatively. The median value for the latent period 
was 11 years and median age at diagnosis was 63 years (range 38 - 89years).
When the patients are subdivided according to operative procedure performed, it is clear 
that vagotomised patients do run a significantly greater risk o f  gastric cancer (observed 24 
: expected 16 ; RR = 1.50 ; P = 0.04). Patients undergoing partial gastrectomy would 
appear to have a decreased risk, o f the order o f 50 %, compared to the population at 
large, though the numbers are small (observed 2 : expected 4 ; RR = 0.5 ; P = 0.91). 
When analysing the cohort as a whole, only laryngeal cancer was found to  be significantly 
excessive with 12 observed cases against an expected 6 (RR = 0.5 ; P = 0.04), and this 
was found to be due to a significant excess in the vagotomised group o f  patients 
(observed 10 : expected 4 ; RR = 2.5 ; P = 0.01). With the exception o f  this and the 
commonest cancers discussed above, none o f the other cancers were any more common
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than would be expected and this persisted even when they were analysed for each specific 
operation sub-group (see below).
As previously mentioned, some sub-groups were also examined, which, by and large, have 
been ignored or excluded from previous studies. Thus, 89 patients underwent simple 
closure o f a perforated peptic ulcer and no further operation. For these patients, no 
significant differences between observed or expected cases o f  cancer were apparent, either 
overall, or for any individual cancers. A similar scenario was evident for patients having 
undergone gastroenterostomy only (24 patients), pyloroplasty only (22 patients - such 
patients were found to have no significant pathology at operation and had exploratory 
gastroduodenotomy closed as a Heinecke-Mickulicz pyloroplasty) and those who also had 
a history o f cholecystectomy in addition to  their ulcer surgery (68 patients). These groups 
are numerically small but their inclusion should not invalidate the results o f  the cohort as a 
whole, as no significant variations in risk are apparent within these select groups. 
Therefore, included within the major subgroups o f vagotomised and gastrectomised 
patients (1,857 in total), 299 had preceding closure o f perforated ulcer, a 
gastroenterostomy or pyloroplasty only. Also included are the 68 patients mentioned 
above who had cholecystectomy in addition to their ulcer operation.
In addition, the small subgroups o f patients who had undergone “multiple procedures” , 
that is, more than one definitive type o f  ulcer surgery were studied. Examples o f  this 
were patients who had vagotomy and drainage followed by a partial gastrectomy, usually 
for recurrent ulcer (143 patients) and/or biliary diversion procedures (19 patients). Such 
patients did not appear to have any significant difference in risk with respect to the 
population at large. However, as the aim o f the study was to accurately assess and 
compare the long term sequelae o f specific operation types, this group o f  patients were 
excluded from analysis o f the major vagotomy and partial gastrectomy operation
subgroups, for two reasons. Firstly, and quite simply, they were unable to be assigned to 
one particular ulcer operation category. Furthermore, and more importantly, such 
patients would have variations in potentially significant factors such as circulating gastrin 
levels and entero-gastric reflux as a result o f the different operations performed, within the 
follow-up period. For instance, a patient may have significant hypergastrinaemia 
following a vagotomy and drainage procedure, but then be rendered normo or even 
hypogastrinaemic after having a subsequent antrectomy some years later. That same 
patient may then undergo a Roux-en-Y biliary diversion for bile reflux some months or 
years following the antrectomy and therefore also have significant alteration the degree o f 
gastro-enteric reflux. As such, it would be very difficult to hypothesise what particular 
pathophysiological change might be responsible for subsequent cancer development, were 
it to occur in such an individual.
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Results - Table 2
Incident Cancers bv Operation Category
Total Cohort(1992)
All Cancers
Observed
352
Expected
412
Relative Risk
0.85
*P vain
0.99
Stomach 27 23 1.17 0.23
Colorectal 30 45 0.67 0.9
Lung 119 106 1.12 0.09
Bladder 15 25 0.6 0.99
Larynx 12 5.52 2.17 0.01
Brcast(F) 12 14.8 0.81 0.8
Prostate(M) 9 30.7 0.29 0.99
Pancreas 7 9.9 0.71 0.86
Kidney r, 7.25 0.83 0.72
Oesophagus 5 10.9 0.46 0.98
Skin 32 48.6 0.66 0.99
**Other 78 - - -
All Cancers
Observed
267
Vagotomy+/- Drainagc(l556) 
Expected
306
Relative Risk
0.87 0.98
Stomach 24 16 1.5 0.04
Colorectal 25 33 0.76 0.94
Lung 95 79 1.2 0.04
Bladder 11 21 0.53 0.99
Larynx 10 4.34 2.32 0.01
Brcast(F) 10 11.6 0.86 0.72
Prostatc(M) 8 22.7 0.35 0.99
Pancreas 7 7.4 0.95 0.61
Kidney 4 5.5 0.73 0.8
Oesophagus 5 8.2 0.61 0.91
Skin 24 40.2 0.6 0.99
**Othcr 44 - _ _
All Cancers
Observed
49
Partial Gastrcctomy(301) 
Expected
79
Relative Risk
0.62 0.99
Stomach 2 4 0.5 0.91
Colorectal 3 8 0.38 0.99
Lung 14 18 0.78 0.86
Bladder 3 5 0.64 0.85
Larynx 1 0.8 1.25 0.55
Brcast(F) 2 3.3 0.66 0.84
Prostatc(M) 0 - . »
Pancreas 0 -
Kidney 2 1.1 1.8 0.3
Oesophagus 0 - - •
Skin 6 9.6 0.63 0.92
**Othcr 16 _
*P value - O ne way analysis. Poisson distribution
**O thcr - sec text
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Results - Table 2 (continued)
Incident Cancers bv Operation Category
Cholccystcctomy(68)
All Cancers
Observed
6
Expected
16
Relative Risk
0.38 0.99
Stomach 0 1 _ -
Colorectal 0 2 - -
Lung 1 3 0.33 0.95
Bladder 0 - - -
Larynx 0 - - -
Brcast(F) 0 - - -
Prostatc(M) 0 - - -
Pancreas 0 - - -
Kidney 0 - - -
Oesophagus 0 - - -
Skin 0 - - -
♦♦Other 5 - - -
All Cancers
Observed
15
Repair of Perforated ulcer Only(89) 
Expected 
19
Relative Risk
0.78 0.85
Stomach 0 1 . _
Colorectal 1 2 0.5 0.99
Lung 7 5 1.4 0.24
Bladder 1 5 0.2 0.99
Larynx 0 - - -
Brcast(F) 0 - - -
Prostatc(M) 0 - - -
Pancreas 0 - - -
Kidney 0 - - -
Oesophagus 0 - - -
Skin 2 9.3 0.22 0.99
♦♦Other 4 - - -
All Cancers
Observed
6
Gastroenterostomy only(24) 
Expected 
8
Relative Risk
0.75 0.81
Stomach 1 1 1 0.99
Colorectal 1 1 1 0.99
Lung 2 2 1 0.59
Bladder 0 - - -
Larynx 0 - - -
Brcast(F) 0 - - -
Prostatc(M) 0 - - -
Pancreas 0 - - -
Kidney 0 - - -
Oesophagus 0 - - -
Skin 0 - - -
♦♦Other 2 _ • _
♦P value - One way analysis, Poisson distribution 
♦♦Other - sec text
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Results - Table 2 (continued)
Incident Cancers bv Operation Category
Pyloroplasty only(22)
Observed Expected Relative Risk *P value
All Cancers 2 3 0.67 0.81
Stomach 0 0 . _
Colorectal 0 0 - -
Lung 1 1 1 0.63
Bladder 0 - - -
Larynx 0 - - -
Brcast(F) 0 - - -
Prostatc(M) 0 - - -
Pancreas 0 - - -
Kidney 0 - - -
Oesophagus 0 - - -
Skin 0 - - -
**Othcr I
Multiple Proccdurcs(143) 
Observed Expected Relative Risk
All Cancers 20 30 0.67 0.97
Stomach 0 2
Colorectal 1 3 0.33 0.9
Lung 5 8 0.63 0.9
Bladder 1 2 0.56 0.83
Larynx 0 - - -
Brcast(F) 2 0.9 2.2 0.23
Prostatc(lM) 0 - - -
Pancreas 0 - - _
Kidney 0 - - -
Oesophagus 0 - - -
Skin 3 3.6 0.83 0.7
**Othcr 8
Jejunal Intcrposition/Roux-cn-Y(19) 
Observed Expected Relative Risk
All Cancers 4 6 0.67 0.84
Stomach 0 0 .
Colorectal 0 1 - _
Lung 2 2 1 0.59
Bladder 0 - - _
Larynx 0 - - -
Brcast(F) 0 - - -
Prostatc(M) 0 - - -
Pancreas 0 - _ _
Kidney 0 - _ _
Oesophagus 0 - - -
Skin 0 - . .
**Othcr 2
♦P value - O ne way analysis, Poisson distribution 
♦♦Other - sec text
*
145
2. C lonogenic Assays
The results for each assay are presented in tabular fashion (Tables 3 - 7 )  and also 
graphically (Figures 2 - 6).
2.1. Cell line LoVo and Omeprazole (Table 3 & Figure 2)
Multivariate analysis by the Kruskal Wallis test confirmed there to  be significant 
differences in colony counts between the various treatment groups in the assay (P = 0.03). 
Separate pairs o f  groups were then analysed by the Mann Whitney U-test. This confirmed 
that treatment with the highest concentration o f omeprazole (0.2mmol/L) resulted in 
significantly fewer surviving cells, as reflected in the lower colony counts, when compared 
to both control (P = 0.006) and all cell groups treated with lesser concentrations o f 
omeprazole (P = 0.004 to 0.006). Cell survival after exposure to all lesser doses o f  
omeprazole did not differ from control cultures (P = 0.07 to 1.00). The W ilcoxon-type 
test for trend was positive (P = 0.03) and inspection o f Figure 1 does indeed show a 
modest reduction in median colony count as omeprazole concentration increases, most 
obvious from 0.32pmol/L upwards.
2.2. Cell line B E. and Omeprazole (Table 4 & Figure 3)
The results for cell line B E. are similar to those for LoVo. Multivariate analysis showed 
there to be significant variation within the assay groups (Kruskal Wallis, P = 0.02), and 
after separate analysis o f pairs o f groups, this was found to be due to significantly reduced 
colony counts after exposure to the highest omeprazole concentration compared to 
control (Mann Whitney, P = 0.04) and all lesser tested drug doses (Mann Whitney, P = 
0.0007 to 0.04). As with LoVo cells, none o f the other drug doses resulted in any
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significant variation in survival compared to control cells (Mann Whitney, P = 0.11 to 
0.96). No significant trend in cell survival existed as omeprazole concentration increased 
(P = 0.94).
2.3. Cell line HT29 and Omeprazole (Table 5 & Figure 4)
Perusal o f  the plotted results for cell line HT29 show that, like the other two cell lines, the 
lowest colony count is obtained at 0.2mmol/L omeprazole. However, the colony counts 
obtained after exposure to this concentration o f omeprazole, and those at all lesser 
concentrations, did not differ significantly from control counts or each other (Kruskal 
Wallis, P = 0.07). Neither was there any significant trend in results as drug concentration 
increased (P = 0.09)
2.4. Assay to assess any potential effect o f  drug vehicle on cell survival 
(Table 6 & Figure 5)
All o f the above assays utilised cells which were grown in culture medium only, as 
controls. To ensure that this was legitimate and that the “inert” drug vehicle, dimethyl 
sulphoxide (DMSO), would not by itself have any confounding effect on the results, a 
single assay was performed, using cell line B E ., exposing groups o f cells to the range o f 
concentrations o f DMSO present at each o f  the tested concentrations o f  omeprazole. 
Multivariate analysis o f the results again confirmed statistically significant variations to 
exist within the assay treatment groups (Kruskal Wallis, P = 0.01). When sub-analysis 
was performed this showed that both the cells treated with omeprazole 0.2mmol/L and 
those exposed to the equivalent concentration o f  DMSO only, had significantly reduced 
counts compared to drug and vehicle-free control cells (Mann Whitney, P = 0.007 and P = 
0.02, respectively) but were themselves similar in magnitude (Mann Whitney, P = 0.55).
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As before, at all lesser concentrations o f both drug and vehicle, no significant differences 
existed compared to Control counts (Mann Whitney, P = 0.06 to 0.91) and like 
omeprazole 0.2mmol/L and its corresponding “vehicle only” concentration, no significant 
differences in colony counts existed between drug exposed/vehicle only exposed cells at 
all the other test concentrations (Mann Whitney, P = 0.21 to 1.00).
2.5. Cell line HT29 and Pentasastrin (Table 7 & Figure 6)
Although the median colony counts o f pentagastrin treated cells at all concentrations were 
modestly elevated in comparison to control, this was not statistically significant (Kruskal 
Wallis, P = 0.55). Nor was there any significant trend with drug concentration (P = 0.6).
156
o ©E mCNa.VO
VO
m<N
VO
CNCN
T3<1)
o
<u
c3
cu
VO
O
VOus
vo ^
>—1 ov
CN rn •*t
Ovm
® CN
E £  
a. ^<n
m VO VO VO m m VO
00 Ov K S vd r r Ov
ov oo o us N" m CN
^r us CN CN CN CN
00
rrvom
QJ
IE
CQ
H
i
C/3|
" 5
C/3
OJ
e» pm
s -
C/3
«
&J
03
C
cj
>
CQ
C/3
C/3
<
CJ • ■■
C
QJ
&Joco
C*s
n
H
S3
QJ
C
so
•■e
U•<->
cV o  
C o
U
■*—V)V
H
£o
E
a.
N•O
o
E
cvo
OV
©
E
cCN
OS
o
E
s
00
m
o
£o
E
aoo
VO
vo
OvTt
o  *>
S vOr-
ooTf
o
VO
CN
T3©
V
c3
Oh
vO in
cn r -  o  us us
m
CN
00
m
CN
VO
T3©
u
v
—CU
~a©•4-»CJ.©
a>
13
Cu
vo
OVVO
cn vo m
us* us cn
US Ous us us
00
us
m
US
^  CN ^  ~o  OO N- ^
vo %n oo ^us us
oo
vo
m
oooo
■*frOv
VO
Ov
CN
vo m cn cn m vo vo
us us o ' cn CN vd CNvs vo r - O CN m
CN m US us
00
CNI/’S
CNCN
us
Ovs
_ _ m  mov ov • ■
O v  v O  v t  ^
m m oo oom  m
r->
if)
vn
VO
Ov
CN
cn vo VO
vd m vd VO*O Tf mus us US cn
VO1/3
CO
00
00CO
00r -CN
O \o
E -Cu m
Tf
If)
00
vo vo cn m
m ov s
o 00 us
CN us us
r -
u s
vo
vd
vo
if)
o
oom
2-4-t
co
U
00
CN
CN
m
us
t"m
i- i  CN
O
CN
m
us
if) vo
£
s
*
vO
s
vo
us
2 * 2
00
If)•moo
Z
S
o
W
N
on
-p
ar
am
et
ric
 
on
e 
wa
y 
an
al
ys
is 
of 
va
ria
nc
e(
K
ru
sk
al
 W
al
lis
)s
ho
w
ed
 
no 
sig
ni
fic
an
t 
di
ffe
re
nc
e 
be
tw
ee
n 
any
 
of 
the
 
gr
ou
ps
157
VO
CJIm
3
Oj
u .
I
3
CJ
(/)
CQ
&J
c
CL>
Cu
O n
fS
H
C/5<D
73>
ecd
*5<u
£
I
oor~~
I I II I I  I
CN
CN
O
00
II II
I II II
00
cn
I I I a,oo
vo
I a.
o o o oo
CN
o o
au■4-tcVVeo
U
)u n o 3  Xuo| 0 3
No
n-
pa
ra
m
etr
ic 
on
e 
wa
y 
an
aly
sis
 o
f 
va
ria
nc
e 
(K
ru
sk
al 
W
all
is)
 s
ho
we
d 
no 
sig
ni
fic
an
t 
dif
fer
en
ce
 b
etw
een
 
any
 
of 
the
 g
ro
up
s
158
3. In vivo Study - Effect of Omeprazole treatment (and the resultant 
hypergastrinaemia) on the Initiation and Promotion Phases o f chemically induced 
Colorectal Carcinogenesis in Rats.
3.1. Endogenous Gastrin Response to Treatment (Figure 7A - C and Appendix 1)
As described in the previous chapter, each rat had blood taken for measurement o f  
endogenous circulating gastrin levels at 3 time points in the study. The first o f  these were 
taken in the week before any dosing with omeprazole, inert drug vehicle or azoxymethane 
began (week 0) and represent “normal” baseline values. The next set o f  samples were 
taken at week 6, the mid-point o f the first phase o f the study, at which time group A were 
being dosed daily with omeprazole and groups B and C were receiving inert drug vehicle. 
Finally, blood samples were collected in the last week o f  the study, when group B were 
receiving omeprazole and groups A and C, the drug vehicle. This was to confirm that 
omeprazole treatment caused the expected elevation o f  the hormone. This was indeed the 
case, as can be seen from inspection o f Figure 6A-C. Omeprazole treatment caused 
significant hypergastrinaemia compared to baseline values and those in the placebo phases 
o f the study in both groups A and B (P < 0.0001 for all tests, Student’s paired T-test).
With one exception, baseline gastrin values and those measured during administration o f  
placebo drug vehicle were very similar (Students paired T-test: Group B, P = 0.12; Group 
C, P = 0.61 and 0.94 for phase 1 and phase 2 o f the study respectively). However, this 
was not the case in group A where baseline measurements were significantly increased 
over vehicle values (P < 0.0001). Inspection o f the plotted values also indicates the group 
at this stage to have significantly elevated baseline levels over those for groups B and C (P 
< 0.0001 for both, Students unpaired T-test). This was unexpected but probably 
represents random, food-stimulated gastrin levels due to these animals inadvertently not
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Results - Figure 7a-c 
Plasma Gastrin Variations
a) Group A
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being fasted for the 2 to 4 hours prior to blood sampling, as the study design protocol 
dictated. They still had significantly lower gastrin levels compared to those in the active 
treatment arm and as such, it is believed that this observation will not significantly affect 
the study end-point.
3.2. Disease incidence, tumour yield, type and stage, distribution and volume & animal 
growth rates
Each o f  the above is discussed individually below but the results are summarised in Table 
8. A complete summary o f  these measured outcomes for each individual animal subject is 
presented in Appendices 2 to 4. The weekly weights, final weights and grow th rates for 
each animal are tabulated in Appendices 5 to 7.
3.2.1. Disease Incidence
Disease incidence in each o f the three groups was very similar. O f the 25 Group A 
animals, who received omeprazole in the initiation phase o f carcinogenesis, 16 had 
macroscopic tumours at the end o f  the study. In Group B, where omeprazole was 
administered during the promotion phase o f carcinogenesis, 18 o f 25 animals developed 
disease. Finally, in the control group C, 17 o f 25 animals were found to have tumours. 
As can be predicted from these values, no significant difference for disease incidence 
existed between any o f the 3 groups (Group A versus Group B, P = 0.38; A versus C, P = 
0.50; B versus C, P = 0.50; Fisher’s exact test).
3.2.2. Total tumour yield
In Group A, a total o f  18 lesions developed in the 16 affected animals. For Group B, the 
total was slightly higher with 24 tumours in the 18 rats to have developed disease.
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Finally, the greatest yield o f  tumours was evident in Group C, with 27 developing in the 
17 affected rats. However, these differences did not reach statistical significance.(Group 
A versus Group B, P = 0.63; A versus C, P = 0.68; B versus C, P = 0.85; Mann Whitney 
U test)
Indeed, the slightly greater number o f tumours in Groups B and C are largely accounted 
for by a minority o f rats found to have multiple lesions (2 animals in group B had 3 
tumours, as did 2 in group C, along with 1 rat with 4 lesions) but the median number o f  
tumours per rat in each group was 1.
3.2.3. Tumour type and stage
Carcinomas were the commonest lesion in all 3 treatment groups, and the relative 
proportions o f  carcinomas to adenomas in each group were similar and did not differ 
significantly (Group A versus Group B, P = 0.28; A versus C, P = 0.22; B versus C, P = 
0.58; Fisher’s exact test).
The stage o f carcinomas was similar in all three groups. O f the 17 carcinomas in group A,
15 were Dukes A and 2 Dukes B+. In group B, there were 15 Dukes A and 5 Dukes B+ 
tumours and finally, in group C, 19 Dukes A and 3 Dukes B+. These ratios were not 
significantly different when compared by Fisher’s exact test (Group A versus Group B, P 
= 0.28; A versus C, P = 0.63; B versus C, P = 0.29). It should be reiterated that as 
grossly normal mesocolon and its contained lymph nodes was not routinely submitted for 
histology, it is possible that some o f the tumours labelled Dukes B are in fact Dukes C by 
virtue o f microscopic metastases in the draining nodes, hence the reason Dukes B lesions 
have therefore been classified as Dukes B+, as seen in Table 8. Only one animal, in group 
A, was noted to have a single visibly and palpably enlarged mesocolic lymph node at post 
mortem, which was retained and examined, microscopy confirming it as containing
I 162I
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metastatic adenocarcinoma, thus confirming the bowel lesion as a Dukes C stage tumour. 
There was no evidence o f more distant disease, for instance, liver metastases or peritoneal 
deposits in any o f the animal subjects.
3.2.4. Tumour distribution in the colorectum (Figure 8A & 8B)
All three groups had a similar distribution o f  lesions within the colorectum (Group A 
versus Group B, P = 0.62; A versus C, P = 0.85; B versus C, P = 0.59, Mann Whitney U 
test), with the majority o f tumours being found in the mid-portion o f  the bowel, 
approximately halfway between the caecum and anus.
Figure 8A - Tumour Distribution in the Colorectum
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Results - Table 8
In vivo experiment results
Group A Group B
Disease Incidence (% ) 16(64) 18(72)
Total Tumour Yield 18 24
N° Tumours per rat M e a n  0.72 0.96
M e d ia n  ( R a n g e ) )  1(0-2) 1(0-3)
Adenomas 1 (6%) 4 (17%)
Carcinomas 17(94%) 20(83%)
D u k e s  A  15 15
D u k e s  13+ 2 5
Tumour Volume(mm3) M e a n  159 148
M e d ia n  ( r a n g e )  95(2-864) 116(18-648)
Tumour distribution* M e a n  50.5 46.6
M e d ia n ( r a n g e )  49.5(8-83) 46(24-61)
Animals M e a n  G r o w th  R a t e  (g r a m s /w e e k )  3.06 3.2
M e a n  F i n a l  W e ig h t  ( g r a m s )  297.52 291.92
Group C
17(68)
27
1.08
1(0-4)
5 (19%) 
22 (81%) 
19 
3
90
65(2-288)
48.8
50(18-67)
3.38
301.44
No statistically significant differences exist between the groups for any of the recorded parameters. 
*distancc from anal verge expressed as % of total colon length.
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3.2.5. Tumour volume
Both Group A and Group B animals had slightly larger lesions than their Group C 
counterparts, mean values being 159 mm3, 148 mm3 and 90mm3 respectively, but these 
were not significantly different (Group A versus Group B, P = 0.80; A versus C, P = 0.61; 
B versus C, P = 0.25, Mann Whitney U test).
3.2.6. Animal Growth Rate (Appendices 5 to 7)
The animals in all 3 treatment groups gained weight at a similar rate o f  approximately 3 
grams per week and ultimately had similar weights at the end o f the study, with no 
significant variation in growth rate (Group A versus Group B, P = 0.57; A versus C, P =
0.17; B versus C, P = 0.41, Student’s unpaired T-test) or final weight (Group A versus 
Group B, P = 0.42; A versus C, P = 0.58; B versus C, P = 0.16, Student’s unpaired T- 
test).
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Chanter 4 - Discussion and Conclusions
1. Cancer Incidence after peptic ulcer surgery
1.1 Summary o f Findings
1.1.1. Overall cancer risk in the cohort
In the study o f patients treated surgically for peptic ulcer some 26 years previously, there 
was no overall increased cancer risk conferred upon the cohort as a result o f  the 
operation. It must be remembered that patients did undergo a variety o f  operative 
procedures, some o f which will result in markedly different ensuing pathophysiological 
changes to the patient, as discussed in Chapter 1. Therefore, each category o f  operation 
was analysed seperately. This sub-divided the study population into a large group o f  
patients, almost 80% o f the total cohort, who had underwent vagotomy, almost always 
accompanied by a drainage procedure, either gastroenterostomy or pyloroplasty, as their 
one and only definitive anti-ulcer procedure. The next largest group o f  patients, 
accounting for 15% o f the study population, had previously undergone partial 
gastrectomy as their definitive anti-ulcer procedure. Thereafter, a number o f  small select 
groups accounted for the remainder. In none o f the operative groups, vagotomy or 
otherwise, was their any propensity for cancer development as a whole, in the years after 
surgery.
1.1.2. Incidence o f site-specific cancers in the whole cohort
When site-specific cancer incidence rates were studied, the incidence o f  laryngeal cancer 
was found to be slightly more than twice as common as one would expect in the general
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population over a similar period o f time, a statistically significant finding. No other form 
o f cancer was found to be significantly raised over expected rates, though bronchial 
carcinoma and gastric cancer were slightly commoner than expected, both falling just 
short o f statistical significance. No other cancers, and in particular colorectal cancer, 
were any more frequent than expected.
1.1.3. Site-specific cancer incidence after specific forms o f gastric surgery 
Analysis o f individual cancer incidence rates within each operative category gives a more 
concise measure o f any risk attendent with a specific operation type. Indeed, within the 
main group o f  vagotomised subjects, a statistically significant excess o f  laryngeal, 
bronchial and gastric neoplasms was apparent within the follow-up period. As observed 
in the study population as a whole, colorectal cancer was no commoner than expected in 
the vagotomy patients. Similar analyses in the gastrectomy group and all other operative 
groups, showed no increase in risk for this or any other form o f cancer.
Clearly, the findings o f this study reflect mainly on the operation o f  vagotomy. However, 
it does mean that caution should be exercised in interpreting the findings for the other 
groups, such as gastrectomy (301 patients) in whom the number o f subjects is small, and 
as such, any conclusions to be drawn are less valid. This, however does not apply to the 
vagotomised patients, who totalled 1,556 in number and who had a substantial period o f 
follow-up. Potential explanations for the significant findings in this group must be sought.
1.2. Bronchial and Laryngeal Cancer
Carcinoma o f the bronchus has been found to be excessive in a large proportion o f 
previous studies o f  a similar nature to the present one 
(165,166,168,170,172,174,191,193). All have concluded that this has little to do with any
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consequence o f  the surgery per se, but reflects the excessive use o f  tobacco by the 
subjects under scrutiny. It is difficult to argue with this conclusion, when one appreciates 
the tobacco consumption by the present study population. As illustrated in Figure 1, 77% 
o f the cohort were, at the time o f surgery, habitual tobacco consumers, mostly in the form 
o f cigarettes, now accepted as one o f the major risk factor for the disease (192). Clearly, 
one accepts that such information has been collected at only one time point in the life o f 
each patient, and that some patients may have reduced their risk by discontinuing the habit 
at a later stage, but the findings o f a recent study would suggest that this is likely to be a 
small minority (338). Ekbom and colleagues (338) demonstrated that although the 
incidence o f  lung cancer was significantly higher in peptic ulcer patients as a whole, the 
risk for the disease was significantly higher still, in those who had previously undergone 
surgery for their ulcer diathesis, which in the case o f  that particular study, was vagotomy. 
Whilst not rejecting outright the possible influences o f physiological and dietary sequelae 
as a result o f  the operative procedure itself leading to this outcome, they hypothesised that 
the findings reflected the continuation o f smoking in the operated subjects, as a result o f 
decreased anti-smoking counselling in the years after surgical “cure” o f their ulcer, as 
opposed to those unoperated, and presumably, symptomatic, patients who were in more 
frequent contact with doctors and therefore more likely to have been given repeated anti­
smoking advice. Thus, the information in Figure 1 is felt to  be a fair reflection o f  the 
smoking habits o f the cohort throughout the follow-up period o f the study. The excess o f 
laryngeal cancers, also strongly associated with smoking (192), is also undoubtedly due to 
the high prevalence o f tobacco use in the group under study.
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1.3. Gastric Carcinoma
Smoking has also become increasingly recognised as an independent risk factor for gastric 
cancer (339,340) but the association is not as strong as that for lung or laiyngeal cancer 
(192,341). There was a 50% increase over expected values for gastric cancer in 
vagotomised patients in this study. This is in concordance with the findings o f  many o f 
the previous studies reviewed in Chapter 1, and although the majority o f  these have dealt 
with gastrectomised patients (175,176,178,179,182,184-189), a similar outcome has also 
been reported in the smaller numbers o f vagotomised subjects studied to date 
(166,170,185).
The fact that this group o f  vagotomy patients would appear to suffer the same outcome as 
their gastrectomised counterparts, suggests that some factor common to both forms o f 
surgery is the underlying mechanism to the appearance o f the disease in the post-operative 
stomach. This factor may well prove to be the prolonged hypochlorhydria which ensues 
after both vagotomy and partial gastrectomy. What the study was not designed to answer 
is what sequelae o f  such acid inhibition are responsible for malignant change in the 
stomach, such as mucosal dysplasia, bacterial colonisation and formation o f  intraluminal 
carcinogens, all o f which have been discussed earlier.
Although one may assume that the majority o f the vagotomy patients will have had 
chronic, modest elevation o f circulating gastrin levels, the fact that a similar risk for the 
development o f gastric cancer has already been shown in gastrectomy patients, whose 
gastrin levels are either unchanged or reduced, would tend to exclude the hormone as 
being o f major importance in the development o f the disease.
One unknown variable is what part, if any, is played by Helicobacter pylori in the 
development o f cancer in the post-operative stomach. The latter organism is now 
recognised as a risk factor for the development o f gastric cancer, at least in the intact
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stomach (222). Bearing in mind that the vast majority o f  the patients treated by vagotomy 
in the present study suffered from duodenal ulcer, o f which approximately 95% o f  cases 
are known to be helicobacter pylori positive (42), then it is not unreasonable to  assume 
that a large proportion o f  these patients will have been carriers o f  the organism. The 
exact number will remain unknown, as will the effects o f  the surgery on the post-operative 
helicobacter status o f the individual, but hypochlorhydria per se is not a hostile 
environment for the organism, and one could also assume that in the years following their 
surgery, such individuals will continue to carry the organism in such an hypoacidic milieu. 
Indeed, a recent study showed that 83% o f patients previously vagotomised for peptic 
ulcer were still carriers o f the organism, when tested a mean o f  10 years later (342). 
Persistence o f the organism after partial gastrectomy was found to be lower at around 
50% (342). This observation, in concert with the other factors cited above, may combine 
to produce an increased potential for malignant change in the gastric mucosa post- 
operatively
1.4. Colorectal Cancer
The colorectal cancer risk after peptic ulcer surgery remains a matter o f  debate. A select 
number o f studies showed there to be an increased incidence o f the disease following both 
vagotomy (166,171) and gastrectomy (165,168,172). The former, by virtue o f  increasing 
circulating gastrin levels, may confer a substantial risk for the disease, given the sizeable 
body o f evidence, which shows gastrin to be a trophic factor for such neoplasms (see 
Chapter 1). Based on the findings o f the present study, however, this hypothesis cannot 
be supported as no excess cases o f the disease occured in the substantial period o f  follow- 
up after vagotomy. This is also the case for all other select operative sub-groups studied,
172
including gastrectomy, though as already mentioned, in the context o f  the present study, 
conclusions for these numerically small patient groups are less valid.
1.5. Summary
In summary, the group o f  patients studied showed no overall excess risk for development 
o f  neoplasia in the years after surgery for peptic ulcer. Only laryngeal cancer was 
significantly more frequent in the study cohort. Small but insignificant increases in gastric 
and bronchial cancer were also evident. When formal analysis by different operation type 
was performed, this showed a significant excess o f cancer at these three sites in the largest 
group under study, namely vagotomy and drainage, but still no increased risk for cancer as 
a whole. Colorectal cancer was not any more frequent than expected in the general 
population, either after vagotomy or any other type o f operation.
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2. In vitro and in vivo studies
The question o f whether elevation o f gastrin levels may lead to increased colorectal 
tum our development, was one o f the reasons central to the study o f  a group o f 
predominantly vagotomised individuals, the findings o f which have been discussed above. 
This was also the stimulus to the experimental work o f Penman and colleagues (311), who 
questioned whether elevation o f  endogenous gastrin levels secondary to administration o f 
the potent acid inhibitory agent, omeprazole, would lead to an increased yield o f 
carcinogen-induced colorectal tumours in rats so treated. Their findings were completely 
unexpected, in that the drug appeared to exert an inhibitory effect on tum our development 
despite significant endogenous hypergastrinaemia occuring with omeprazole treatment. 
The aims o f the studies performed for this thesis were to try and identify at which stage in 
the carcinogenesis process this unexplained action o f  omeprazole had occurred, and 
hopefully give some idea as to how the drug had acted. Only one other study had 
suggested that omeprazole may have such an anti-neoplastic action on colonic tum our 
cells and this was from Tobi (312), who found that in one o f 3 cell lines o f colonic tum our 
origin treated by omeprazole in vitro, there was a significant inhibition o f  tum our cell 
growth. Although not postulated as a possible mode o f such an action for the drug by 
Penman and his colleagues (311), the results o f this in vitro study suggested that some 
form o f  direct action o f  the drug on the tumour cell might account for their findings. To 
this end, the clonogenic assays were performed. The three cell lines, all derived from 
classical human colonic adenocarcinomas, were exposed to a wide range o f  concentrations 
o f  omeprazole in cell culture, spanning, and exceeding, the normal pharmacological 
concentrations seen in humans during both normal and supra-normal dosing with the drug 
(313.329).
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2.1. Effect o f omeprazole on survival o f colorectal cancer cells in vitro 
For all 3 cell lines, omeprazole did not exert any effect, inhibitory or otherwise, on the 
growth or survival o f  the tumour cells. Although it initially appeared that treatment with 
the highest test concentration, 0.2mmol/L, significantly reduced the numbers o f  surviving 
cells, this was probably due to a direct toxic action o f  the organic solvent, DMSO, in 
which omeprazole was initially dissolved. At this concentration o f  omeprazole, DMSO 
was present in the cell culture medium at a concentration o f 1 in 50, and when cells were 
treated with DMSO at this concentration, in the absence o f omeprazole, similar reductions 
in colony count to those obtained with omeprazole 0.2mmol/L were obtained (see Results 
- Table 6 and Figure 5). All lesser concentrations o f  DMSO were shown not to 
significantly affect cell growth compared to those in DMSO-free medium. Even if  the 
reduced cell survival seen after exposure to omeprazole 0.2mmol/L were due to a specific 
action o f the drug, it should be appreciated that this concentration is approximately twenty 
times greater than recorded maximal plasma concentrations after a supra-therapeutic 
90mg oral dose in humans (313). Furthermore, it is over 100 times greater than that after 
a standard 20mg oral dose, and close to maximal levels found in mice during 
carcinogenicity studies (313). Any potential clinical use o f the drug at. this level would 
probably not be feasible. It therefore seems unlikely that the reduction in tum our yield 
seen in Penman’s original experiment was consequent upon any direct action o f 
omeprazole on tumour cells. In addition, the only cell line o f the 3 employed in Tobi’s 
study to exhibit an inhibitory response was a tumour with carcinoid features and as such, 
one should exercise caution in inferring a similar response by cells from a classical 
adenocarcinoma o f colorectal mucosa, a disease with markedly differing clinical and 
prognostic parameters from carcinoid tumours. This point has already been emphasised by 
Hurwitz and colleagues (342).
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2.2. Effect o f pentagastrin on human colonic tum our growth in vitro 
Using an identical assay technique to that above, the opportunity to re-examine the effect 
o f  pentagastrin on colonic tumour cell growth was taken, as several previous workers 
have confirmed the trophic action o f both natural and synthetic gastrin on human colonic 
tum our growth in vitro (247-250). Whilst a modest increase in colony numbers can be 
observed at all concentrations o f pentagastrin compared to control values (see Results - 
Figure 6), the differences were not significant. This is similar to the findings o f  Sirinek 
and colleagues (247) who observed a 29% increase in HT29 cell numbers to pentagastrin 
treatment compared to controls, which was not significant. They postulated that this 
might be the result o f  acquired changes in this maintained cell line over time, rendering it 
less responsive to hormonal stimulation, as the other four freshly prepared colonic 
carcinoma cell cultures utilised in their study, did show a significant growth response to 
pentagastrin, with a mean increase in cell numbers o f  59% compared to control cells. 
Palmer Smith (249) also used cell line HT29 and found it to respond significantly to 
gastrin-17 at a dose o f  400 picomoles per litre, though the mean increase in cell count is 
similar to that o f Sirinek’s, at 28%. There are marked differences in the design, 
methodology and statistical analysis o f the results between the studies, and these are likely 
to account for the apparent inconsistency in the statistical significance o f  the similar 
growth responses seen.
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2.3. In vivo study
The in-vivo investigation failed to show any significant differences in either tum our 
incidence, number, size or stage in omeprazole treated rats compared to untreated 
controls, either during the initiation or promotion stages o f carcinogenesis.
Hypothetical explanations for the reduced colorectal tumour yield seen in Penman’s study 
included interference with carcinogen metabolism by omeprazole, as previously discussed. 
W ere omeprazole to have such an action on carcinogen metabolism, one would not expect 
to see any effect on tum our development if the drug is not administered concurrently with 
carcinogen. However, in the present experiment (as in Penman’s study), rats in Group A 
received omeprazole concurrently with azoxymethane, and therefore if some significant 
action o f omeprazole on carcinogen metabolism exists, one would expect to see a 
reduction in tum our development in this group. However, disease incidence in Group A 
was virtually identical to that o f both the control group C (16/25 versus 17/25 
respectively, P = 0.5) and the “promotion” group B (16/25 versus 18/25, P = 0.4). 
Although the tum our yield was higher in control group C than either o f  the omeprazole 
treated groups, this did not reach significance and was largely accounted for by one animal 
in Group C which was found to have a total o f  4 separate neoplasms (3 carcinomas & 1 
adenoma). Indeed, the median number o f tumours per animal in all three groups was 
identical. One possible confounding variable which may have caused the reduced tumour 
incidence in omeprazole-treated rats in Penman’s study, cited both by the authors and 
others (31 1,342), was the possible anti-tumorigenic effect that is observed in experimental 
rodents with reduced caloric intake and growth rate (343,344), which was evident in 
omeprazole treated rats in that study, which were on average 12% lighter than the control 
group by the end o f  the study (P<0.005) (311). In the present investigation, the average 
weekly growth rate and final animal weights in all three treatment groups were very
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similar and this could possibly explain the discrepancy in outcome between the two 
studies. However, in the present study, there was no appreciable relationship between 
tum our development and either o f these parameters (Figure 2A and B), as assessed by 
Spearman’s rank correlation co-efficient (rs = 0.097, P = 0.59 and rs = 0.13, P = 0.26 
respectively) to suggest that this would account for any such effect on the results.
Results for animals in group B, treated with omeprazole in the promotion phase o f  
carcinogenesis, were also similar to controls. This was not particularly unexpected as 
there is little existing evidence to suggest that omeprazole exerts any significant effect on 
colorectal tumours once established and is in accordance with findings o f  those studies 
(albeit not specifically designed to assess any specific action o f  omeprazole per se on 
tum our growth) where omeprazole treatment has commenced after the phase o f  tum our 
initiation has been completed (284,285).
These latter two studies also concluded that omeprazole-induced hypergastrinaemia did 
not enhance colonic tumour growth (284,285). Our results concur in this respect. Both 
Group A and Group B animals, which were rendered significantly hypergastrinaemic 
whilst receiving omeprazole (Results - Figure 2A & B), both developed similarly sized 
neoplasms that were not significantly larger than those in control rats (Group A v C, P = 
0.60; B v C, P = 0.25; A v B, P = 0.80, Mann Whitney U).
The suggestion that drugs such as omeprazole, widely used in upper gastrointestinal acid 
related disorders with excellent tolerability and low incidence o f  adverse effects, could 
have a place in the management o f such a common and often fatal disease as colorectal 
neoplasia is an exciting one and the potential for use is wide. For instance, would high 
risk groups such as members o f hereditary cancer families, patients with previously 
excised benign colonic polyps and long term ulcerative colitis sufferers benefit from 
prophylactic treatment? Could it have a place as an adjuvant therapy in patients following
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Discussion - Figure 2
a) Relationship between Growth Rate and Tumour 
Development
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a) rs = 0.13 , P = 0.26 b) rs = 0.097 , P = 0.59
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tum our excision? Thinking such as this has been controversially described as “loose and 
heretical” by Rehfeld in a recent editorial on the subject (344), but the evidence, though 
sparse and confined to laboratory based studies, was certainly worthy o f further 
investigation, as Rehfeld later agreed (345). However, the results o f these present studies 
do not support those potentially exciting earlier findings.
It is also noteworthy that omeprazole-induced hypergastrinaemia did not significantly 
affect tum our number, growth or aggressiveness compared to normogastrinaemic 
controls. With the results o f the previous similar studies o f Graffner (284), Pinson (285), 
and even those o f Penman (311), such findings should allay concerns regarding long term 
usage o f  such drugs, at least from the colorectal cancer perspective. However, it seems 
that the controversy on the subject o f endogenous gastrin on colorectal tum our growth is 
not yet ended as a recent study by Chu and colleagues (254) showed significant 
enhancement o f growth, invasion and metastatic potential o f  a human colonic carcinoma 
transplanted into athymic rats rendered hypergastrinaemic by gastric fiindectomy. The 
tum our used in this study was shown to express gastrin receptor mRNA and to be 
responsive to a specific gastrin receptor antagonist. It could be argued that the chemically 
induced tumours utilised in the present study and others may lack the appropriate 
receptors which would allow gastrin to exert its trophic action. However, a recent report 
showed high expression o f gastrin receptors on azoxymethane-induced colonic tumours 
(337). Therefore, quite why elevation o f antroduodenal gastrin by surgery, and not by 
drug administration, should lead to enhanced tumour growth is unclear but the findings o f  
the present study do not support any action o f the drug per se, to account for 
“neutralisation” o f the hormone’s action on colorectal neoplasia. Indeed, this may suggest 
that factors other than gastrin, which are invoked following acid reducing gastric surgery 
but not necessarily by acid suppression itself, are responsible. For example, bile
composition has been shown to be significantly altered following vagotomy in humans 
(171,291) and bile acids have been implicated as having a potential role to play in 
colorectal carcinogenesis (304-307). Once again however, the findings o f  the clinical 
study would tend to contradict even this hypothesis.
Thus, it is possible that studies such as the present one, where elevation o f  endogenous 
gastrin levels is achieved by administration o f  omeprazole and similar drugs are invalidated 
for the simple reason that neither the drug nor the hormone (at least o f  antroduodenal 
origin) interact significantly in the genesis or growth o f large bowel cancer.
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3. Summary
A number o f common conclusions may be drawn from the combined findings o f  the three 
main lines o f investigation, spanning in vitro, through in vivo, to clinical study, undertaken 
in this thesis.
The studies were all performed primarily to examine the effects o f treatment for peptic 
ulcer, both old and new, on the development and growth o f colorectal cancer. A small 
number o f previously performed studies had suggested an increased incidence o f  the 
disease in patients treated operatively for their ulcer. In addition, a substantial volume o f 
experimehtal evidence had accumulated to suggest that the antral hormone, gastrin, may 
be an important trophic factor in colorectal tumour growth. Recognising that chronic 
elevation o f this hormone occurs as a result o f the operation o f vagotomy for peptic ulcer, 
it seemed appropriate to study such a group o f patients to see whether such a 
phenomenon could be observed. However, the rate o f colorectal cancer in a sizeable 
cohort o f such patients followed up for approximately 25 years was not significantly 
different from that which was expected in the general population over the same period o f 
time. As such, no sequelae o f the surgery, whether hypergastrinaemia or otherwise, have 
been seen to exert any carcinogenic effect on the colonic mucosa over a sustained period 
oftime.
Fulherm ore, in the in-vivo study, rats rendered hypergastrinaemic by treatment with 
omeprazole did not exhibit any exagerrated response in either colonic tum our number, 
st&>e or size as a result. It is accepted that the 24-week timespan o f this laboratory based 
study and the much longer follow-up period o f vagotomised patients in the clinical study 
are temporally incomparable, but the results o f both are against any significant influence o f 
elevated endogenous gastrin levels on the genesis or growth o f  colorectal tumours.
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The absence o f an obvious promoting action o f omeprazole-induced hypergastrinaemia on 
colorectal tumour growth in this study, as well as the absence o f  any excess o f such 
tumours in the group o f vagotomised patients should consolidate the reassurances already 
given by others as to the relative unimportance o f elevated antral gastrin levels in the 
development o f  the disease (344,346). This conclusion, however, should not be 
interpreted as meaning that gastrin is not a growth factor for some tumours, as has been 
shown (247-250) However, any such action is possibly more likely due to autocrine 
production and local release o f the hormone and its precursors by some colorectal 
tumours (277-281), to act on appropriate cell surface receptors also synthesised by the 
tumour cells (258). The concentrations o f such self-produced hormone within the 
immediate extracellular environment may be more important than circulating blood levels 
in promotion o f tumour growth.
At the same time, although no obvious tumour-promoting action o f  elevated circulating 
gastrin levels was seen, this was not due to any confounding effect o f  omeprazole itself, as 
omeprazole did not exert any cytotoxic action on human colorectal tum our cells in vitro. 
Furthermore, animals treated with omeprazole either during the initiation or promotion 
phases o f colorectal carcinogenesis, both had similar tumour numbers, o f similar stage and 
size, to normogastrinaemic controls. These findings do not support any anti-neoplastic 
action o f this drug on colorectal tumour growth as suggested by the studies o f  Penman 
(311) and Tobi (312), but are consistent with those o f Graffner (284) and Pinson (285). 
The other notable findings o f the work undertaken here are the statistically significant, 
though modest, increased risks for bronchial, laryngeal and gastric cancer in vagotomised 
patients. Noting that the great majority o f  these patients were habitual smokers probably 
explains the observations for bronchial and laryngeal cancer, and is probably partly 
contributory to the development o f  gastric cancer in the cohort. In the case o f the latter,
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it is more likely that the prolonged acid suppression in such patients is more important in 
its aetiology, as has been noted in previous groups o f patients treated by vagotomy or 
antrectomy and in patients with pernicious anaemia. What effect long-term acid 
suppression by medical means such as omeprazole will have in years to come remains to 
be seen, but the findings o f the present study may indicate a potential hazard for patients 
so treated, and may warrant endoscopic surveillance o f such groups. Despite this, it is 
likely that these patients will succumb to diseases strongly associated with smoking such 
as lung cancer, as found here, and other non-malignant conditions such as ischaemic heart 
disease and chronic respiratory disease, rather than gastric cancer, unless there is a major 
change in the lifestyle o f today and tom orrow ’s patients with dyspeptic disorders.
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4. Scope for further study
A plethora o f information has been collated for the 1,992 patients reviewed in the clinical 
study and further analysis o f this database may provide an important insight into why 
persons who have been submitted to ulcer surgery have come to be associated with such 
poor health in the years after it. Although the present study was confined to cancer 
incidence, computerised linkage to the national mortality statistics held by the Registrar 
General’s Office, would allow disease-specific mortality rates for the cohort, not only for 
cancer, but all diseases, to be compared to those o f the general population.
In a manner similar to that for smoking, alcohol consumption and socio-economic status 
have also been recorded for each patient in the study and any correlation to outcome for 
each o f these factors could be determined.
Data has also been collected on the results o f post-operative “Hollander” insulin tests, 
used to assess the completeness o f vagotomy in those so treated, and a study o f the 
completeness o f vagotomy in both the gastric and colorectal cancer patients identified 
would be o f interest. An inadequate vagotomy would be synonymous with persistence o f 
vagally stimulated acid secretion, and also continuation o f  negative feedback control o f  
circulating gastrin, both factors which, as already explained, may be influential in the 
development o f  these diseases. Comparison o f disease incidence between complete and 
incompletely vagotomised subjects would possibly give a more precise indicator o f  the 
influence o f that procedure on colonic or gastric tumour development.
Further experimental studies, similar to those performed here, using newer forms o f 
proton pump inhibitors, such as lansoprazole and pantoprazole, might be considered. 
However, the absence o f  any demonstrable action o f  either omeprazole, nor the 
hypergastrinaemia produced by it, on colorectal tumour growth in vitro or in vivo, would
suggest that similar results would be obtained with these newer compounds, which elevate 
endogenous gastrin levels to a similar degree as omeprazole (347) and which interact 
similarly (348-350), or in the case o f pantoprazole, to a much lesser degree (349,350), 
with members o f  the cytochrome P450 family o f enzymes than omeprazole. It was the 
interaction o f the latter with such enzymes that was postulated by Penman to be 
responsible for its anti-neoplastic action, an hypothesis which the findings o f this study
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5. Conclusions
1. Previous peptic ulcer surgery, particularly vagotomy, does not confer an increased risk 
for development o f colorectal cancer in the years following such surgery.
2. Hypergastrinaemia induced by present-day medical treatment for peptic ulcer disease, in 
the form o f  the proton pump inhibitor, omeprazole, does not enhance the development or 
grow th o f chemically-induced colorectal neoplasms in Sprague-Dawley rats.
3. Omeprazole does not inhibit the growth o f such chemically-induced colorectal 
nepolasms in-vivo nor does it possess any obvious cytotoxic action on three human 
colorectal carcinoma cell lines studied in-vitro.
4. The risk o f gastric cancer is increased by 50% over that o f the general population in 
patients previously treated by vagotomy for peptic ulcer.
5. Despite the modest increase in risk for gastric cancer, lung cancer was the commonest 
neoplasm in the study cohort in the years after surgery, and with laryngeal cancer was 
significantly more frequent in the study cohort than the general population. Diseases such 
as these with a strong association with smoking are more likely to cause morbidity and 
mortality in such patients, rather than any long-term deleterious effects o f the surgery on 
the gastric mucosa.
6. The modest, but significant increased risk for gastric cancer seen after vagotomy, may 
have implications for the safety o f long-term acid supppression by present-day means such 
as omeprazole and related drugs.
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Appendices
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Materials and Methods - Appendix 1 
Pentic Ulcer Clinic Study - Patient Data Collection Form
SEX : MALE : 1 FEMALE : 2
PATIENT N° :
DIAGNOSIS : DOUDENAL ULCER - 1 ,  GASTRIC ULCER - 2 ,  BOTH DU & GU - 3 ,  RECURRENT ULCER - 4 
OTHER - 5 ,  NO ABNORMALITY - 6
OPERATIVE PROCEDURE : VAGOTOMY AND PYLOROPLASTY - 1 ,  VAGOTOMY AND GASTROENTEROSTOMY - 2 
BILROTH I GASTRECTOMY - 3 , POLYA GASTRECTOMY - 4
GASTROENTEROSTOMY ONLY - 5 ,  PYLOROPLASTY ONLY - 6 ,  VAGOTOMY ONLY - 7 
JEJUNAL INTERPOSITION - 8 ,  ROUX-EN-Y - 9 ,  REPAIR OF PERFORATED ULCER ONLY- 10 
CHOLECYSTECTOMY - 11, OTHER -12
IF OTHER. SPECIFY:
DATE OF OPERATION :
AGE AT OPERATION :
AGE GROUP : (<15years) - 1 ,  (15-19) - 2 , (20-24) - 3 , (25-29) - 4 ,  (30-34) - 5 ,  (35-39) - 6 ,  (40-44) - 7 
(45-49) - 8 , (50-54) - 9 ,  (55-59) - 1 0 ,  (60-64) - 1 1 ,  (65-69) - 12 , (70-74) - 13 , (75-79) - 14 
(80-84) - 15 , (>85years) -16
POST OPERATIVE INSULIN TEST
RESULT : NEGATIVE - 1 ,  POSITIVE - 2 , NONE - 3, INCONSISTENT - 4 ,  NOT APPLICABLE -5
SOCIO-ECONOMIC STATUS : 1 2 3 4 5 NOT SPECIFIED - 6
SMOKING STATUS AT OPERATION : ZERO - 1 .  1-10 - 2 . 11-20 - 3 . 21+ - 4 .  CIGAR - 5 . PIPE - 6 . NOT SPECIFIED - 7
EX-SMOKER - 8
ALCOHOL INTAKE : ZERO - 0 , OCCASIONAL - 1 ,  OFTEN - 2 , HEAVY/HABITUAL - 3 , NOT SPECIFIED - 4
REGISTRATION WITH CANCER REGISTRY : YES - 1 .  NO - 2
IF YES. DATE OF DIAGNOSIS OF CANCER :
TIME FROM GASTRIC SURGERY TO DIAGNOSIS OF MALIGNANCY :
TYPE OF MALIGNANCY: COLON - 1 ,  RECTUM - 2 ,  STOMACH - 3 ,  LUNG - 4 ,  OTHER - 5
IF OTHER. SPECIFY:
DIED ? : YES- 1 ,  N O -2
IF YES. DATE OF DEATH :
UNDERLYING CAUSE OF DEATH :
TIME FROM GASTRIC SURGERY TO DEATH :
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Materials and Methods - Appendix 2 
Preparation of Culture Medium used in Clonogenic Assays
The culture medium employed is a fifty/fifty mixture o f Ham ’s F10 Nutrient M ixture and 
D ulbecco’s modified Eagles containing glutamine 2mmol/L and 10% foetal calf serum.
“F10/DM EM ” was prepared in the following proportions:
• 400 mLs distilled water
• 22.5 mLs F 10-Hams Nutrient Mixture (Integra Biosciences,Northumbria Biologicals, U.K.)
• 22.5 mLs Dulbecco's Minimum Essential Medium(DMEM)
(Gibco BRL,LifeTechnologies Ltd,Paisley, Scotland, U.K.)
• 5 mLs Sodium Bicarbonate 7.5%
• 5 mLs 1 M olar Sodium Hydroxide
This constituted the stock medium, and prior to  use was added:
• 50 mLs Foetal calf serum (Globepharm Ltd, Esher, Surrey, U.K.)
• 5 mLs L-glutamine 200mmol/L (GibcoBRL, Paisley)
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Reconstitution of Omeprazole
M olecular Formula
M olecular Weight
: C 17H 19N 3O3S 
: 345.42 grams
Dosage 
Dose Volume
: 40pmol/kg/day 
: 5mLs/kg
Conversion : lpm ol = 0.345mgs
Concentration o f Suspension : 2.76mgs/mL.
Pure Omeprazole powder was suspended in 0.25% methylcellulose solution, buffered with 
0.2% sodium bicarbonate and the pH adjusted to 9 with sodium hydroxide to  give the final 
concentration shown above. This suspension is stable for one year in a deep freezer ( -18°C 
to -2 2 °C ), one week in a reffigarator and one day at room temperature.
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